SEQUENCES CHARACTERISTIC OF HUMAN GENE TRANSCRIPTION PRODUCT

Abstract: Partial and complete human cDNA and genomic sequences corresponding to particular expressed sequence tags (ESTs). The ESTs are cDNA sequences that are generally between 150 and 500 base pairs in length, are derived from human brain cDNA libraries, correspond to genes transcribed in human brain, and have base sequences identified herein as SEQ ID NOS: 1-315.

Description: SEQUENCES CHARACTERISTIC OF HUMAN GENE TRANSCRIPTION PRODUCT Technical Field The present invention relates to newly identified polynucleotide sequences corresponding to transcription products of human genes, and to complete gene sequences associated therewith. Background This invention relates to human genes. Identification and sequencing of human genes is a major goal of modern scientific research. The sequence of human genes is more than just a scientific curiosity. For example, by identifying genes and determining their sequences, scientists have been able to make large quantities of valuable human "gene products." These include human insulin, interferon, Factor VIII, tumor necrosis factor, human growth hormone, tissue plas inogen activator, and numerous other compounds. Additionally, knowledge of gene sequences can provide the key to treatment or cure of genetic diseases (such as muscular dystrophy and cystic fibrosis) . The present invention represents a quantum leap forward in mankind's knowledge of human gene sequences. There are several basic concepts of molecular biology which figure prominently in the invention. A brief explanation of those concepts follows. Additional background information and definitions for scientific terms can be found in the literature. See, for example, "Glossary of Genetics, Classical and Molecular" by R. Rieger, A. Michaelis, and M.M. Green (Fifth Edition, Springer-Verlag, New York (1991)). The contents of this and other publications cited in the specification are incorporated by reference herein. At an initial level, the present invention is based on identification and characterization of gene segments. Genes are the basic units of inheritance. Each gene is a string of connected bases called nucleotides. Most genes are formed of deoxyribonucleic acid, DNA. (Some viruses contain genes of ribonucleic acid, RNA.) The genetic information resides in the particular sequence in which the bases are arranged. A short sequence of nucleotides is often called a polynucleotide or an oligonucleotide. Like genes, polypeptides are built from long strings of individual units. These units are amino acids. The nucleotide sequence of a gene tells the cell the sequence in which to arrange the amino acids to make the polypeptide encoded by that gene. In general, chains of up to about 200 amino acids are called polypeptides, while proteins are larger molecules made up of polypeptide subunits; both types of molecules are referred to generally herein as polypeptides. A triplet of nucleotides (codon) in DNA codes for each amino acid or signals the beginning or end of the message (anticodon) . The term codon is also used for the corresponding (and complementary) sequences of three nucleotides in the mRNA into which the original DNA sequence is transcribed. Generally, enzymes in the cell transcribe the permanent DNA of the gene into a temporary RNA copy, called messenger RNA or mRNA. The mRNA, in turn, can be translated into a polypeptide by the cell. This entire process is called gene expression, and the polypeptide is the gene product encoded by the gene. Scientists have previously discovered how to reverse the transcription process and copy mRNA back into DNA using an enzyme called reverse transcriptase. The resulting is called complementary DNA, or cDNA. This is schematically shown in the single Figure. When substantially all of the mRNA from one cell or tissue is converted to cDNA at once and cloned into multiple copies of a recombinant vector to allow replication and manipulation in the -laboratory, -the result is called a cDNA library. The various types of genes include those which code for polypeptides, those which are transcribed into RNA but are not translated into polypeptides, and those whose functional significance does not demand that they be transcribed at all. Most genes are found on large molecules of DNA located in chromosomes. Double stranded cDNA carries all the information of a gene. Each base of the first strand is joined to a complementary base (hybridized) in the second strand. The linear DNA molecules in chromosomes have thousands of genes distributed along their length. Chromosomes include both coding regions (coding for polypeptides) and noncoding regions; the coding regions represent only about three percent of the total chromosome sequence. An individual gene has regulatory regions that include a promoter which directs expression of the gene, a coding region which can code for a polypeptide, and a termination signal. The regulatory DNA sequence is usually a noncoding region that determines if, where, when, and at what level a particular gene is expressed. The coding regions of many genes are discontinuous, with coding sequences (exons) alternating with noncoding regions (introns) . The final mRNA copy of the gene does not include these introns (which can be much longer than the coding region itself) , although it does contain certain untranslated regions that usually do not code for the polypeptide gene product. Untranslated sequences at the beginning and end of the mRNA are known as 5 1 - and 3'-untranslated regions, respectively. This nomenclature reflects the orientation of the nucleotide constituents of the mRNA. A cDNA is a DNA copy of a messenger RNA, which contains all of the exons of a gene. The cDNA can be thought of as having three parts: an untranslated 5* leader, an uninterrupted polypeptide-coding sequence, and a 3' untranslated region. The untranslated leader and trailing sequences are important for initiation of translation, mRNA stability, and other functions. The untranslated leader and trailing sequences are called 5'- and 3 '-untranslated sequences, respectively. The 3' untranslated sequence is usually longer than the 5' untranslated leader, and can be longer than the polypeptide-coding sequence. The untranslated regions typically have many, randomly-distributed stop codons, and do not display the nonrandom base arrangements found in coding sequences. The 5'-untranslated sequence is relatively short, generally between 20 and 200 bases. The 3 1 - untranslated sequence is often many times longer, up to several thousand bases. The translated or coding sequence begins with a translational start codon (AUG or GUG) and ends with a translational stop codon (UAA, UGA, or UAG) . Generally, translation begins at the first "start" codon on the mRNA and proceeds to the first "stop" codon. Coding sequences can be distinguished by their nonrandom distribution of bases; numerous computer algorithms have been developed to distinguish coding from noncoding regions in this way. Human DNA differs from person to person. No two persons (except perhaps identical twins) have identical DNA. While the differences, called allelic variations or polymorphisms, are slight on a molecular level, they account for most of the physical and other observable differences between individuals. It has been estimated that approximately 14 million sequence polymorphism differences exist between individuals. The ability of one strand of DNA to attach or hybridize to a complementary strand has already been exploited for several purposes. For example, small pieces of DNA (15 to 25 base pairs long) can be made which will hybridize to longer strands of DNA which have a complementary sequence. These short "primers" can be selected such that they hybridize to a specific, unique location on the longer strand. Once the primers have hybridized to their target on the DNA, the polymerase chain reaction (PCR) can be employed to generate millions of copies of (or amplify) the particular segment of DNA between the locations to which two primers are bound. Briefly, this technique allows amplification of a DNA region situated between two convergent primers, using oligonucleotide primers that hybridize to opposite strands. Primer extension proceeds inward across the region between the two primers, and the product of DNA synthesis of one primer serves as a template for the other primer. Repeated cycles of DNA denaturation, annealing of primers, and extension result in an exponential increase in the number of copies of the region bounded by the primers. Similarly, a labeled segment of single-stranded DNA can be hybridized to a longer DNA sequence, such as a chromosome, to mark a specific location on the longer sequence. Segments of DNA 50 bases long or longer that hybridize to a unique DNA location in the human genome are extremely unlikely to hybridize elsewhere in the human genome. The Human Genome Project is an effort to sequence all human DNA (the human genome) . The human genome is estimated to comprise 50,000 - 100,000 genes, up to 30,000 of which might be expressed in the brain (Sutcliffe, Ann. Rev. Neurosci. 11:157 (1988)). Once dedicated human chromosome sequencing begins in three to five years, it was expected that 12-15 years will be required to complete the sequence of the genome (Report of the Ad Hoc Program Advisory Committee on Complex Genomes, Reston, Va. , Feb. 1988, D. Baltimore Ed. (NIH, Bethesda, Md, 1988)). At that rate, the majority of human genes would remain unknown for at least the next decade. The present invention can greatly accelerate the pace at which human genes can be identified and mapped. Most gene researchers, in conjunction with publication of their results in this field, submit sequence data to the GenBank database. Prior to the present invention, GenBank listed the sequences of only a few thousand human genes and less than two hundred human brain mRNAs (GenBank Release 66.0, December, 1990). The role of sequencing complementary DNA (cDNA) , reverse transcribed from mRNA, as a part of the human genome project has been vigorously debated since the idea of determining the complete nucleotide sequence of humans first surfaced. The coding sequence of all human genes represents most of the information content of the genome, but only 3-5% of the total DNA. In contrast, cDNA (which is only made from the transcription product of active genes) is one-half to three- fourths (the remainder being 5'- and 3'-untranslated sequence) meaningful genetic information. Thus, some have argued that cDNA sequencing should take precedence over genomic sequencing (Brenner, CIBA Found. Sy p. 149:6 (1990)). However, until now, such arguments have not been heeded. Genomic sequencing proponents have argued the difficulty of finding every mRNA expressed in all tissues, cell types, and developmental states, and that much valuable information from intronic and intergenic regions, including control and regulatory sequences, will be missed by cDNA sequencing. (Report of the Committee on Mapping and Sequencing the Human Genome, National Research Council (National Academy Press, Washington, D.C. 1988)). Further, sequencing of transcribed regions of the genome using cDNA libraries has heretofore been considered impractical or unsatisfactory. Libraries of cDNA were believed to be dominated by repetitive elements, mitochondrial genes, ribosomal RNA genes, and other nuclear genes comprising common or housekeeping sequences. It was believed that cDNA libraries would provide few sequences corresponding to structural and regulatory polypeptides or peptides. See, for example, Putney, et al.. Nature 302;718- 721 (1983) . Putney, et al. sequenced over 150 clones from a rabbit muscle cDNA library and identified clones for 13 of the 19 known muscle polypeptides, including one new isotype but no unknown coding sequences. Another perceived drawback of cDNA sequencing was that some mRNAs are abundant, and some are rare. The cellular quantities of mRNA from various genes can vary by several orders of magnitude. This led critics to believe that most information obtained from cDNA sequencing would be repetitious and useless. The present invention demonstrates that, despite such skepticism, cDNA sequencing now provides a rapid method for obtaining enormous amounts of valuable genetic information and DNA products of great utility for the biotechnology and pharmaceutical industries. Not only can many distinct cDNAs be isolated and sequenced, even partial cDNAs can be used, with conventional, well-understood methods, to isolate entire genes, and to determine the chromosomal locations and biological functions of these genes. As is demonstrated here, fragments of only a few hundred bases are sufficient, in many cases, to identify the probable function of a new human gene if it is similar in structure to a gene from another animal, or from plants or bacteria. Similarly, even fragments of untranslated regions of a cDNA can be used to: i) isolate the coding sequence of the cDNA; ii) isolate the complete gene; iii) determine the position of the gene on a human chromosome, and hence the potential of the gene to cause a human genetic disease; and iv) determine the function of the gene by means of experiments in which the function of the native gene is disrupted by the addition of a short DNA fragment to the cell, e.g., using triple helix or antisense probes. Because coding regions comprise such a small portion of the human genome, identification and mapping of transcribed regions and coding regions of chromosomes is of significant interest. There is a corresponding need for reagents for identifying and marking coding regions and transcribed regions of chromosomes. Furthermore, such human sequences are valuable for chromosome mapping, human identification, identification of tissue type and origin, forensic identification, and locating disease-associated genes (i.e., genes that are associated with an inherited human disease, whether through mutation, deletion, or faulty gene expression) on the chromosome. SUMMARY OF THE INVENTION Contrary to the expectations of the scientific community, cDNA screening and sequencing techniques have now been used to discover a large number of heretofore unknown human genes. Disclosed herein are over 300 new human polynucleotide sequences. The novelty of these sequences has been established through comparison to both nucleotide sequence databases and amino acid sequence databases. Surprisingly, approximately 80% of the sequences generated were unrelated to any sequences previously described in the literature. The sequences of the present invention were ascertained using a fast approach to cDNA characterization. This approach could facilitate the tagging of most expressed human genes within a few years at a fraction of the cost of complete genomic sequencing, provide new genetic markers, provide new DNA-based therapeutics and diagnostics, and provide other valuable nucleotide reagents. The sequences disclosed herein, styled Expressed Sequence Tags ("ESTs") , are markers for human genes actually transcribed in vivo . Techniques are disclosed for using these ESTs to obtain the full coding region of the corresponding gene. The use of ESTs, complete coding sequences, or fragments thereof for marking chromosomes, for mapping locations of expressed genes on chromosomes, for individual or forensic identification, for mapping locations of disease- associated genes, for identification of tissue type, and for preparation of antisense sequences, probes, and constructs is discussed in detail below. Unlike the random genomic DNA sequence tagged sites (STSs) (Olson et al.. Science 245:1434 (1989)), ESTs point directly to expressed genes. Various aspects of the present invention thus include the individual ESTs, corresponding partial and complete cDNA, genomic DNA, mRNA, antisense strands, triple helix probes, PCR primers, coding regions, and constructs. Also, where one skilled in the art is enabled by this specification to prepare expression vectors and polypeptide expression products, they are also within the scope of the present invention, along with antibodies, especially monoclonal antibodies, to such expression products. BRIEF DESCRIPTION OF THE DRAWING The single drawing Figure schematically illustrates the progression from chromosome to gene to mRNA to cDNA. DETAILED DESCRIPTION OF THE INVENTION The detailed description that follows provides not only the actual sequence of each new EST, but also explains how the ESTs were obtained, how to obtain the corresponding complete cDNA sequence and the corresponding genomic DNA sequence, how to make DNA constructs from the ESTs and corresponding sequences, how to use those sequences as reagents in molecular biology and other fields, how to produce gene products from the ESTs and corresponding sequences and antibodies to those gene products, and the functional categories of many ESTs and corresponding genes. Furthermore, numerous actual working examples and predictive examples are provided to demonstrate and exemplify numerous aspects of the invention. I. ESTs from cDNA Libraries The sequences of the present invention were isolated from commercially available and custom made cDNA libraries using a rapid screening and sequencing technique. In general, the method comprises applying conventional automated DNA sequencing technology to screening clones, advantageously randomly selected clones, from a cDNA library. Preferably, the library is initially "enriched" through removal of ribosomal sequences and other common sequences prior to clone selection. According to the present method, ESTs are generated from partial DNA sequencing of the selected clones. The ESTs of the present invention were generated using low redundancy of sequencing, typically a single sequencing reaction. While single sequencing reactions may have an accuracy as low as 97%, this nevertheless provides sufficient fidelity for identification of the sequence and design of PCR primers. Most human genes can be identified by EST sequencing from libraries of cDNA copies of messenger RNAs. However, some genes are expressed only at specific times during embryonic development, or only in small amounts in a few specific cell types. Other genes have mRNAs that are degraded very quickly by the cell in which they are expressed. If any of these are the case, transcripts of the gene will not be represented in cDNA libraries so the gene will not be identifiable by EST sequencing. A new method called "exon amplification", however, can be used to isolate and identify transcripts of such genes. Exon amplification works by artificially expressing part or all of a gene that is contained in a cloned fragment of genomic DNA such as a cosmid or yeast artificial chromosome (YAC) . The gene is cloned into a special vector, designed at MIT, that uses control elements from virus genes to express the protein-coding exons of the human gene of interest. Exon trapping shows considerable promise as a general technique for identifying those genes in the human genome that cannot be found by cDNA cloning and EST sequencing. Exon amplification will also be useful for identifying the genes in regions of genomic DNA to which disease genes have been mapped. The exon amplification method can be used directly with the cosmid and YAC clones from human chromosomes that are being obtained by both NIH and DOE supported human genome centers. ESTs comprise DNA sequences corresponding to a portion of nuclear encoded messenger RNA. An EST is of sufficient length to permit: (1) amplification of the specific sequence from a cDNA library, e.g., by polymerase chain reaction (PCR); (2) use of a synthetic polynucleotide corresponding to a partial or complete sequence of the EST as a hybridization probe of a cDNA library, generally having 30 - 50 base pairs; or (3) unique designation of the pure cDNA clone from which the EST was derived (the EST clone) for use as a hybridization probe of a cDNA library. Preferably, EST-derived primer pairs and sequences amplify or detectably hybridize to a sequence from a genomic library. It has been found that sufficient information is contained in the 150-400 base ESTs from one sequencing run to effect preliminary identification and exact chromosome mapping. Accordingly, the ESTs disclosed herein are generally at least 150 base pairs in length. The length of an EST is determined by the quality of sequencing data and the length of the cloned cDNA. Raw data from the automated sequencers is edited to remove low quality sequence at the end of the sequencing run. High quality sequences (usually a result of sequencing templates without excessive salt contamination) generally give about 400 bp of reliable sequence data; other sequences give fewer bases of reliable data. A 150 bp EST is long enough to be translated into a 50 amino acid peptide sequence. This length is sufficient to observe similarities when they exist in a database search. Furthermore, 150 bp is long enough to design PCR primers from each end of the sequence to amplify the complete EST. Sequences shorter than 150 bp are difficult to purify and use following PCR amplification. Furthermore, a 150 bp polynucleotide is likely to give a very strong signal with low background in a screen of a genomic library. Finally, it is highly unlikely that a sequence of the same 150 bp exists in any genes in the genome besides the one tagged by the EST. Some closely related gene family members have very similar nucleotide sequences, but no examples of pairs of human genes with long segments of identical sequence have been reported to date. For instance, there are three known ^-tubulin genes in humans. Several ESTs were found that matched one or another of these tubulin genes, but several new members of this gene family were also found and could be clearly distinguished from the three known members. ESTs that match perfectly to several different genes can be detected by hybridizing to chromosomes: if many chromosomal loci are observed, the sequence (or a close variant) is present in more than one gene. This problem can be circumvented by using the 3'-untranslated part of the cDNA alone as a probe for the chromosomal location or for the full-length cDNA or gene. The 3'-untranslated region is more likely to be unique within gene families, since there is no evolutionary pressure to conserve a coding function of this region of the mRNA. As demonstrated in the Examples that follow, ESTs can be used to map the expressed sequence to a particular chromosome. In addition, ESTs can be expanded to provide the full coding regions, as detailed below. In this manner, previously unknown genes can be identified. While a variety of cDNA libraries can be used to obtain ESTs, human brain cDNA libraries are exemplified and represent a preferred embodiment. Suitable cDNA libraries can be freshly prepared or obtained commercially, e.g. , as shown in Examples 1 and 9. The cDNA libraries from the desired tissue are preferably preprocessed by conventional techniques to reduce repeated sequencing of high and intermediate abundance. clones and to maximize the chances of finding rare messages from specific cell populations. Preferably, preprocessing includes the use of defined composition prescreening probes, e.g., cDNA corresponding to mitochondria, abundant sequences, riboso es, actins, myelin basic polypeptides, or any other known high abundance peptide; these prescreening probes used for preprocessing are generally derived from known ESTs. Other useful preprocessing techniques include subtraction, which preferentially reduces the population of certain sequences in the library (e.g., see A. Swaroop et al., Nucl. Acids Res. 19:1954 (1991)), and normalization, which results in all sequences being represented in approximately equal proportions in the library (Patanjali et al, Proc. Natl. Acad. Sci. USA 88:1943 (1991)). The cDNA libraries used in the present method will ideally use directional cloning methods so that either the 5' end of the cDNA (likely to contain coding sequence) or the 3' end (likely to be a non-coding sequence) can be selectively obtained. Libraries of cDNA can also be generated from recombinant expression of genomic DNA. After they are amplified, ESTs can be obtained and sequenced, e.g., as illustrated in Example 9. The sequences of the present invention include the specific sequences set forth in the Sequence Listing and designated SEQ ID NO: 1 - SEQ ID NO: 315. In one aspect of this embodiment, the invention relates to those sequences of SEQ ID NOS: 1 - 315 that comprise the cDNA coding sequences for polypeptides having less than 95% identity with known amino acid sequences (see Table 2) and more preferably less than 90% or 85% identity. In a second aspect, the invention relates to those sequences of SEQ ID NOS: 1 - 315 that encode polypeptides having no similarity to known amino acid sequences (see Examples that follow) . Precisely because they do not contain coding regions and are therefore more unique in their sequence structures, those sequences which meet neither of the preceding criteria can be most useful and are generally preferred for mapping. Consistent with the NIH mission and its responsibilities to disseminate knowledge and share the tangible fruits of its research, the present inventors have taken a number of steps to facilitate sequence data and clone availability. All EST sequences have been submitted to GenBank. The corresponding cDNA clones have been submitted to the American Type Culture Collection and information on clones and sequences has been submitted to the Genome Data Base (Pearson, P. Nucl. Acids Res. 19 (Suppl.): 2237-9 (1991)). II. Complete Coding Sequences from ESTs The ESTs of the present invention generally represent relatively small coding regions or untranslated regions of human genes. Although most of these sequences do not code for a complete gene product, the ESTs of the present invention are highly specific markers for the corresponding complete coding regions. The ESTs are of sufficient length that they will hybridize, under stringent conditions, only with DNA for that gene to which they correspond. Suitably stringent conditions comprise conditions, for example, where at least 95%, preferably at least 97% or 98% identity (base pairing) , is required for hybridization. This property permits use of the EST to isolate the entire coding region and even the entire sequence. Therefore, only routine laboratory work is necessary to parlay the unique EST sequence into the corresponding unique complete gene sequence. Thus, each of the ESTs of the present invention "corresponds" to a particular unique human gene. Knowledge of the EST sequence permits routine isolation and sequencing of the complete coding sequence of the corresponding gene. The complete coding sequence is present in a full-length cDNA clone as well as in the gene carried on genomic clones. Therefore, each EST "corresponds" to a cDNA (from which the EST was derived) , a complete genomic gene sequence, a polypeptide coding region (which can be obtained either from the cDNA or genomic DNA) , and a polypeptide or amino acid sequence encoded by that region. The first step in determining where an EST is located in the cDNA is to analyze the EST for the presence of coding sequence, e.g., as described in Example 12. The CRM program predicts the extent and orientation of the coding region of a sequence. Based on this information, one can infer the presence of start or stop codons within a sequence and whether the sequence is completely coding or completely non-coding. If start or stop codons are present, then the EST can cover both part of the 5•-untranslated or 3'-untranslated part of the mRNA (respectively) as well as part of the coding sequence. If no coding sequence is present, it is likely that the EST is derived from the 3'-untranslated sequence due to its longer length and the fact that most cDNA library construction methods are biased toward the 3• end of the mRNA. One general procedure for obtaining complete sequences from ESTs is as follows: 1. Purify selected human DNA from an EST clone (the cDNA clone that was sequenced to give the EST), e.g., by endonuclease digestion using ECOR1, gel electrophoresis, and isolation of the aforementioned clone by removal from low- melting agarose gel. 2. Radiolabel the isolated insert DNA, e.g., with 32 P labels, preferably by nick translation or random primer labeling. 3. Use the labeled EST insert as a probe to screen a lambda phage cDNA library or a plasmid cDNA library. 4. Identify colonies containing clones related to the probe cDNA and purify them by known purification methods. 5. Nucleotide sequence the ends of the newly purified clones to identify full length sequences. 6. Perform complete sequencing of full length clones by Exonuclease III digestion or primer walking. Northern blots of the mRNA from various tissues using at least part of the EST clone as a probe can optionally be performed to check the size of the mRNA against that of the purported full length cDNA. An EST is a specific tag for a messenger RNA molecule. The complete sequence of that messenger RNA, in the form of cDNA, can be determined using the EST as a probe to identify a cDNA clone corresponding to a full-length transcript, followed by sequencing of that clone. The EST or the full- length cDNA clone can also be used as a probe to identify a genomic clone or clones that contain the complete gene including regulatory and promoter regions, exons, and introns. ESTs are used as probes to identify the cDNA clones from which an EST was derived. ESTs, or portions thereof, can be nick-translated or end-labelled with 32 P using polynucleotide kinase and labelling methods known to those with skill in the art (Basic Methods in Molecular Biology, L.G. Davis, M.D. Dibner, and J.F. Battey, ed. , Elsevier Press, NY, 1986). The lambda library can be directly screened with the labelled ESTs of interest or the library can be converted en masse to pBluescript (Stratagene, La Jolla, California) to facilitate bacterial colony screening. Both methods are well known in the art. Briefly, filters with bacterial colonies containing the library in pBluescript or bacterial lawns containing lambda plaques are denatured and the DNA is fixed to the filters. The filters are hybridized with the labelled probe using hybridization conditions described by Davis et al. The ESTs, cloned into lambda or pBluescript, can be used as positive controls to assess background binding and to adjust the hybridization and washing stringencies necessary for accurate clone identification. The resulting autoradiograms are compared to duplicate plates of colonies or plaques; each exposed spot corresponds to a positive colony or plaque. The colonies or plaques are selected, expanded and the DNA is isolated from the colonies for further analysis and sequencing. The ESTs can additionally be used to screen Northern blots of mRNA obtained from various tissues or cell cultures, including the tissue of origin of the EST clone. Northern analysis will most often produce one to several positive bands. The bands can be selected for further study based on the predicted size of the mRNA. Positive cDNA clones in phage lambda are analyzed to determine the amount of additional sequence they contain using PCR with one primer from the EST and the other primer from the vector. Clones with a larger vector-insert PCR product than the original EST clone are analyzed by restriction digestion and DNA sequencing to determine whether they contain an insert of the same size or similar as the mRNA size on a Northern blot. Once one or more overlapping cDNA clones are identified, the complete sequence of the clones can be determined. The preferred method is to use exonuclease III digestion (McCombie, W.R, Kirkness, E., Fleming, J.T., Kerlavage, A.R., Iovannisci, D.M. , and Martin-Gallardo, R. , Methods: 3: 33-40, 1991) . A- series of deletion clones is generated, each of which is sequenced. The resulting overlapping sequences are assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position) , resulting in a highly accurate final sequence. A similar screening and clone selection approach can be applied to obtaining cosmid or lambda clones from a genomic DNA library that contains the complete gene from which the EST was derived (Kirkness, E.F., Kusiak, J.W., Menninger, J. , Gocayne, J.D., Ward, D.C., and Venter, J.C. Genomics 10: 985- 995 (1991) . Although the process is much more laborious, these genomic clones can also be sequenced in their entirety. A shotgun approach is preferred to sequencing clones with inserts longer than 10 kb (genomic cosmid and lambda clones) . In shotgun sequencing, the clone is randomly broken into many small pieces, each of which is partially sequenced. The sequence fragments are then aligned to produce the final contiguous sequence with high redundancy. An intermediate approach is to sequence just the promoter region and the intron-exon boundaries and to estimate the size of the introns by restriction endonuclease digestion (ibid.). Using the sequence information provided herein, the polynucleotides of the present invention can be derived from natural sources or synthesized using known methods. The sequences falling within the scope of the present invention are not limited to the specific sequences described, but include human allelic and species variations thereof and portions thereof of at least 15-18 bases. (Sequences of at least 15-18 bases can be used, for example, as PCR primers or as DNA probes.) In addition, the invention includes the entire coding sequence associated with the specific polynucleotide sequence of bases described in the Sequence Listing, as well as portions of the entire coding sequence of at least 15-18 bases and allelic and species variations thereof. Furthermore, to accommodate codon variability, the invention includes sequences coding for the same amino acid sequences as do the specific sequences disclosed herein. Finally, although the error rate in the automated sequencing used in the present invention is small, there remains some chance of error. Therefore, claims to particular sequences should not be so narrowly construed as to require inclusion of erroneously identified bases or to exclude corrections. Any specific sequence disclosed herein can be readily screened for errors by resequencing each EST in both directions (i.e., sequence both strands of cDNA) . The sequences, constructs, vectors, clones, and other materials comprising the present invention can advantageously be in enriched or isolated form. As used herein, "enriched" means that the concentration of the material is at least about 2, 5, 10, 100, or 1000 times its natural concentration (for example) , advantageously 0.01%, by weight, preferably at least about 0.1% by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated. Further, removal of clones corresponding to ribosomal RNA and "housekeeping" genes and clones without human cDNA inserts results in a library that is "enriched" in the desired clones. The term "isolated" requires that the material be removed from its original environment (e.g., the natural environment if it is naturally occurring) . For example, a naturally- occurring polynucleotide present in a living animal is not isolated, but the same polynucleotide, separated from some or all of the coexisting materials in the natural system, is isolated. It is also advantageous that the sequences be in purified form. The term "purified" does not require absolute purity; rather, it is intended as a relative definition. Individual EST clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. The sequences obtained from these clones could not be obtained directly either from the library or from total human DNA. The cDNA clones are not naturally occurring as such, but rather are obtained via manipulation of a partially purified naturally occurring substance (messenger RNA) . The conversion of mRNA into a cDNA library involves the creation of a synthetic substance (cDNA) and pure individual cDNA clones can be isolated from the synthetic library by clonal selection. Thus, creating a cDNA library from messenger RNA and subsequently isolating individual clones from that library results in an approximately 10 6 -fold purification of the native message. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. In a cDNA library there are many species of mRNA represented. Each cDNA clone can be interesting in its own right, but must be isolated from the library before further experimentation can be completed. In order to sequence any specific cDNA, it must be removed and separated (i.e. isolated and purified) from all the other sequences. This can be accomplished by many techniques known to those of skill in the art. These procedures normally involve identification of a bacterial colony containing the cDNA of interest and further amplification of that bacteria. Once a cDNA is separated from the mixed clone library, it can be used as a template for further procedures such as nucleotide sequencing. Although claims to large numbers of ESTs and corresponding sequences are presented herein, the invention is not limited to these particular groupings of sequences. Thus, individual sequences are considered as applicants' discoveries or inventions, as are subgroupings of sequences. All of the functional subgroupings set forth in the tables define groupings for which separate claims are contemplated as being within the scope of this invention. Moreover, in addition to claims to individual clones, it is intended that the present disclosure also support claims to numerical subgroupings. Thus, subgroupings of 50 ESTs (and corresponding sequences) are contemplated (e.g., SEQ ID NOS 1-50, 51-100, 101-150, etc.) as being within the scope of this invention, as are subgroupings of 5, 10, 25, 100, 200, and 300 ESTs and corresponding sequences. III. DNA Constructs The present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a sense or antisense orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example. Bacterial; pBs, phagescript, ΦX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukarγotic: pWLneo, pSV2cat, pOG44, pXTl, pSG (Stratagene); pSVK3, pBPV, pMSG, pSVL (Pharmacia). Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lad, lacZ, T3, T7, gpt, lambda P R , and trc. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. In a further embodiment, the present invention relates to host cells containing the above-described construct. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a procaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE dextran mediated transfection, or electroporation (Davis, L. , Dibner, M. , Battey, I., Basic Methods in Molecular Biology, (1986)). The constructs in host cells can be used in a conventional manner to produce the gene product coded by the recombinant sequence. Alternatively, the encoded polypeptide can be synthetically produced by conventional peptide synthesizers. Certain ESTs have already been preliminarily categorized by analogy to related sequences in other organisms (see Table 2) . Table 10 of Example 8 categorizes particular ESTs broadly as metabolic, regulatory, and structural sequences where known. Constructs comprising genes or coding sequences corresponding to each of these categories are, therefore, specifically and individually contemplated. Table 11 more particularly separates 27 new ESTs into 11 categories using a different criteria. These are genes related to cell surface; developmental control; energy metabolism; kinase and phosphatase; oncogenes; peptidases and peptidase inhibitors; receptors; structural and cytoskeletal; signal transduction; transcription, translation, and subcellular localization; and transcription factors. Table 11 further identifies the EST by the particular gene product for which it apparently codes. Each of these categories individually comprises a preferred category of EST, and preferred constructs and resulting polypeptide can be prepared from those ESTs or the corresponding complete gene sequence. IV. ESTs and corresponding Sequences as Reagents Each of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. The sequences can be used as diagnostic probes for the presence of a specific mRNA in a particular cell type. In addition, these sequences can be used as diagnostic probes suitable for use in genetic linkage analysis (polymorphisms) . Further, the sequences can be used as probes for locating gene regions associated with genetic disease, as explained in more detail below. The EST and complete gene sequences of the present invention are also valuable for chromosome identification. Each sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. The present invention constitutes a major expansion of available chromosome markers. Using the techniques described in Example 3 or 4, ESTs and their corresponding complete sequences can be mapped to chromosomes. The mapping of ESTs and cDNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease. Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the ESTs. Computer analysis of the ESTs is used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids .containing the human gene corresponding to the EST will yield an amplified fragment. PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular EST to a particular chromosome. Three or more clones can be assigned per day using a single thermal cycler. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map an EST to its chromosome include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific cDNA libraries. Results of mapping ESTs to chromosomal segments are listed in Tables 3 and 4. Fluorescence in situ hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with cDNA as short as 500 or 600 bases; however, clones larger than 2,000 bp have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. FISH requires use of the clone from which the EST was derived, and the longer the better. 2,000 bp is good, 4,000 is better, and more than 4,000 is probably not necessary to get good results a reasonable percentage of the time. For a review of this technique, see Ver a et al. , Human Chromosomes: a Manual of Basic Techniques; Pergamon Press, New York (1988) . Reagents for chromosome mapping can be used individually (to mark a single chromosome or a single site on that chromosome) or as panels of reagents (for marking multiple sites and/or multiple chromosomes) . Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping (see Tables 8 and 9) . Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library) . The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes) . Next, it is necessary to determine the differences in the cDNA or genomic sequence between affected and unaffected individuals. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease. With current resolution of physical mapping and genetic mapping techniques, a cDNA precisely localized to a chromosomal region associated with the disease could be one of between 50 and 500 potential causative genes. (This assumes l megabase mapping resolution and one gene per 20 kb.) Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that cDNA sequence. Ultimately, complete sequencing of genes from several individuals is required to confirm the presence of a mutation and to distinguish mutations from polymorphisms. In addition to the foregoing, the sequences of the invention, as broadly described, can be used to control gene expression through triple helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide sequence to DNA or RNA. Polynucleotides suitable for use in these methods are usually 20 to 40 bases in length and are designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al, Nucl. Acids Res. 6: 3073 (1979) ; Cooney et al, Science 241: 456 (1988); and Dervan et al. Science 251: 1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neuroche . 56: 560 (1991) ; Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be efficient in model systems. Information contained in the sequences of the present invention is necessary for the design of an antisense or triple helix oligonucleotide. The present invention is also a useful tool in gene therapy, which requires isolation of the disease-associated gene in question as a prerequisite to the insertion of a normal gene into an organism to correct a genetic defect. The high specificity of the cDNA probes according to this invention have promise of targeting such gene locations in a highly accurate manner. The sequences of the present invention, as broadly defined, are also useful for identification of individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current 1imitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP. However, RFLP is a pattern based technique, which does not directly focus on the actual DNA sequence of the individual. The sequences of the present invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA. One can, for example, take an EST of the invention and prepare two PCR primers from the 5' and 3' ends of the EST. These are used to amplify an individual's DNA, corresponding to the EST. The amplified DNA is sequenced. Panels of corresponding DNA sequences from individuals, made this way, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences, due to allelic differences. The sequences of the present invention can be used to particular advantage to obtain such identification sequences from individuals and from tissue, as explained in Examples 10 - 12. The EST sequences from Example 1 and the complete sequences from Example 11 uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Each of the ESTs or complete coding sequences comprising a part of the present invention can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences of Table 9 for example, could comfortably provide positive individual identification with a panel of perhaps 100 to 1,000 primers which each yield a noncoding amplified sequence of 100 bp. If predicted coding sequences, such as those from Table 6, are used, a more appropriate number of primers for positive individual identification would be 500-2,000. If a panel of reagents from ESTs or complete sequences of this invention is used to generate a unique ID database for an individual, those same reagents can later be used to identify tissue from that individual. Positive identification of that individual, living or dead can be made from extremely small tissue samples. Another use for DNA-based identification techniques is in forensic biology. PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc. In one prior art technique, gene sequences are amplified at specific loci known to contain a large number of allelic variations, for example the DQα class II HLA gene (Erlich, H. , PCR Technology, Freeman and Co. (1992)) . Once this specific area of the genome is amplified, it is digested with one or more restriction enzymes to yield an identifying set of bands on a Southern blot probed with DNA corresponding to the DQα class II HLA gene. The sequences of the present invention can be used to provide polynucleotide reagents specifically targeted to additional loci in the human genome, and can enhance the reliability of DNA-based forensic identifications. Those sequences targeted to noncoding regions (see, e.g.. Tables 8 and 9) are particularly appropriate. As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Reagents for obtaining such sequence information are within the scope of the present invention. Such reagents can comprise complete ESTs or corresponding coding regions, or fragments of either of at least 15 bp, preferably at least 18 bp. There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the ESTs or complete sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue culture for contamination. V. Production of Polypeptide Corresponding to ESTs As previously explained, each EST corresponds not only to a coding region, but also to a polypeptide. Once the coding sequence is known, or the gene is cloned which encodes the polypeptide, conventional techniques in molecular biology can be used to obtain the polypeptide. At the simplest level, the amino acid sequence encoded by the polynucleotide sequence can be synthesized using commercially available peptide synthesizers. This is particularly useful in producing small peptides and fragments of larger polypeptides. (Fragments are useful, for example, in generating antibodies against the native polypeptide.) Alternatively, the DNA encoding the desired polypeptide can be inserted into a host organism and expressed. The organism can be a bacterium, yeast, cell line, or multicellular plant or animal. The literature is replete with examples of suitable host organisms and expression techniques. For example, naked polynucleotide (DNA or mRNA) can be injected directly into muscle tissue of mammals, where it is expressed. This methodology can be used to deliver the polypeptide to the animal, or to generate an immune response against a foreign polypeptide (Wolff, et al., Science 247:1465 (1990); Feigner, et al., Nature 349:351 (1991). Alternatively, the coding sequence, together with appropriate regulatory regions (i.e., a construct), can be inserted into a vector, which is then used to transfect a cell. The cell (which may or may not be part of a larger organism) then expresses the polypeptide. (See Example 23.) Antibodies generated against the polypeptide corresponding to a sequence of the present invention can be obtained by direct injection of the naked polypeptide into an animal (as above) or by administering the polypeptide to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptide itself. In this manner, even a sequence encoding only a fragment of the polypeptide can be used to generate antibodies binding the whole native polypeptide. Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide. Moreover, a panel of such antibodies, specific to a large number of polypeptides, can be used to identify and differentiate such tissue. VI. Examples Certain aspects of the present invention are described in greater detail in the non-limiting Examples that follow. EXAMPLE 1 cDNA Sequences Determined by Random Clone Selection: First set METHODOLOGY: With reference to the data presented in Table 1, lambda ZAP libraries were converted en masse to pBluescript plasmids, transfected into E. coli XLl-Blue cells, and plated on X- gal/IPTG/ampicillin plates. A total of 1058 clones were picked at random from three human brain cDNA libraries: fetal brain, two-year-old hippocampus, and two-year-old temporal cortex (Stratagene catalog #936206, 936205, 935, respectively. Stratagene, 11099 N. Torrey Pines Rd., La Jolla, CA 92037). An analysis of these clones is summarized in Table I (see below) In addition, clones selected from the hippocampus library were also analyzed after subtractive hybridization with the fibroblast library. These results are listed in the "Hippocampus Subtracted" column of Table 1. Templates for DNA sequencing were PCR products or plasmids prepared by the alkaline lysis method. About half of the templates prepared by PCR failed to yield an amplified fragment suitable for sequencing. This was primarily due to use of PCR conditions that minimized the need for further purification of the product but also selected against amplification of long inserts (5 μl fresh or frozen overnight culture of E. coli carrying the pBluescript plasmid, 7.5 μM each dNTP, and 0.1 μ each primer for 35 cycles: 94°C, 40 sec; 55°C, 40 sec; 72°C, 90 sec) . A further percentage of the PCR-generated templates failed to sequence, largely due to primer-dimer or other amplification artifacts. QiagenN columns improved the percentage of plasmid templates, increasing the yields of usable sequence from about 60% with a standard alkaline lysis protocol to over 90%. Overall, 117 PCR-generated templates and 497 plasmid templates resulted in usable sequence. Dideoxy chain termination sequencing reactions were performed with fluorescent dye-labeled M13 universal or reverse primers. After a cycle sequencing protocol, carried out in a Perkin- Elmer thermal cycler, sequencing reactions were run on an Applied Biosystems, Inc. (Foster City, CA) 373A automated DNA sequencer. (Cycle sequencing was performed in a Perkin Elmer Thermal Cycler for 15 cycles of 95°C, 30 sec; 60°C, 1 sec; 70 β C, 60 sec and 15 cycles of 95°C, 30 sec; 70 β C, 60 sec with the Applied Biosystems, Inc. Taq Dye Primer Cycle Sequencing Core Kit protocol) . Some sequencing reactions were performed on an ABI robotic workstation (Cathcart, Nature 347: 310 (1990) hereby incorporated by reference) . RESULTS: Singe-run DNA sequence data were obtained from 609 randomly chosen cDNA clones. The number of clones sequenced from each library is summarized in Table 1. Double-stranded cDNA clones in the pBluescript vector were sequenced by a cycle sequencing protocol with dye-labeled primers and Applied Biosystems, Inc. 373A DNA Sequences. The average length of usable sequence was 397 bases with a standard deviation of 99 bases. Subtractive hybridization has been used successfully to reduce the population of highly represented sequences in a cDNA library by selectively removing sequences shared by another library. (Schmid and Girou, Neurochem. 48: 307 (1987); Fargnoli et al, Anal. Biochem. 187: 364 (1990); Duguid and Dinauer, Nucl. Acids. Res. 18: 2789 (1990); Schweinfest, et al, Genet. Anal. Techn. Appl. 7: 64 (1990); Travis and Sutcliffe, Proc. Natl. Acad. Sci. USA 85: 1696 (1988); Kato, Eur. J. Neurosci. 2: 704 (1990)). Subtractive hybridization was therefore tested as a way of enhancing the number of brain-specific clones in the hippocampus library by hybridizing the hippocampus library with a WI38 human lung fibroblast cell line cDNA library and removing the common sequences (Schweinfest et al. Genet. Anal. Techn. Appl. 7: 64 (1990); Sive and St. John, Nucl. Acids Res. 16: 10937 (1988)). Clones from this subtraction are listed in the column "Hippocampus Subtracted" in Table 1. The EST sequences from this Example 1 are identified as SEQ ID NOs 1-315. TABLE 1. cDNA Library Composition Determined By Random Clone Sequencing EXAMPLE 2 EST Characterization: First Set ESTs including SEQ ID NOs 1-315 were analyzed as follows. Initially, the EST sequences were examined for similarities in the GenBank nucleic acid database (GenBank Release 65.0), Protein Information Resource Release 26.0 (PIR) , and ProSite (MacPattern from the EMBL data library, Fuchs R. Comput. Appl. Biosci. 7: 105 (1990) Release 5.0 were used). BLAST was used to search Genbank and the PIR (both maintained by the National Center for Biotechnology Information) ESTs without exact GenBank matches were translated in all six reading frames and each translation was compared with the protein sequence database PIR and the ProSite protein motif database. Comparisons with the ProSite motif database were done by means of the program MacPattern from the EMBL Data Library. GenBank and PIR searches were conducted with the "basic local alignment search tool" programs for nucleotide (BLASTN) and peptide (BLASTX) comparisons (Altschul et al, J. Mol. Biol. 215: 403 (1990)). PIR searches were run on the National Center for Biotechnology Information BLAST network service. The BLAST programs contain a very rapid database-searching algorithm that searches for local areas of similarity between two sequences and then extends the alignments on the basis of defined match and mismatch criteria. The algorithm does not consider the potential gaps to improve the alignment, thus sacrificing some sensitivity for a 6-80 fold increase in speed over other database-searching programs such as FASTA (Pegarson and Lipman, Proc. Natl. Acad. Sci. USA, 85: 2444 (1988)). Sequence similarities identified by the BLAST programs were considered statistically significant with a Poisson P- value than 0.01. The Poisson P-value less than the probability of as high a score occurring by chance given the number of residues in the query sequence and the database. After the BLASTN search, 30 unmatched ESTs were compared against GenBank by FASTA to determine if significant matches were missed due to the use of BLASTN for the database search. No additional statistically significant matches were found. Statistical significance does not necessarily mean functional similarity; some of the reported matches may indicate the presence of a conserved domain or motif or simply a common protein structure pattern. Those ESTs identified as fully corresponding to known human genes or proteins are not included in this disclosure. Statistically significant matches are reported in Table 2, together with the length and percent identity or similarity of each alignment. On the basis of database searches, 609 EST sequences were classified into eight groups as shown in Table 1 (see Example 1 above) . Four groups, with 197 or 32% of the sequences, consist of matches to human sequences: repetitive elements, mitochondrial genes, ribosomal RNA genes, and other nuclear genes. Forty-eight (8%) of the sequences matched non-human entries in GenBank or PIR while 230 (38%) had no significant matches. The remaining 134 (22%) sequences contained no insert or consisted entirely of polyA between the EcoRI cloning sites. Thirty-six ESTs matched previously sequenced human nuclear genes with more than 97% identity. Four of these ESTs are from genes encoding enzymes involved in maintaining metabolic energy, including ADP/ATP translocase, aldolase C, hexokinase, and phosphoglycerate kinase. Human homologs of genes for the bovine mitochondrial ATP synthase F 0 B-subunit and porcine aconitase were also found (Table 2) . Brain- specific cDNAs included synaptophysin, glial fibrillary acidic protein (GFAP) , and neurofilament light chain. At least six ESTs are from genes encoding proteins involved in signal transduction: 2' ,3'-cyclic nucleotide 3'-phosphodiesterase (2 ESTs), calmodulin, c-erbA-α-2, G s α, and Na + /K* ATPase α-subunit. Other ESTs were matches to genes for ubiquitous structural proteins — actins, tubulins, and fodrin (non-erythroid spectrin) . ESTs also document the presence in the hippocampus cDNA library of the ret proto-oncogene, the ras-related gene rhoB, and one of the chromosome 22 breakpoint cluster region transcripts. Eight ESTs are from genes known to be associated with genetic disorders (Online Mendelian Inheritance in Manl . More than half of the human-matched ESTs from Example 1 have been mapped to chromosomes, indicating the bias of GenBank entries toward well-studied genes and proteins. ESTs without significant GenBank matches were also compared to the ProSite database of recognized protein motifs. Not counting post-translational-modification signatures, fifty-four sequences contained motifs from the database. Some patterns, particularly the "leucine zipper", are found in scores or hundreds of proteins that do not share the functional property implied by the presence of the motif. Similarities to sequences from other organisms were also detected in the BLAST searches of GenBank and PIR (Table 2) . Several ESTs displayed similarity to "housekeeping" genes, including the ribosomal proteins S10 and L30 (rat) and the above glycolytic enzymes. EST00257 (SEQ ID NO:77) shows strong nucleotide sequence similarity to the squid (67%) and Drosophila (70.4%) kinesin heavy chain. Kinesin was first described as a microtubule-associated motor protein involved in organelle transport in the squid giant axon (Vale et al, Cell 42: 39 (1985)). Six oncogene-related sequences were also among the cDNA clones sequenced. EST00299 (SEQ ID NO:180) and EST00283 (SEQ ID NO:271) show similarity to several ras- related genes and EST00248 (SEQ ID NO:102) matched the 3' untranslated region of the bovine substrate of botulinum toxin ADP-ribosyltransferase. Similarities with an S. cerevisiae RNA polymerase subunit and Torpedo electromotor neuron- associated protein were also observed. Two ESTs may represent new members of known human gene families: EST00270 matched the three β-tubulin genes with 88-91% identity and EST00271 (SEQ ID NO:248) matched α-actinin with 85% identity at the nucleotide level. Among the most interesting of the primary sequence relationships was the similarity of ESTs to the Drosophila genes Notch and Enhancer of split. Nucleotide and peptide alignments of EST00256 (SEQ ID NO:188) and EST00259 (SEQ ID NO:227) with the Drosophila genes have been demonstrated. Both genes are part of a signal cascade encoded by the "neurogenic" genes that are involved in the differentiation of neuronal and epidermal cell lineages in the neuroectoderm of the developing Drosophila embryo (Campos-Ortega, Trends in Neuro. Sci. 11: 400 (1988)) . It has been proposed that the Enhancer of split protein interacts with a membrane protein that is the product of the Notch gene to convert a developmental signal into an altered pattern of gene expression (id. J. Mol. Biol. 215: 403 (1990)). EST00256 (SEQ ID NO:188) matches near the 5' end of the Enhancer of split coding sequence, away from the mammalian G protein β subunit- and yeast cdc4-like elements (Hartley et al. Cell 55: 785 (1988); Klambt et al. EMBO J. 8: 203 (1989)). Part of the EST00259 (SEQ ID NO:227) match to Notch in the cdclO/SW16 region that is similar to three cell-cycle control genes in yeast and is tightly conserved in the Xenopus Notch homolog, Xotch. In Drosophila, Enhancer of split is absolutely required for formation of epidermal tissue. Notch contains several epidermal growth factor-like repeats and appears to play a general role in cell-cell communication during development (Banerjee and Zipursky, Neuron 4:177 (1990) ) . Seven genes were represented by more than one EST. Comparisons of all the ESTs against one another revealed two overlaps of unknown ESTs: EST00233 (SEQ ID NO:32) and EST00234 (SEQ ID NO:8) match in opposite orientations and EST00235 (SEQ ID NO:204) and EST00236 (SEQ ID NO-.148) match in the same orientation beginning at the same nucleotide. Five human genes were represented by more than one EST: β-actin (3) , λ-actin (2) , α-tubulin (2) , α-2-macroglobulin (2) , and 2'3'-cyclic-nucleotide-3'-phosphodiesterase (2). Those few instances where two or more ESTs represent different portions of a single cDNA can be readily ascertained when the sequence of the full cDNA insert is determined in accordance with Example 11. Table 2: ESTs Identified by Database Hatches There is little redundancy in EST sequencing according to the present invention. Of the nuclear-encoded messenger RNAs, the most common ESTs were to the -actin (approximately 0.6% of the EST clones) and myelin basic protein genes (MBP, approximately 0.5% of the clones). MBP, a highly expressed structural component of nerve tissue (Kamholtz, J. , de Ferra, F. , Puckett, C. , & Lazzarini, R. Proc. Natl. Acad. Sci., USA 83: 4962-4966 (1986)), displays four alternate splicing forms, of which it is believed at least two are present among the ESTs reported here. Other common ESTs were Gs-alpha gamma-actin and both a- and alpha- tubulin. By matching ESTs to known database sequences, a phenotypic characterization of the tissue begins to emerge. Protein superfamilies matched by ESTs were grouped into three broad functional categories to assess the biological spectrum represented by these randomly selected cDNA clones. Structural and metabolic classes comprised about 30% of the ' ESTs with database matches. Twenty-five percent were involved in regulatory pathways and the remainder were not classifiable. In addition, it is believed that several genes not previously known to be expressed in the brain were matched, including spermine/spermidine acetyltransferase (Casero, R. , Celano, P, Ervin, S., Applegren, N. , Wiest, L. & Pegg, A. J. Biol. Chem. 266: 810-814 (1991)) and osteopontin (Young, M. , Kerr, J., Termine, J., Wewer, U. , Wang, M. , McBride, W. & Fisher, L. Genomics 7:491-502 (1990) ) . EXAMPLE 3 Mapping of ESTs to Human Chromosomes Randomly selected ESTs corresponding to Sequence Identification numbers were assigned to chromosomes via PCR (see Table 3) . Oligonucleotide primer pairs were designed from EST sequences to minimize the chance of amplifying through an intron. The oligonucleotides were 18-23 bp in length and designed for PCR amplification using the computer program INTRON (National Institutes of Mental Health, Bethesda, MD) . The program is based on the assumptions that: 1) introns are genomic sequences that interrupt the coding and noncoding sequences of genes (Smith, J. Mol. Evol. 27:45-55 (1988)); 2) there are consensus sequences for splice junctions (Shapiro, et al., Nucl. Acids Res. 15:7155-7174 (1987)); and 3) that 90% of the human genes studied have 3' untranslated regions of mRNA not interrupted by introns in the genomic DNA (Hawkins, Nucl. Acids Res. 16:9893-9908 (1988)). The program evaluates the likelihood that a given GG or CC dinucleotide represents a former exon-intron boundary. Specifically, every input strand is processed by the INTRON program twice, first evaluating the sense mRNA strand, and then processing the complementary or anti-sense strand. The program evaluates each sequence by finding all GG or CC pairs (possible former splice sites) , searching for STOP codons in all three reading frames, and analyzing the GG or CC pairs surrounded by stop codons. All regions of the EST that are unlikely to contain splice junctions based on CC content, GG content, and stop codon frequency are then marked by the program in uppercase. The creation of PCR primers from known sequences is well known to those with skill in the art. For a review of PCR technology see Erlich, H.A. , PCR Technology; Principles and Applications for DNA Amplification. 1992; W.H. Freeman and Co., New York. ESTs were examined for the presence of stop codons in each reading frame and for consensus splice junctions. The presence of stop codons and absence of splice junction sequences are more characteristic of 3' untranslated sequences than of introns. The untranslated sequences are unique to a given gene; thus, primers from these regions are less likely to prime other members of a gene family or pseudogenes. The primers were used in polymerase chain reactions (PCR) to amplify templates from total human genomic DNA. PCR conditions were as follows: 60 ng of genomic DNA was used as a template for PCR with 80 ng of each oligonucleotide primer, 0.6 unit of Tag polymerase, and 1 uCu of a 32 P-labeled deoxycytidine triphosphate. The PCR was performed in a microplate thermocycler (Techne) under the following conditions: 30 cycles of 94°C, 1.4 min; 55°C, 2 min; and 72°C, 2 min; with a final extension at 72°C for 10 min. The amplified products were analyzed on a 6% polyacrylamide sequencing gel and visualized by autoradiography. If the size of the resulting product was equivalent to the EST from which the primers are derived, then the PCR reaction was repeated with DNA templates from two panels of human-rodent somatic cell hybrids; BIOS PCRable DNA (BIOS Corporation) and NIGMS Human-Rodent Somatic Cell Hybrid Mapping Panel Number 1 (NIGMS, Camden, NJ) . PCR was used to screen a series of somatic cell hybrid cell lines containing defined sets of human chromosomes for the presence of a given EST. DNA was isolated from the somatic hybrids and used as starting templates for PCR reactions using the primer pairs from EST sequences selected above. Only those somatic cell hybrids with chromosomes containing the human gene corresponding to the EST will yield an amplified fragment. ESTs were assigned to a chromosome by analysis of the segregation pattern of PCR products from hybrid DNA templates. For a review of techniques and analysis of results from somatic cell gene mapping experiments. (See Ledbetter et al., Genomics 6:475- 481 (1990).) The single human chromosome present in all cell hybrids that give rise to an amplified fragment represents the chromosome containing that EST. The assignment of 81 ESTs and corresponding genes to chromosomes by PCR is shown in Table 3. Table 3: Assignment of ESTs to Chromosomes by PCR SE D # Chr PRIMER #1 PRIMER #2 9 TCTGGGCTTCTGTGGTTCAA CTGGCTGCTCAGCAACTCAT 10 AGCTGTTCCTGAGAGATGCA CCTTGTGAAGAAAGACTTTC 10 TCAGCAACAGGTCACTTTGG CTAAGCATCTGCATGTCCAG 10 TACTAGCATTTCTTACTCTC TATGCTGATTGTTTGCACTC 10 GGTGATTAGAGAGTCTGTTG GAACTCTGTAGTGTTCTAAA 11 GGAAATTAGGCTTAGCTCAC GTGCAGAATACTTAGAGTCC 11 GTTTGAAGGAAGTGATTTCC TAGGGCCACCTCCAGTTCAT 11 GTCTTTGGATTCTACGTAGA CGATAATGACATTTCTTCTGG 11 AL2-CTAACCACAACCCACACATTG CCTCAGCACAAGAGAAGAATGG 12 AACTTGCAACATAAATACTAG GAGCAATGATTTCTAACAGT 13 TTGTGTACTGTCTGATAGAC TAAGCCATGGGCATCTATAA 14 GGTGCTTAAGGCCACTTTTG CTTAGAGGATCATAGGTCTG 14 CCAGGAGAGTAAGAAGATCA GCAGAGTTGAATATGAACCT 14 GTGCCAAGATGGCTCATGTA GTATAGCTTTAAGCCAGTTC 14 AATGCATTATGCCTGGTCTT GGAAAAGTCTAGAACTTAGT 14 AAGCTGGCTGGGAAATGTTC GTCATGCTAGTAAACTTACAC 15 GTGACAGACCATGTCTATTG AAGTGAGCGATTGCACCTTC 15 AGGATGACCTGAGTGAGCTG CCATGGCAGCAAGGAACTCT 16 TGTGTGAAAGGGAGTCTTGT CCATTTTGACTGTTCCATAG 16 TGGCTAGGGCAGGCCTTAAA GAGAAGAATATCAAATGGGG 16 CCATCTGTGTCCCAATTAAGC AGGGAAGAAGTCTAGAGCGA 17 CAAAGACGGGAGACGAATGA AGTGGAACGCGTGGCCTATG 19 AGAGATGTCAGTCCATTATC CTATTCCACCTTACTCAAGG 19 CATCATGTCGGAGACGCATT TGGATGACCTGAGTCTGCAG 20 AGTTCTGGAGGCTAGGAGTT ATGTAAGGACCCCTAGATGG 20 TGTCAACTTCCCTTTGGCCT GAAGCTTGCTCATTCAGGAA 20 AL2-TCGGAGAAGTTGCAGTTTCTG GTTAAAAGCTGTTAGACGGGGC 22 CACTGACTGACTCCTCTTTA GGAACCGTAACTCTCCATAG X ATTGACCTTCAATGTAATAA TTGGATTGGGCAAAATAG X ATGTGAGCATCTATACCTGC AATGAAGGCATGAGAATAGG Abbreviation: AL2 : Amino-Link-2 Fluorescent Tag, Chr.: Chromosome. T The foregoing techniques have been used to further localize 6 ESTs and their associated genes to precise locations onto chromosome 6 or chromosome X, as reflected in Table 4 (in Example 5 below) , using sublocalization techniques that employ somatic cell hybrids. ESTs were used as hybridization probes and mapped to other chromosomes using techniques disclosed in Example 5. Somatic cell hybrids were prepared that contained defined subsets of chromosomes 6 and X. Methods for preparing and selecting somatic cell hybrids are known in the art. For a review of an exemplary procedure to generate somatic cell hybrids containing the short arm of human chromosome 6, see Zoghbi, et al., Genomics 9(4):713-720 (1991). For a general review of somatic cell hybridization see Ledbetter et al. (supra) . The hybrids were processed to obtain DNA and analyzed by PCR and by fluorescence in situ hybridization. SEQ ID NOs 19, 22, 1, 224, 288 mapped to chromosome 6, while SEQ ID NO 162 mapped to chromosome X using somatic cell hybrids. EXAMPLE 4 Mapping of All ESTs to Human Chromosomes The procedure of Example 3 is repeated for all of the ESTs from Example l not previously mapped to human chromosomes. Data are generated corresponding to the data in Table 3 for all of the unmapped ESTs. As previously mentioned, virtually all of the ESTs will map to a unique chromosomal location. The inability of any ESTs to localize to a unique location will be readily ascertainable during the mapping process. EXAMPLE 5 Alternative Technigue for Mapping to Chromosomes Mapping of ESTs to chromosomes using fluorescence in situ hybridization This technique is used to map an EST to a particular location on a given chromosome. Cell cultures, tissue, or whole blood can be used to obtain chromosomes. 0.5 ml. of whole blood is added to RPMI 1640 and incubated 96 hours in a 5%C0 2 /37 β C incubator. 0.05 ug/ml colcemide is added to the culture one hour before harvest. Cells are collected and washed in PBS. The suspension is incubated with a hypotonic solution of KC1 added dropwise to reach a final volume of 5 ml. The cells are spun down and fixed by resuspending the cells in methanol and glacial acetic acid (3:1). The cell suspension is dropped onto glass slides and dried. The slides are then treated with RNase A and washed then dehydrated in a series of increasing concentrations of ethanol. The EST to be localized is nick-translated using fluorescently labeled nucleotide (Korenberg, Jr., et al., Cell 53(3) :391-400 (1988)). Following nick translation, unincorporated label is removed by spin dialysis through Sepharose. The probe is further extracted with phenol-chloroform to remove additional protein. The chromosomes are denatured in formamide using techniques known in the art and the denatured probe added to the slides. Following hybridization, the cells are washed. The slides are studied under a fluorescent microscope. In addition, the chromosomes can be stained for G-banding or Q-banding using techniques known in the art. The resulting metaphase chromosomes have fluorescent tags localized to those regions of the chromosome that are homologous to the EST. Thus, a particular EST is localized to a particular region on a given chromosome. For a review of the technique, see Verma et al., Human Chromosomes: A Manual of Basic Techniques. Pergamon Press, NY (1988) , which is hereby incorporated by reference. Table 4: Precise Chromosomal Localization of ESTs EXAMPLE 6 Automated DNA Sequencing Accuracy ESTs that match human sequences in GenBank are excellent tools for the analysis of the accuracy of double- strand automated DNA sequencing. EST/GenBank matches from a number of clones were examined for the number of nucleotide mismatches and gaps required to achieve optimal alignment by the Genetics Computer Group (GCG) program BESTFIT (Devereux et al, Nucleic Acids Research 12: 387 (1984)). The number of mismatches, insertions and deletions was counted for each hundred bases of the sequence (Table 5) . As expected, the sequence quality was best closest to the primer and decreased rapidly after about 400 bases. The number of deletions and insertions relative to the GenBank reference sequence increased five- to ten-fold beyond 400 bases, while the number of mismatches doubled. The average accuracy rate for individual double-stranded sequencing runs was 97.7% to 400 bases. TABLE 5. Accuracy Of Single-Run Double-Stranded Automated Sequencing ESTs statistically identical to known human sequences and those matching mitochondrial and ribosomal genes were aligned with sequenced from GenBank using the GCG program BESTFIT. The first 85 nucleotides was polylinker sequence which was not aligned with the pBluescript SK reference sequence. Tabulation of errors began 15 bases into the BESTFIT alignment and thus is reported beginning with bases 101-200. Error rates are reported as number of mismatches, insertions, or deletions per hundred aligned bases. "Mismatches" includes ambiguous base calls. EXAMPLE 7 Probability of ESTs Containing Coding Sequences The ESTs of the present invention were statistically evaluated using the coding-region prediction program CRM via the GRAIL server (Uberbacher, E. & Mural, R. Proc. Natl. Acad. Sci. USA, 88: 11261-5 (1991)). The CRM program uses a neural network to combine results from several different coding regions by looking at different 6 bp sequences found in coding exons and in introns. The program additionally conducts reading frame searches and assesses randomness at the third position of codons. This protocol categorizes sequences as having an excellent, good, marginal, or poor probability of containing coding regions. The results are reported in Tables 6-9. There were 32 ESTs categorized as "excellent" (Table 6) ; 14 categorized as "good" (Table 7) ; 13 categorized as "marginal" (Table 8) ; and 213 categorized as "poor" (Table 9) . These results indicate that most ESTs of the present invention comprise noncoding regions. Table 6: ESTs with Excellent Probability of Containing Coding Sequence Table 7: ESTs with Good Probability of Containing Coding Sequence Table 8 : ESTs with Marginal Probability of Containing Coding Sequence Table 9: ESTs with Poor Coding Probability EXAMPLE 8 Functional Groupings of ESTs and Corresponding Genes By matching new human ESTs to known sequences from other species, the apparent function of the gene corresponding to the EST can be ascertained. The data generated in Example 2 have been used to categorize 28 of the ESTs of the present invention, and their corresponding genes, into predicted functional groups. (These 28 are ESTs with database matches to sequences from other species for which a function was known.) Two different grouping schemes have been used. The first scheme separates the sequences into three broad categories: metabolic; regulatory; and structural. These groupings are set out in Table 10. The second grouping scheme separates the sequences into 13 specific categories: cell surface proteins; developmental control; energy metabolism; kinases and phosphatases; oncogenes; other metabolism-related polypeptides; peptidases and peptidase inhibitors; receptors; structural and cytoskeletal; signal transduction; transporters; transcription, translation, and subcellular localization; and transcription factors. These groupings are set out in Table 11. Table 10: Three-Class Functional Groupings of ESTs Table 11: Thirteen-Class Functional Groupings of ESTs SEO ID ST Gro Putative Identification 60K filarial antigen Lysosomal membrane glycoprotein 1 (LAMP-1) Enhancer of split Maternal G10 protein Notch/Xotch Aconitase Fo ATPase beta subunit, mitochondrial Protein-tyrosine phosphatase LRP Transforming protein (dbl) ras p21-like small GTP-binding protein (smg GDS) rho H12/ ARH12 Prolyl endopeptidase trkB Actin, other Agrin Kinesin Kinesin Microtubule-associated protein IB Tubulin, beta MARCKS (myristoylated alanine-rich protein kinase smg p25A GDP dissociation inhibitor Processing enhancing protein RNA polymerase II 6th subunit (RPO26) Ribosomal protein L30 Ribosomal protein S10 Wilm's tumor-related protein Zinc Finger Proteins Group Key: CS: Cell Surface, DC: Developmental Control, EM: Energy Metabolism, KP: Kinases and Phosphatases, OG: Oncogenes, PI: Peptidases and Peptidase Inhibitors, RT: Receptors, SC: Structural and Cytoskeletal, ST: Signal Transduction, TT: Transcription, Translation, and Subcellular Localization, TX: Transcription Factors. EXAMPLE 9 cDNA Libraries Generated From Specific Genomic DNA by Exon Expression & Amplification Exon amplification is used to express potential exons from genomic DNA in a recombinant vector that contains some of the signals necessary for splicing. If an exon is present in the proper orientation in the vector, that exon will be spliced in a mammalian cell and will become part of the mRNA of that cell. The exon splice-product can be purified from other mRNA in the cell by conversion of the mRNA to cDNA and selective amplification of the recombinant splice-product cDNAs. Cosmid DNA from human chromosome 19ql3.3 is digested with Ba HI or BamHI/Bglll restriction enzymes. The fragments generated are collected and size specifically cloned into an expression vector (Buckler, et al. Proc. Nat'l. Acad. Sci. USA, 88:4005-4009 (1991)). After transfection by electroporation of these constructs into COS cells, RNA transcripts are generated using the SV40 early promoter and a polyadenylation signal derived from SV40 both present in the expression vector. When a fragment of genomic DNA contains an entire exon with flanking intron sequence in the sense orientation, the exon should be retained in the mature poly(A)+ cytoplasmic RNA. Therefore, the mRNA is used as template for cDNA synthesis using reverse transcriptase and vector-priming. Subsequently, the cDNAs are amplified by vector-priming using PCR. A fraction of this first PCR product is reamplified using internal vector-primers containing terminal cloning sites. These products are end- repaired with T4 DNA polymerase, digested with the appropriate restriction enzymes, gel purified and cloned into pBluescript vectors. The constructs are transfected into XLl-Blue competent cells and plated on LB/X-gal/IPTG/ampicillin plates. When multiple cosmids or YAC clones are used as the source DNA, a pool of specific expressed exons is obtained as a cDNA library. EXAMPLE 10 PCR Amplification from Predicted Exons Computational analyses can be applied to genomic DNA sequences to predict protein coding regions. The coding region prediction program CRM (E. Uberbacher and R. Mural, Proc. Natl. Acad. Sci. USA 88:11261-5 (1991)) finds open reading frames and classifies them according to their probability of being coding regions. These regions are subsequently examined using the GM program (C. Fields and C. Soderlund, Comp. Applic. Biosci. 6: 263, 1990), which predicts intron-exon structure. PCR primers are then designed to amplify the predicted exons and used to test human cDNA libraries (for example, fetal brain or placental libraries) for the presence of these putative exons using a PCR assay. This strategy has been successfully applied in two large scale genomic sequencing projects, the Huntington's locus of human chromosome 4pl6.3 (McCombie, et al., submitted) and human chromosome locus 19ql3.3 (Martin-Gallardo, et al., submitted) . EXAMPLE 11 Complete Sequence of EST Clone Inserts There are a number of methods known to those with skill in the art of molecular biology, to obtain sequence information from the cDNAs corresponding to the EST sequences. Procedures for these methods are provided in Basic Methods in Molecular Biology (David et al. supra) . One way to acquire more information about the cDNA from which an EST was derived is to sequence the remainder of the cDNA clone. The complete sequence of the inserts of four EST clones (representing SEQ ID NOs 188, 189, 223, and 227) was determined using Exonuclease III deletions. Briefly, EST clones were digested with the restriction enzymes Sail and Kpnl or Pstl and BamHI (for deletions from the Forward primer and Reverse primer ends of the insert, respectively) . The Kpnl and Pstl enzymes leave 3* sticky ends following digestion, which Exonuclease III is unable to bind. This results in unidirectional deletions into the cDNA insert leaving the vector sequence undisturbed. After addition of Exonuclease III to the Forward and Reverse deletion reactions, aliquots of the reaction were removed at defined time intervals and the reaction was stopped to prevent further deletion. SI nuclease and Klenow DNA polymerase were added to create blunt ended fragments suitable for ligation. Samples for each time point was purified by electrophoresis through an agarose gel and religated. Two to four representative clones from each time point in each direction were sequenced to give between 200 and 400 base pairs of sequence data. Careful selection of deletion conditions and time points allow a deletion series of approximately 100-200 base pairs difference in length at each consecutive time point. Sequence fragments were reassembled into a redundant contiguous sequence using the INHERIT software from Applied Biosystems, Inc. (Foster City, CA) . In this way, the complete insert from these four cDNA clones was sequenced on both strands to an average redundancy between three and four (each base was sequenced between three and four times, on average) . EXAMPLE 12 Determining Re ding Frame, Orientation, Coding Regions: ESTs and Complete cDNA Sequences Once the complete cDNA sequence has been determined in accordance with Example 11, the reading frame, orientation, and coding regions are determined by computer techniques. (The complete coding region is considered to be the largest open reading frame from a methionine to a stop codon.) Specifically, the CRM program on the GRAIL server is used as explained in Example 7 to determine probable coding regions. This information is supplemented by location of start and stop codons. Where possible, the results of the CRM analysis are validated by comparison of the cDNA sequence to known sequences using database matching, in accordance with Example 2. If a match of 50% (or even less) is found in any particular reading frame and orientation, this serves to verify corresponding CRM results. Alternatively, database matches can be used to determine reading frame and orientation without use of the CRM program. Of course, if the cDNA is derived from a directional library, the probable orientation is already known. EXAMPLE 15 Preparation of PCR Primers and Amplification of DNA The EST sequences and the corresponding cDNA sequences and genomic sequences may be used, in accordance with the present invention, to prepare PCR primers for a variety of applications. The PCR primers are preferably at least 15 bases, and more preferably at least 18 bases in length. The procedure of Example 3 is repeated using the desired EST, or using the corresponding cDNA or genomic DNA sequence from Example 11. It is preferred that the primer pairs have approximately the same G/C ratio, so that melting temperatures are approximately the same. When screening cDNA, introns are of no concern; however, when screening genomic DNA, primers should be selected to avoid reading across introns, which usually are too large to amplify. The PCR primers and amplified DNA of this Example find use in the Examples that follow. EXAMPLE 14 Forensic Matching bv DNA Sequencing In one exemplary method, DNA samples are isolated from forensic specimens of, for example, hair, semen, blood or skin cells by conventional methods. A panel of PCR primers derived from a number of the sequences of Example 1, 9, 10 and/or 11 is then utilized in accordance with Example 10 to obtain DNA of approximately 100-200 bases in length from the forensic specimen. Corresponding sequences are obtained from a suspect. Each of these identification DNAs is then sequenced, and a simple database comparison determines the differences, if any, between the sequences from the suspect and those from the sample. Statistically significant differences between the suspect's DNA sequences and those from the sample conclusively prove a lack of identity. This lack of identity can be proven, for example, with only one sequence. Identity, on the other hand, should be demonstrated with a large number of sequences, all matching. Preferably, a minimum of 50 statistically identical sequences of 100 bases in length are used to prove identity between the suspect and the sample. EXAMPLE 15 Positive Identification by DNA Sequencing The technique outlined in the previous example may also be used on a larger scale to provide a unique fingerprint-type identification of any individual. In this technique, primers are prepared from a large number of sequences from Examples 1, 9, 10 and/or 11. Preferably, 20 to 50 different primers are used. These primers are used to obtain a corresponding number of PCR-generated DNA segments from the individual in question in accordance with Example 13. Each of these DNA segments is sequenced, using the methods set forth in Example 1. The database of sequences generated through this procedure uniquely identifies the individual from whom the sequences were obtained. The same panel of primers may then be used at any later time to absolutely correlate tissue or other biological specimen with that individual. EXAMPLE 16 Southern Blot Forensic Identification The procedure of Example 15 is repeated to obtain a panel of from 10 to 2000 amplified sequences from an individual and a specimen. This PCR-generated DNA is then digested with one or a combination of, preferably, four base specific restriction enzymes. Such enzymes are commercially available and known to those of skill in the art. After digestion, the resultant gene fragments are size separated in multiple duplicate wells on an agarose gel and transferred to nitrocellulose using Southern blotting techniques well known to those with skill in the art. For a review of Southern blotting see Davis et al. (Basic Methods in Molecular Biology. 1986, Elsevier Press, pp 62-65). A panel of ESTs or complete cDNA sequences from Examples 1, and/or 11, or fragments thereof of at least 15 bases, are radioactively or colorimetrically labeled using end-labeled oligonucleotides derived from the ESTs, nick translated sequences or the like using methods known in the art and hybridized to the Southern blot using techniques known in the art (Davis et al., supra) . Preferably, at least 5 to 10 of these labeled probes are used, and more preferably at least about 20 or 30 are used to provide a unique pattern. The resultant bands appearing from the hybridization of a large sample of ESTs will be a unique identifier. Since the restriction enzyme cleavage will be different for every individual, the band pattern on the Southern blot will also be unique. Increasing the number of EST probes will provide a statistically higher level of confidence in the identification since there will be an increased number of sets of bands used for identification. EXAMPLE 17 Dot Blot Identification Procedure Another technique for identifying individuals using the sequences disclosed herein utilizes a dot blot hybridization technique. Genomic DNA is isolated from nuclei of subject to be identified. Oligonucleotide probes of approximately 30 bp in length were synthesized that correspond to sequences from the ESTs. The probes are used to hybridize to the genomic DNA through conditions known to those in the art. The oligonucleotides are end labelled with 32 P using polynucleotide kinase (Pharmacia) . Dot Blots are created by spotting about 50 ng cDNA of preferably at least 10 sequences corresponding to a variety of the Sequence ID NOs provided in Table 7 onto nitrocellulose or the like using a vacuum dot blot manifold (BioRad, Richmond California) . The nitrocellulose filter containing the EST clone sequences is baked or UV linked to the filter, prehybridized and hybridized with labeled probe using techniques known in the art (Davis et al. supra) . The 32 P labeled DNA fragments are sequentially hybridized with successively stringent conditions to detect minimal differences between the 30 bp sequence and the DNA. Tetramethyl mmonium chloride is useful for identifying clones containing small numbers of nucleotide mismatches (Wood et al., Proc. Natl. Acad. Sci. USA 82(6) :1585-1588 (1985) which is hereby incorporated by reference. A unique pattern of dots distinguishes one individual from another individuals. EXAMPLE 18 Alternative "Fingerprint" Identification Technique EST sequences and the corresponding complete cDNA sequences can be used to create a unique fingerprint for an individual. Thus pools of EST sequences can be used in forensics, paternity suits or the like to differentiate one individual from another. Entire EST sequences . can be used; similarly oligonucleotides can be prepared from EST sequences. In this example, 20-mer oligonucleotides are prepared from 200 EST sequences using commercially available oligonucleotide services such as Oligos Etc., Wilsonville, OR. Patient cell samples are processed for DNA using techniques well known to those with skill in the art. The nucleic acid is digested with restriction enzymes EcoRI and Xbal. Following digestion, samples are applied to wells for electrophoresis. The procedure, as known in the art, may be modified to accommodate polyacrylamide electrophoresis, however in this example, samples containing 5 ug of DNA are loaded into wells and separated on 0.8% agarose gels. The gels are transferred using Southern blotting techniques onto nitrocellulose. 10 ng of each of the oligos are pooled and end-labeled with 32 P. The nitrocellulose is prehybridized with blocking solution and hybridized with the labeled probes. Following hybridization and washing, the nitrocellulose filter is exposed to X-Omat AR X-ray film. The resulting hybridization pattern will be unique for each individual. It is additionally contemplated within this example that the representative number of EST sequences can be varied for additional accuracy or clarity. EXAMPLE 19 Identification of genes associated with hereditary diseases This example illustrates an approach useful for the association of EST sequences with particular phenotypic characteristics. In this example, a particular EST is used as a test probe to associate that EST with a particular phenotypic characteristic. A search of Mendelian Inheritance in Man (supra) revealed 6p21 to be a very gene rich region of the genome containing several known genes and several diseases for which genes have not been identified. Any cDNA encoded by an EST located in this region would thus becomes an immediate candidate for each of these genetic diseases. Cells from patients with these diseases are isolated and expanded in culture. PCR primers from the EST sequences are used to screen genomic DNA and RNA or cDNA from the patients. ESTs that are not amplified in the patients can be positively associated with a particular disease by further analysis. EXAMPLE 20 Identification of a gene associated with Angel an's disease Angelman's disease (AD) is characterized by deletions on the long arm of chromosome 15 (15qllql3) (Williams et al. Am. J. Med. Genet. 32:339-345 (1989) hereby incorporated by reference) . The symptoms of the disease include developmental delay, seizures, inappropriate laughter and ataxic movements. These symptoms suggest that the disorder is a neurologic deficiency. This prophetic example illustrates how ESTs, preferably obtained from a cDNA library from human brain, may be used in identifying the defective gene or genes associated with Angelman's Disease. (The example is based on analogous work with genomic DNA, rather than cDNA and ESTs, in identifying the genetic defect associated with Angelman's Disease.) This example also illustrates how EST sequences may generally be used for identifying gene sequences associated with an inherited disease that is mapped to a chromosome location. ESTs are screened using techniques described in Example 3 and Example 5 to identify those ESTs that localize to the long arm of chromosome 15 and preferably localize to chromosome 15 bands 15qllql3 from normal patients. ESTs that bind to the long arm of chromosome 15 are hybridized to chromosome 15 from AD patients. These studies are preferrably performed using either fluorescence in situ hybridization or using somatic cell hybrids that contain fragments from the long arm of chromosome 15 from AD patients. Those chromosome 15-specific ESTs that do not map to chromosome 15 from AD patients are useful as markers for Angelman's Disease and can be incorporated into diagnostics for genetic screening. These ESTs are associated with chromosome deletions present in Angelman's disease. Identification of the gene associated with these AD negative ESTs and an analysis of the polypeptides encoded by the genes from normal patients is essential for providing gene or other therapies for AD patients. Genetic diseases are not always accompanied by gene deletions. Therefore, it is also important to use the ESTs that bind to bands 15qllql3 from AD patients as tools to identify the polymorphisms present within the disease population. Restriction fragment length polymorphism (RFLP) analysis can be performed on patient cells from AD disease or from somatic cell hybrids created using the long arm of chromosome 15. For a review of RFLP techniques see Donis- Keller et al. (Cell 51:319-337 (1987) hereby incorporated by reference) . DNA is isolated from the somatic cell lines or from cells from AD patients. The DNA is digested with one or more restriction enzymes according to techniques of Donis- Keller et al. The resulting fragments are separated by gel electrophoresis, denatured, transferred to nitrocellulose and hybridized with the selected radio-labeled ESTs that localize to the region of interest. The autoradiographic pattern is compared both to a number of AD patients and to normal patients. Common patterns of EST hybridization in AD patients that are not present in normal patients indicates that the genes associated with these ESTs are candidate genes affected by AD. cDNA libraries are prepared from the somatic cell hybrids from AD patients. Libraries are prepared using Lambda Zap II Library Kits (Stratagene, La Jolla, California) or other commercially available library kits. The ESTs of interest are used as probes to identify those bacterial colonies carrying genes corresponding to the EST probes. Positive clones are sequenced and the sequences are compared to homologous gene sequences derived from normal patients. Alterations, including deletions and substitutions, within gene sequences, associated with bands 15qllql3, are thus positively identified and associated with AD disease. Wagstaff et al. were able to identify deletions and substitutions in sequences encoding the GABA A receptor protein subunit from patients with Angelman's disease (Am. J. Hum. Genet. 49:330-337, (1991)). It is likely that other genes will additionally be associated with the disease. EXAMPLE 21 Preparation and Use of Antisense Oligonucleotides Antisense RNA molecules are known to be useful for regulating translation within the cell. Antisense RNA molecules can be produced from EST sequences or from the corresponding gene sequences. These antisense molecules can be used as diagnostic probes to determine whether or not a particular gene is expressed in a cell. Similarly, the antisense molecules can be used as a therapeutic to regulate gene expression once the EST is associated with a particular disease (see Example 20) . The antisense molecules are obtained from a nucleotide sequence by reversing the orientation of the coding region with regard to the promoter. Thus, the antisense RNA is complementary to the corresponding mRNA. For a review of antisense design see Green et al., Ann. Rev. Biochem. 55:569- 597 (1986) , which is hereby incorporated by reference. The antisense sequences can contain modified sugar phosphate backbones to increase stability and make them less sensitive to RNase activity. Examples of the modifications are described by Rossi et al., Pharmacol. Ther. 50(2) :245-254, (1991) . Antisense molecules are introduced into cells "that express the gene corresponding to the EST of interest in culture. In a preferred application of this invention, the polypeptide encoded by the gene is first identified, so that the effectiveness of antisense inhibition on translation can be monitored using techniques that include but are not limited to antibody-mediated tests such as RIAs and ELISA, functional assays, or radiolabelling. The antisense molecule is introduced into the cells by diffusion or by transfection procedures known in the art. The molecules are introduced onto cell samples at a number of different concentrations preferably between lxlO " 0 M to lxlO "4 M. Once the minimum concentration that can adequately control translation is identified, the optimized dose is translated into a dosage suitable for use in vivo. For example, an inhibiting concentration in culture of lxlO "7 translates into a dose of approximately 0.6 mg/kg bodyweight. Levels of oligonucleotide approaching 100 mg/kg bodyweight or higher may be possible after testing the toxicity of the oligonucleotide in laboratory animals. The antisense can be introduced into the body as a bare or naked oligonucleotide, oligonucleotide encapsulated in lipid, oligonucleotide sequence encapsidated by viral protein, or as oligonucleotide contained in an expression vector such as those described in Example 23. The antisense oligonucleotide is preferably introduced into the vertebrate by injection. It is additionally contemplated that cells from the vertebrate are removed, treated with the antisense oligonucleotide, and reintroduced into the vertebrate. It is further contemplated that the antisense oligonucleotide sequence is incorporated into a ribozyme sequence to enable the antisense to bind and cleave its target. For technical applications of ribozyme and antisense oligonucleotides see Rossi et al. EXAMPLE 22 Preparation and use of Triple Ηelix Probes Triple helix oligonucleotides are used to inhibit transcription from a genome. They are particularly useful for studying alterations in cell activity as it is associated with a particular gene. The EST sequences or complete sequences of the present invention or, more preferably, a portion of those sequences, can be used to inhibit gene expression in individuals having diseases associated with a particular gene. Similarly, a portion of the EST or corresponding gene sequence can be used to study the effect of inhibiting transcription of a particular gene within a cell. Traditionally, homopurine sequences were considered the most useful. However, homopyrimidine sequences can also inhibit gene expression. Thus, both types of sequences from either the EST or from the gene corresponding to the EST are contemplated within the scope of this invention. Homopyrimidine oligonucleotides bind to the major groove at homopurine:homopyrimidine sequences. As an example, 10-mer to 20-mer homopyrimidine sequences from the ESTs can be used to inhibit expression from homopurine sequences. SEQ ID NOs such as 282 and 240 contain homopyrimidine 15-mers. Moreover the natural (beta) anomers of the oligonucleotide units can be replaced with alpha anomers to render the oligonucleotide more resistant to nucleases. Further, an intercalating agent such as ethidium bromide, or the like, can be attached to the 3' end of the alpha oligonucleotide to stabilize the triple helix. For information on the generation of oligonucleotides suitable for triple helix formation see Griffin et al. (Science 245:967-971 (1989) , which is hereby incorporated by this reference) . The oligonucleotides may be prepared on an oligonucleotide synthesizer or they may be purchased commercially from a company specializing in custom oligonucleotide synthesis. The sequences are introduced into cells in culture using techniques known in the art that include but are not limited to calcium phosphate precipitation, DEAE-Dextran, electroporation, liposo e- mediated transfection or native uptake. Treated cells are monitored for altered cell function. These cell functions are predicted based upon the homologies of the gene, corresponding to the EST from which the oligonucleotide was derived, with known genes sequences that have been associated with a particular function. The cell functions can also be predicted based on the presence of abnormal physiologies within cells derived from individuals with a particular inherited disease, particularly when the EST is associated with the disease using techniques described in Example 20. EXAMPLE 23 Gene expression from DNA Sequences Corresponding to ESTs A gene sequence of the present invention coding for all or part of a human gene product is introduced into an expression vector using conventional technology. (Techniques to transfer cloned sequences into expression vectors that direct protein translation in mammalian, yeast, insect or bacterial expression systems are well known in the art.) Commercially available vectors and expression systems are available from a variety of suppliers including Stratagene (La Jolla, California) , Promega (Madison, Wisconsin) , and Invitrogen (San Diego, California) . If desired, to enhance expression and facilitate proper protein folding, the codon context and codon pairing of the sequence may be optimized for the particular expression organism, as explained by Hatfield, et al., U.S. Patent No. 5,082,767, incorporated herein by this reference. The following is provided as one exemplary method to generate polypeptide from cloned cDNA sequences. The cDNA from the EST of interest is sequenced to identify the methionine initiation codon for the gene and the poly A sequence. If the cDNA lacks a poly A sequence, this sequence can be added to the construct by, for example, splicing out the Poly A sequence from pSG5 (Stratagene) using Bgll and Sail restriction endonuclease enzymes and incorporating it into the mammalian expression vector pXTl (Stratagene) . pXTl contains the LTRs and a portion of the gag gene from Moloney Murine Leukemia Virus. The position of the LTRs in the construct allow efficient stable transfection. The vector includes the Herpes Simplex Thymidine Kinase promoter and the selectable neomycin gene. The cDNA is obtained by PCR from the bacterial vector using oligonucleotide primers complementary to the cDNA and containing restriction endonuclease sequences for Pst I incorporated into the 5'primer and Bglll at the 5' end of the corresponding cDNA 3' primer, taking care to ensure that the cDNA is positioned inframe with the poly A sequence. The purified fragment obtained from the resulting PCR reaction is digested with Pstl, blunt ended with an exonuclease, digested with Bgl II, purified and ligated to pXTl, now containing a poly A sequence and digested Bglll. The ligated product is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc. , Grand Island, New York) under conditions outlined in the product specification. Positive transfectants are selected after growing the transfected cells in 600ug/ml G418 (Sigma, St. Louis, Missouri) . The protein is preferrably released into the supernatant. However if the protein has membrane binding domains, the protein may additionally be retained within the cell or expression may be restricted to the cell surface. Since it may be necessary to purify and locate the transfected product, synthetic 15-mer peptides synthesized from the predicted cDNA sequence are injected into mice to generate antibody to the polypeptide encoded by the cDNA. If antibody production is not possible, the cDNA sequence is additionally incorporated into eukaryotic expression vectors and expressed as a chimeric with, for example, β- globin. Antibody to -globin is used to purify the chimeric. Corresponding protease cleavage sites engineered between the -globin gene and the cDNA are then used to separate the two polypeptide fragments from one another after translation. One useful expression vector for generating 0-globin chimerics is pSG5 (Stratagene) . This vector encodes rabbit ø-globin. Intron II of the rabbit β-globin gene facilitates splicing of the expressed transcript, and the polyadenylation signal incorporated into the construct increases the level of expression. These techniques as described are well known to those skilled in the art of molecular biology. Standard methods are published in methods texts such as Davis et al. and many of the methods are available from the technical assistance representatives from Stratagene, Life Technologies, Inc., or Promega. Polypeptide may additionally be produced from either construct using in vitro translation systems such as In vitro Express™ Translation Kit (Stratagene) . EXAMPLE 24 Production of an Antibody to a Human Protein Substantially pure protein or polypeptide is isolated from the transfected or transformed cells as described in Example 23. Concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the protein can then be prepared as follows: A. Monoclonal Antibody Production by Hybridoma Fusion Monoclonal antibody to epitopes of any of the peptides identified and isolated as described can be prepared from murine hybridomas according to the classical method of Kohler, G. and Milstein, C. , Nature 256:495 (1975) or derivative methods thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected protein over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media) . The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by i munoassay procedures, such as Elisa, as originally described by Engvall, E., Meth. Enzymol. 70:419 (1980) , and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al. Basic Methods in Molecular Biology Elsevier, New York. Section 21-2. B. Polyclonal Antibody Production by Immunization Polyclonal antiserum containing antibodies to heterogenous epitopes of a single protein can be prepared by immunizing suitable animals with the expressed protein described above, which can be unmodified or modified to enhance immunogenicity. Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than other and may require the use of carriers and adjuvant. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. J. Clin. Endocrinol. Metab. 33:988-991 (1971). Booster injections can be given at regular intervals, and antiserum.harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, 0. et al., Chap. 19 in: Handbook of Experimental Immunology D. Wier (ed) Blackwell (1973) . Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 μM) . Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher, D. , Chap. 42 in: Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980). Antibody preparations prepared according to either protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. EXAMPLE 25 Identification of Tissue Types or Cell Species bv Means of Labeled Tissue Specific Antibodies Identification of specific tissues is accomplished by the visualization of tissue specific antigens by means of antibody preparations according to Example 24 which are conjugated, directly or indirectly to a detectable marker. Selected labeled antibody species bind to their specific antigen binding partner in tissue sections, cell suspensions, or in extracts of soluble proteins from a tissue sample to provide a pattern for qualitative or semi-qualitative interpretation. Antisera for these procedures must have a potency exceeding that of the native preparation, and for that reason, antibodies are concentrated to a mg/ml level by isolation of the gamma globulin fraction, for example, by ion-exchange chromatography or by ammonium sulfate fractionation. Also, to provide the most specific antisera, unwanted antibodies, for example to common proteins, must be removed from the gamma globulin fraction, for example by means of insoluble immunoabsorbents, before the antibodies are labeled with the marker. Either monoclonal or heterologous antisera is suitable for either procedure. A. Immunohistochemical Techniques Purified, high-titer antibodies, prepared as described above, are conjugated to a detectable marker, as described, for example, by Fudenberg, H. , Chap. 26 in: Basic * Clinical immunology, 3rd Ed. Lange, Los Altos, California (1980) or Rose, N. et al., Chap. 12 in: Methods in Immunodiagnosis, 2d Ed. John Wiley & Sons, New York (1980). A fluorescent marker, either fluorescein or rhodamine, is preferred, but antibodies can also be labeled with an enzyme that supports a color producing reaction with a substrate, such as horseradish peroxidase. Markers can be added to tissue-bound antibody in a second step, as described below. Alternatively, the specific antitissue antibodies can be labeled with ferritin or other electron dense particles, and localization of the ferritin coupled antigen-antibody complexes achieved by means of an electron microscope. In yet another approach, the antibodies are radiolabeled, with, for example 125 I, and detected by overlaying the antibody treated preparation with photographic emulsion. Preparations to carry out the procedures can comprise monoclonal or polyclonal antibodies to a single gene copy or protein, identified as specific to a tissue type, for example, brain tissue, or antibody preparations to several antigenically distinct tissue specific antigens can be used in panels, independently or in mixtures, as required. Tissue sections and cell suspensions are prepared for immunohistochemical examination according to common histological techniques. Multiple cryostat sections (about 4 μ , unfixed) of the unknown tissue and known control, are mounted and each slide covered with different dilutions of the antibody preparation. Sections of known and unknown tissues should also be treated with preparations to provide a positive control, a negative control, for example, pre-immune sera, and a control for non-specific staining, for example, buffer. Treated sections are incubated in a humid chamber for 30 min at room temperature, rinsed, then washed in buffer for 30- 45 min. Excess fluid is blotted away, and the marker developed. If the tissue specific antibody was not labeled in the first incubation, it can be labeled at this time in a second antibody-antibody reaction, for example, by adding fluorescein- or enzyme-conjugated antibody against the immunoglobulin class of the antiserum-producing species, for example, fluorescein labeled antibody to mouse IgG. Such labeled sera are commercially available. The antigen found in the tissues by the above procedure can be quantified by measuring the intensity of color or fluorescence on the tissue section, and calibrating that signal using appropriate standards. B. Identification of Tissue Specific Soluble Proteins The visualization of tissue specific proteins and identification of unknown tissues from that procedure is carried out using the labeled antibody reagents and detection strategy as described for immunohistochemistry; however the sample is prepared according to an electrophoretic technique to distribute the proteins extracted from the tissue in an orderly array on the basis of molecular weight for detection. A tissue sample is homogenized using a Virtis apparatus; cell suspensions are disrupted by Dounce homogenization or osmotic lysis, using detergents in either case as required to disrupt cell membranes, as is the practice in the art. Insoluble cell components such as nuclei, microsomes, and membrane fragments are removed by ultracentrifugation, and the soluble protein-containing fraction concentrated if necessary and reserved for analysis. A sample of the soluble protein solution is resolved into individual protein species by conventional SDS polyacrylamide electrophoresis as described, for example, by Davis, L. et al., Section 19-2 in: Basic Methods in Molecular Biology (P. Leder, ed) , Elsevier, New York (1986) , using a range of amounts of polyacrylamide in a set of gels to resolve the entire molecular weight range of proteins to be detected in the sample. A size marker is run in parallel for purposes of estimating molecular weights of the constituent proteins. Sample size for analysis is a convenient volume of from 5-50 μl, and containing from about 1 to 100 μg protein. An aliquot of each of the resolved proteins is transferred by blotting to a nitrocellulose filter paper, a process that maintains the pattern of resolution. Multiple copies are prepared. The procedure, known as Western Blot Analysis, is well described in Davis, L. et al., (above) Section 19-3. One set of nitrocellulose blots is stained with Coomassie Blue dye to visualize the entire set of proteins for comparison with the antibody bound proteins. The remaining nitrocellulose filters are then incubated with a solution of one or more specific antisera to tissue specific proteins prepared as described in Example 24. In this procedure, as in procedure A above, appropriate positive and negative sample and reagent controls are run. In either procedure A or B, a detectable label can be attached to the primary tissue antigen-primary antibody complex according to various strategies and permutations thereof. In a straightforward approach, the primary specific antibody can be labeled; alternatively, the unlabeled complex can be bound by a labeled secondary anti-IgG antibody. In other approaches, either the primary or secondary antibody is conjugated to a biotin molecule, which can, in a subsequent step, bind an avidin conjugated marker. According to yet another strategy, enzyme labeled or radioactive protein A, which has the property of binding to any IgG, is bound in a final step to either the primary or secondary antibody. The visualization of tissue specific antigen binding at levels above those seen in control tissues to one or more tissue specific antibodies, prepared from the gene sequences identified from EST sequences, can identify tissues of unknown origin, for example, forensic samples, or differentiated tumor tissue that has metastasized to foreign bodily sites. The entire contents of all references cited above are hereby incorporated by reference. While the present invention has been described in some detail for purposes of clarity and understanding, one skilled in the art will appreciate that various changes in form and detail can be made without departing from the true scope of the invention. VII. Correlation of EST and Clone Identifiers The EST sequences of the present invention are identified herein by SEQ ID NO, and are identified in the GenBank database by a different number, are identified in the inventors' lab (and upcoming publications) by EST number, and clones have been submitted to the American Type Culture Collection (Rockville, Maryland USA) under clone names. Table 12 cross references those different numbers for the ESTs from CDNA, SEQ ID NOS 1-315. Table 12. SEQ ID NO Cross References I NOTE REGARDING SEQUENCE LISTINGS: The listings of SEQ ID NOS: 1-315 are in numerical order. However, an occasional number (for example, SEQ ID NO: 44) is not found in this list. In all, 7 SEQ ID NOS are not used. Nevertheless, the convention "1-315" is used, for example, to refer to all the SEQ ID NOS in the following list. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Venter, J. Craig Adams, Mark D. Moreno, Ruben F. (ii) TITLE OF INVENTION: Sequences Characteristic of Human Gene Transcription Product (iii) NUMBER OF SEQUENCES: 308 (1-315, with 7 SEQ ID NOS unused. ) (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Knobbe, Martens, Olson, and Bear (B) STREET: 620 Newport Center Dr. Sixteenth Floor (C) CITY: Newport Beach (D) STATE: CA (E) COUNTRY: USA (F) ZIP: 92660 (V) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 07/716,831 (B) FILING DATE: 20-JUN-1991 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Israelsen, Ned A. (B) REGISTRATION NUMBER: 29,655 (C) REFERENCE/DOCKET NUMBER: NIH004.004CP1 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 619-235-8550 (B) TELEFAX: 619-235-0176 (2) INFORMATION FOR SEQ ID N0:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 362 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:1: CTTCCCTTTT GTTCCCCTCA GTGTCCCTTT TAATTGCTTC CCTCCATTTT CCTTAGCAGC 60 ATCCTAGTTG ATGGTCTGGG TTATCAGAGG AGCAAAAACA TTTAAGTGTC AAATAATGCT 120 CATTGTCTCC CTGGGATTTC TAAACAGAAA AAATGAAGAA AGAGGCAGAG AAGAGCTTCA 180 CAAGGTGTGT GCCAGCTCTG CATCATTTCC AGCTGCTCAA CCACCATTTC TCCCATTTTA 240 GGTCCCCAAA AGTAGGAGGT GGGGCCTCAC AGAGCTGCTG TGGGCTTTGG GTATCAAAAG 300 CTGCAGCCAC CATATGGGGC ACTCCTGGCT GGTGTACAGG GTGGGCATTG CCCAGGTCTT 360 TT 362 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 214 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2: GTTTTNCTTT TTTCTTAGCT TCATTTCTCT TAAAAAACAA GGAACAAGAA AACATTGCAC 60 CAGCGTTCTA AGCCTCAAAC AAAANACAAA ACAAATCCCC CTGCGAAGAA CAATAAACTT 120 TACATCTCTT TGGCAACAAT AACTTAAAAT CACCCAACTT CCATTCGCTC CAACCACAGC 180 AGTTAGTTAG TTACAAAAAT ATTCCNTGTG CTGC 214 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 344 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: ATTAATAGGA AAGATGATTG TATAGATGGT GGGCTATTAA CTCAGATCAG GATGAGAATC 60 GGGAGTGCCT TTACATGTGT GGTACCCAAA TGGGTGGTTG GATATAAGAG TAACAAAAGG 120 ACTGAAAGGG TTAAAAAAGA AAGAAAAAAA AAAAACTCCC TGGTTGGGAG GGTGTTAAGT 180 ATCGAGTGTT TTTCCAAACC ATTCCTCCTC TGCTCACCTA CCCCTAGGTG ATTAAAGGAG 240 ATAACTTTTA AAAAAGAAAG AATTGGCTCA AAGGTACTGT AAATTCTAGG ATTATATACC 300 TTTATATAGG TTCATTCCCT GATCCCTGTA TTATCAAGGC ACAG 344 (2) INFORMATION FOR SEQ ID N0:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 352 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4: GGACACTCAT CTGTGCCCCA CGTCCAGATC CCTGGAGGCA GCTGACCAAT GATGGGCGGT 60 GACCCGGTAA CCGAGGCGGC AAGGAGGCCA GGTAGTCCCG GCACCTCTCA CTCTGCAGAG 120 ACCAGCGGCT TCGTGGGAGG CCTGTGGGTC ACACGTAGGG GCTAGAGCCA GCCTGCATCC 180 TGCCCACCGG GCTCCACTTG GAGATCAGCA GGAGGGCCAG TGTGGGACCC CTGCTGCCAC 240 CTCTCCTGGG CCTGT TCCT TTCTGGAAAT TAAGAAGGTG TGCTCCAGAG CCAAGAGGAG 300 CAATAAGAAA CCTCGTGTGC CAGCTTCTTA AGGGTKGCAG TGCAAGACCC CA 352 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 562 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: ATACCCTTAC ATATATATTC ACAGAAAATC ATATTGCATA TACTCTTTCT CCACATCATA 60 AAAATGGGTG TTGGGCTCTC TAGGACACAA GGGAAGCAGG CCAAATTTCT CATATTTTCA 120 GGAATAAACT GAGTGCCCCG AAGGTGTAAT AGGAACCTTT TACTAACCTC ATCTGACTTC 180 ATCCTCACAC CAGCATTTTG TGTGTAAGGA AACTGGCCGA GAGTGGTTAA GAAATATATC 240 CAAAGACGTA TAGTTCCAAA TGGAACACGG ATCTTTTTAT TTAAATTCCA ATCATCTTTC 300 CATTATATCA GCCAATGATG GAGCAGAAAG CTGGTCCAGG CAATCCCAGA ATAGATCTTT 360 CTAGGCACCC GTTCAGTGTG AGGAGGGGGA AGTGGCCTTG CCAAGGGGCC AGTGAGCTCA 420 ATTAGGGTTA ACGCTGCTTC TTAGCCTACC CCAGGGGNCA CCGCACTTAG GTTGTTTTGT 480 GCCCAGCTTT GGCAGGAAGC ATTCCTCCTT TCAAAGATTN NAGCCTTGCG GTCATATATC 540 GGGTGTAATA GGGTTCTTTT TT 562 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 359 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: ACATGTTCTC CCTCTTTCAA TTTTAGCAGT AATGTGATCC TCAAAAATGC ATTAATACTA 60 GTTGAAGTAA ATAAACGGAA GAGCTCCAAA ATGCCTGCAT TAAATGCATT TTTCCACACT 120 AATGCCAATC ATCCAAAGCT ATTTTCAACA AGTCAGGTAT TCAAAGCTAT TCACACCACT 180 TGAAAGAGTA ATTACCATTT ACTGAAGCAC TTATCTGTCC TACACTGATG GGAGTAAATG 240 CTTCTCATAG GTTATCTCAT GTACATTATG CCACTTTNAC TTAAAATGAT CACAATTNAG 300 TGCTATAGGT TTTTGGGTTA ATGTTTTCCC NGGGGGAGTT GTTAAAAACA TGGCATTTC 359 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 218 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: AACTTGCAAC ATAAATACTA GAAAAAGAGA AAATATCATC AAAATACAAA TAACTGTTAG 60 AAATCATTGC TCAAAAGAAR AACCTGGCAA TGCATGATTA CGAAATGCAA AAGAMGATAC 120 AGTTGCTCTC TGTATATGCG CTTTCCACAT CCACAGATTC AAACAACTGT GGATAAAAAA 180 GGATTTTTCA ATGCCATTAA ACAVCAATGC AACAGTAA 218 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 345 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: CTACAATAGA AGGCAAACTA TGTCCCTCCT TTGCTCAGAA ACTTTTAATA TCTKCCTATT 60 TCCCCATGTA AAAGCCAATC CTCAACCACA GTGTAGAAGG GCTATCCATT TCTAGCTACA 120 CATCTCCTCA GTCACTGCCC CCAGCCCCAG TACTTGGGGA CTTTGCCCTT GCAGTTCCCT 180 GTGCCAGCAA ACTCTTCCTC CAGATGTCCA CATGACTCAC CCNNCTCCTT CAGGGGTCTT 240 CTCAAATGTC ACTTTACCAG AGGTGGCTTC CCTGACCATC CTGTATAAAT AGCATCACCC 300 TACCTCCTAT CTCTCTCTCT AATGTCTCAG GAATTCGATA TCAAG 345 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 189 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear • (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: GTGAACAGAC TAAGGCCTTT NTGGAGGCCC AGAATAAGAT TACTGTGCCA TTTCTTGAGC 60 AGTGTCCCAT CAGAGGTTTA TACAAAGAGA GAATGACTGA ACTATATGAT TATCCCANGT 120 ATAGTTGCCA CTTCAAGAAA GGAGAACGGT GTTTTTATTT TTACAATACA GGNTTTNAGA 180 ACCACCGGG 189 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 267 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: CTCCCTTCGC CACCTGCTGG ACGCGAGGGG CTACTACGAT GCCATGGGTG TCCTGRTTTT 60 TTATTTCTCA GACAGGACTG CTCTGTATNT GTCTTTGGAT TCTACGTAGA TTTATATTTG 120 TAAAATATTA CATTTGTCAT GACCAGAAGA AATGTCATTA TCGTAAAATT TAGATTCTGG 180 NGTCTATATA TGNAAGNAAT ACTAACTACT AACTGTTATA ACA CAAAAT GTGGGNTGTA 240 TATCTACARG CCNGAGCCGA CTTGTCA 267 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 247 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: CTCATAAAGC CAGGGTGATA AAAWTGGTAG TTTCATGTTA TCTACAAGRC TAAGKTCAAA 60 ATTCCATGCA TGTGCTGRTA AAAGACCCAT NATGGKCCTM ACTGTACTTA CTCCCCATTT 120 ATTAGCATTC ATTCTGGTCA CCAGCTCTAG TTCCTCTGCT TAGCGAATCT CGCTTGTCTT 180 CAAGATGTCA TTCAAATGTC ACATTTTGTG GGAAGCCTTG CCTTTTTTGA CACGGTCTCC 240 CTGCCAC 247 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 280 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12" AAGGCGAGAG GCTTCTGGAG AAACCCACCC CACCAACGTC TTGATCTTGG ACTTTTAVCC 60 TCCAGAGCTA TGAGAAAACA AVTTTCTGTV VATVGVGGCC ACTCAGCCTG TGGATACTGG 120 CAGCCCTAGC AAACTCATAC ACACATACAT TTTAAACTCG GTTTAATCCT GTGRCCATTC 180 ACTTATGGTT CAGTTTTTAA ATAGTCCTAG TCTTATGVCC ACTGTTAAAG TTCACCAGGA 240 CATAGGSCAT TGGGGAAAGG GGCCTGTAAC TCTTGGATTA 280 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 339 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: VCTVTCTVCC AACTTCATTC AGATATTGAC TCTGGTGATG GGAACATTAA ATACATTCTC 60 TCAGGGGAAG GAGCTGGAAC CATTTTTVTR ATTGATGACA AATCAGGGAA CATTCATGCC 120 ACCAAGACGT TGGATCGAGA AGAGAGAGCC CAGTACACGT TGATGGCTCA GGCGGTGGAC 180 AGGGACACCA ATCGGCCACT GGAGCCACCG TCGGAATTCA TTKTCAAGGK CCAGGACATT 240 AATGACAGTC CTCCGGAGGT TTCCTGCACG AGACCTATCA TGCCAACTGT GCCSTGTARA 300 GGTCCAATKT TGGGTGSTGT ACGGTAGTGG GGAGGCCTG 339 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 342 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: GGGVGCAAAG TAGCAGATTC TAGTAAAGGA CCAGATGAGG CAAAAATTAA GGCACTCTTG 60 GAAAGAACAG GCTACACACT TGATGTGACC ACTGGACAGA GGAAGTATGG AGGACCACCT 120 CCAGATTCCG TTTATYCAGG TCAGCAGCCT TCTGTTGGCA CTGAGATATT TGTGGGAAAG 180 ATCCCAAGAG ATCTATTTTG AGGATGAACT TGTTCCATTA TTTGAGAAAG CTTGGACCTA 240 TATGGGATCC TTCGTCTAAT GATGGATCCA CTCACTGGTC TCAATAGAGG TTAATGCGTT 300 TGTCACTTTT TTGTACAAAA GGAGCARGCT CAAGGAGGGC TG 342 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 354 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: ATGTTGATGC TGAAATTVAA GATCCACCAA TTCCAGAAAA ACCATGGAAG GTTCATGTGA 60 AATGGATTTT GGACACTGAT ATTTTCAATG AATGGATGAA TGAGGAGGAT TATRAGGTGG 120 ATGAAAATAG GAAGCCTGTR AGTTTYCGTC AGCGGATTTC AACCAAGAAT GAAGAGCCAG 180 TCAGAAGTCC AGAAAGAAGA GATAGAAAAG CATCASCTAA TGCTCGAAAG AGGAAACATT 240 CGCCTTCGCC TCCCCCTCCG ACACCAACAG AWTCACGGGA AGAAGAGTGG GAAGAAAGGC 300 CAAGCTAGCC TTTTATGGGG AAGCCGCAAG AAGTCCAGAA AGAGGGW GG TTGA 354 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 348 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: CAGGCAAGTT TCTTCCAGGA TGAGAAATCA GTGGAAAGTG AGGGCCAGCC AACAGCCACC 60 ACCAACCACC CAACACGCGA GCGAGACCAT CTTAAAAGAG CCCCAGCCAA GCTGACCATG 120 GGTCTGACCC CAAACTGAAG AAATGCCCAG CCCAGCCAAA CCCAAATTGC TAACTTGTAT 180 TATAAGCAAG TACAATGGTC CTTACCTTAA GCCACTAAGT TTTGGGATGC TTTGTTACAC 240 AGCTATAGAT AAGCTGATAC AGGGAATGTC AGAWTCCATG ATGAGAGACC GAGCCTTTCA 300 KTCTGTCAGA GGYACCTTVG GTTGGCAAAA CTTCAAAAAG AGGGACCT 348 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 415 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: AGCAYGGGCT GGGGGGCCGG GAGTTAGGGC TGGGGCTTGT TTTACGCTCT GCCCCCCACA 60 CCCCCTCCTC TTCCGTCCTG ATTAAGCCCA AGGGTTGGTG GACTTAACTT TCAGCCCATC 120 TCTAAGGGTT TCACAGACTG GATCTTTCTA AACTTTATTG GGTACCTGCT TCCCCTTTTC 180 CCTGGTAGTT TTCATCTACA AAAAGTCAAA ACCTGATCGA AATAGAAATA AGATCATCAA 240 ATTGGACCAT TCTCTTAGCG TTCGAGTGTG CCGGCCAGAC TGGCATTCAG TACACGCTGA 300 GATCCAACCA CATCACACTG GCCTCAGGTC ACCAACTCGC CACTCAGGGC ACAAGGCCTG 360 CCCTTGTGGT CACAAGGCTT TCCTTAATGT CGTCGGTGCC CAGGTGAACC ACAAG 415 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 356 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: GTATGTATGT CTGTAGGTAT TTCTATACTT AACCATCTGT GTCCCAATTA AGCTAAACAT 60 GATTCATTCT GATGCCAACC CCCATCCATC ATGCCATGGA TCGCTCTAGA CTTCTTCCCT 120 TGTAACCTCC CACTCAAACA GTGAGAAACC TTTGCCCAGT ATGTTTTGGA GTAACCTCAC 180 TGGGAGTTTG CAGTCCCACT AGATGAATGC CAACCCATTT GTTCATTTAA AAGGACTTTT 240 GGAACCATAG AGCAATGGCT GGGCTGGGTC TVGCACGTTC ATCTTGACTG AAACAATTGG 300 CCATGAAGGC ACTTGCCAAG GAAACTCTAG GGGCCACAAG GGTCCTGGGT GCTTGC 356 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 339 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: CATGCTTCCA TTTTTTTTAG TTTTAAACCA CCAAACCAAT ATTTTYCCTT TAAATTTTAA 60 TCTTATAATA TAGAAATCTT ATGTAAATGA AATTTTGTCA TGTTTCAAAT AAAGAGAACT 120 GAAGTAGAAA ATAGAAATGC CAGTAAACAA CATAATGTTT AATTTACAAC TTACATTAGG 180 GGTTTGGGGG VATGCTAATT ATATATTGAG AATATACATT AGAACTCTTC AAAATGGGCT 240 CTTCTAATGA GGTCACTACT GAACATAATT GTTCCCTCTT CTGTTAAATA GAATAGGTTT 300 AAATGACTAG TCCAAATGGA ATTATTGCCT TCTKGTTAA 339 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 437 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: AGAACAAGGG AACTCAGCAG CCCCTCCCTT CCCATCAGCT GTTCCTGAGA GATGCAATAT 60 AGTAGTCATC GACATCATCC TTATCAACAG CATCATCACT CAGACAGTGG TGAAAGTCTT 120 TCTTCACAAG GAAAAACAAA GATAAAGAAA TACATGAGCA TTAATCAGAA ATTTTCAAAG 180 CTTGGATTCT AATGATATGC ATTATCATTA GACATTCAAA TGCTATACAT CTTCTGATGA 240 AGCCTCCTTG ACAGCAGCTA CACTTATTTC ACATTAGAAT GCCTAGAGAA ATCCTGACTG 300 CCCAGCTTGG TCATGGGACC TTCCCCACTC TCCTCTTGGA GGAATGAAAA GATGTGGCGG 360 CTTTCTACTT TTGCTACTGA GCTGGGGTAT ATGGCTAGGT CCACTTTCTA AGGGGCTTGG 420 AAGGGTTATT CCATCTG 437 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 385 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: GTTTGATTTG CTTTTTTTTT AGAGTTTTAC ATCAGTGTTT TTCAGGAATA TTGGTCTTTC 60 ATTTTCTTTT CTTGGAATAT TTTCTAGTTT TACTTTGTCA GAGTAAATTC TGGCTTCACA 120 GAATTATTTG TAGTCTCTCC TGTCTTGGTT TATTCATGCT GCTATAACAA AATACCACAG 180 ACAAGGTGGT AATAAATAAC ACAAATTTAT TTTTCCCAGT TCTGGAGGCT AGGAGTTCAA 240 GAAGCTGGCA AGTTCAATGT CTGGTGAGAC CCATTCCTTC ATAGGTGGCA CCATCTAGGG 300 GTCCTTACAT GRCAAAGAGA TGGAAGGGCC AAAAAGATGG TGACCTATTG TGAGGCCTTT 360 TTTAAAGGGC CTTVAAATCC CAGTC 385 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 374 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: ACCTTCATGG TCATGAAGGC CATGCAGTCT CTCAAGTCCC GAGGCTACGT GAAGGAACAG 60 TTTGCCTGGA GACATTTCTA CTGGTACCTT ACCAATGAGG GTATCCAGTA TCTCCGTGAT 120 TACCTTCATC TGCCCCCGGA GATTGTGCCT GCCACCCTAC GCCGTAGCCG TCCAGAGACT 180 GGCAGGCCTC GGCCTAAAGG TCTGGGAGGG TGAGCGACCT GCGAGACTCA CAAGAGGGGA 240 AGCTGACAAG AGATACCTAC AAGACGGGAG TRCCTGTGCC ACCTGGTGCC GACAAGAAAG 300 CCGAGGCTTG GGTCTGGGTC AGCAACCGAA TTCCAGTTTA GAGGCGGATT TVGGTCGTKG 360 ACGGTGTCAG CCAC 374 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 322 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: CAAAACGTGA TCACCACAGC TCCGTTCCTG CAGTGACACT TAACATACTC AGCATCTTCA 60 TGAATTCTGA ATAATTTACT GATCGTAAAG TCTAAAAGTA TCAATTTCAG GTGAGCAGTT 120 TTAAATCAGA AAATAGTCAA TAGTTAATCA TGACTCTTCA GGGTATTTCC TTCACGTCCT 180 CTGAAGAGTT TCCCAGAACA TTCTTGTGAA AAGGAATGCC TCCCAACAAT GGAGAGCAAC 240 AATAGCAACA GGCATCTGAA TCAGCCTGGC CTCTGAAAAC AGACCANAGA GGAGTTTATC 300 TGTTTCTTCC AGTGGAGGAA GG 322 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 113 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: CCTGAAATCG GAGTCTTTTG GACTGACTCC AAATTCAATG GGTGGCACAG GCAGCACGGA 60 GTCCACGTGA ATCTCCACCC CGTTAACAGG CGGGACGACA GCCCCTTGCA GCC 113 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 399 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: GGAAAGAATG AAGGAAAAAC AAGACAAAAT CTACTTCATG GCTGGGTCCA GCAGAAAAGA 60 GCAGACGCTG GCCTCAGACA CAGACAGCAG TCTTGATGCC TCGACGGGAC CCCTTGAAGG 120 CTGTCGATGA TAGGTTAGAA ATAGCAAACC TGTCAGCATT GAAGGAACTC TCACCTCCGT 180 GGGCCTGAAA TGCTTGGGAG TTGATGGAAC CAAATAGAAA AACTCCATGT TCTGCATGTA 240 AGAAACACAA TGCCTTGCCC TACTCAGACC TGATAGGATT GCCTGCTTAG ATGATAAAAT 300 GAGGCAGAAT ATGTCTTGAA GAAAAAANTT GCAAGCCACA CTTCTNGAGA TTTTGTTCAA 360 GATCCATTTC AGGGTGAGCA GTTAGAGTAG GTTGAATTT 399 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 355 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: GATTGGTATA CGGGCAACAA TGGATTGATA GCCTTAATAT AGAAATAGTT CCAGCAGGCC 60 AGATGCAGTG GCTCAATTCT GTAAACCCAG TGCTCTGCAC AGCTAGGAAG GAAGATCACT 120 TGGGCCCAGG AGTTCAAGGC TCCAGTGAGC CATGATCACG CCACTKCCTC CAGCCTGGGT 180 GACAGAGTNA GGCCCTGTCT CTAAAAAATG AAATAGCTCC ATCAAGTCAA TAATTAAAAG 240 TTCAACAGCC CAACAGANCA AAAATTGTAA ATGANCACAA ATTAGAAAAT GTACAAATTA 300 AATATTAATG ACCCATAACC CTATAAGGGA AAGTTTAACC TCTCTAGTAT TTTTT 355 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 322 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: AAAACGTGAT CACCACAGCT CCGTTCCTGC AGTGACACTT AACATACTCA GCATCTTCAT 60 GAATTCTGAA TAATTTACTG ATCGTAAAGT CTAAAAGTAT CAATTTCAGG TGAGCAGTTT 120 TAAATCAGAA AATAGTCAAT AGTTAATCAT GACTCTTCAG GGTATTTCCT TCACGTCCTC 180 TGAAGAGTTT CCCAGAACAT TCTTGTGAAA AGGAATGCCT CCCAACAATG GAGGAGCAAC 240 AATAGCAACA GGCATCTGAA TCAGCCTGGG CTCTGAAAAC AGACCAAAGA GGNGTTTTTC 300 TGCTTTCTTC CAGTGAGGAA GG 322 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 287 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: TATTTTTATT AAAGGACCAC CCTGGCTGTM GTGAGATGAA TGGATTCAAA CAGGGCAAGA 60 GTGGATACAG MGAGATAAGT TAGGAAGCTG GTATAGAAAT CTGGATGAGA TATGGTGGCT 120 TGGATGATAC TAGCAGTGAG TATGGGAAGT AGGTGGATTA CTTTACACTT TTTTAGATCA 180 GTCKATTCTT GATGTCTTGA AGACAAATTA ATCTCATATA TAACTCTAAA CAACATATTT 240 ATATTTCATG TAAATAAGGA TAATGCTGAC CAAATATTAG CACCTTT 287 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 282 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: CAGGGCAGGG AAGCCTGGAA GCAAAGGAGG ACCTGGCTCC TGACTCTCAG AGAGGATAGG 60 CTGGGATCCC TGGGGCAGGC CTGTTCCTTG GCTGGCCAAT TTAGTCTTTC AATTGTCTAA 120 GGGCTCTCCA TTGCCTGCCC TTGCCTCTTT CTAGCCTGTT ATTTCTAGGC TCCTCTGAAT 180 AAATCTCAGG TTTCCTACTG TCATGCCTTT AGTTCAAAAA TGAGAATCTG CCCTACAGTG 240 CTGGCCTCCT TCCGGCCTGA AAGCCAGCAC CTTKCGACCC GG 282 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 345 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: GAAGCTGGTG AATACATTTC AAGACACAAC ATGGCACCTG TGTCTAGCTC TATGGTACAA 60 CATGGTACTA TGACACATAT AATGGGTTGC CAGATGGGGA AGGCAGCTTC TCTGCAACTG 120 AGCTGAGATC TCAAAATAGA CAATGTCAAG ATGGAATGAG AAGGGAAAAA CAGCATGTGT 180 AGACAGGTAG TGACAAAAGG CTAATTAAGG ACTGAAAGAA ACCAGTGGCC AACAAGGGAA 240 TCTACGGGTG ATAAAGATAA GACGGTGAGA GAGATAAGGC TAGATTGTAT AAGGCTTGAC 300 AGACCATAGC AAGATAAGCA AGGACCTGTG TCCTGTTAAC CATTT 345 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 343 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: ATAAAATTGG TCTGGGTACC CTAAGGTGTT TGCKTTGATA GAAAATTGAC ACCCCAAACT 60 AAGTGTTCTA CTTAGCTTCT ACAATAGTTA TTCCTAGACC TTAGATTAGT CATTACATTT 120 TTATTTAAGG TACTATGTTA CTTTCATGAC TACAAAATGA GGCACTCGTA CAAAACAGGA 180 ATGAAAACAT ACATATACTG TCTTGTCTTT ATGTCGTATT AATGCCAAAG ATATTGTCAG 240 GGATTATTTT AAAGAAGCCC TTACTCATGA TGGCTATTTT TAAAAATGGC ACAGGACAGT 300 AACAGGCTGA AAAGAAACAC CTGGTTTGAG GGGCCAAATT AAG 343 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 153 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: ACAGGATGGT CAGGACAAGC CACCTCTGGT AAAGTGACAT TTGAGANGAC CCCTGAAGGN 60 GGGGGGTTGA GTCATGTGGA CATCTTGAGG AAGAGTTTAC TGGCACAGGG AACTGCAAGG 120 KCAAAGTCCC CAAGTACTAG GGCTGGGGGC AGT 153 (2) INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 257 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: TCAGTCAGCT TATCGCAGGT GCAGCCAAAC ACAAAGCTTC AGGACAAATT GTACAAACTT 60 TACAATGTGG GATTTAAATT TAAAATATGA TACATAAAAA TCTACACAAA ACTGATAAAA 120 ATCAAGCACA GNTACCAGGA TTGAAACTTA TAATAATCCA TGTGTGAAAG GGAGTCTTGT 180 TTCCTTTCAA GTGCTTTTAT TCTGCTATGG AACAGTCAAA ATGGAAGNTG TAAAGCTTTG 240 TGGTTAGTTT AAATTAT 257 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 307 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: CTCCCACCCA TATCTAATCC AACAAGTCCA GCTGCCTCTC TCTNAAMAAT ACCNARGATC 60 AGGCCCCTTC TCAGCACCCC CACAGCTGCT GCCCCAAAGG AAGCCACGTC ATCTCTCACG 120 GAGATTGTKC AGCAGCCACT GCCTCCTTGT CACCTTCGCC TGTGGTCATT CTCCCCACAT 180 GGCCAGGGAA TGCGTCCTGT TAAAGTCTGC TAGGTCACGG TCCTTCCTAC TCAAAATGCT 240 CCCYTGGCTC CCACTGCCCC CAGAGTAAAA AGCCCAGACC TTCAAATGAC ACAAAGGCCT 300 ACAACGA 307 (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 266 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: TCCACAGGTC ATCAGATRCC TGCTNGATAA TATATAAACA GTAAAAACAA CTTTCACTTC 60 TTCCTATTNT AATCGTGTGC CATGGATCTG ATCTGTACCA TGACCCTACA TAAGGCTGGA 120 TGGACCTCAG GCTGAGGGCC CAATGTATGT KTGGCTGTGG GTGTGGTTGG GAGTGTGTCT 180 GCKGAGTAAG AACACGNTTT TCAAGATTCT AAAGCTCAAT TMAAGTGGCA CATTAATRAT 240 AAACTCAGAT CTGNTCAAAA GTCCGG 266 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 388 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: CAGCTTTGGA AAGACTTTGA CCTCTGAACA AAAAGCCAGA AGGCTGCTTA AAGAAATAGT 60 AAGGGTTTCA CTTGCCCTGG ATAGTCACAA ATCTAGGAGT ACTGGTTCAC TGCCTTGGGT 120 TACCAGGTAT CAGCTCTTTC ACAATCTCTC CTCTTCCCAT GCTTCCCCTT AAAGTCCAGT 180 TGACAAATGA AAAAGAAAAA AAGGCCTTGA TTTATAGTAT TGCCAAACAA CCTCATAAGA 240 ATGGGTAAAA TTACATACAC ACATACATAG AGAAGGGAGG TAATGCTGTG AATCTACTTG 300 AGCTGGATTG CATGCTCCCT AGGGACCACG GTGCCCAACC TGTAATTTTA TTTCTAACTT 360 TTATAAATAT ACTCCTTTTT CACGGATG 388 (2) INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 342 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: GAATGTCTAC ACAAGGAAGT ACAGGATTTG GCTTTTCTAG ATGTCATATC CAAACTTCGC 60 AGTCATGAGA ACAAAAGTGT TGCCCAGCAG GCCTCTCTCA CAGAGCAGAG ACTTACTGTG 120 GAAAGCTGAG AACTGCCCGA TACACGGCAT CATCCCATCT CTAATTTCCC CTCTGTCCTC 180 CATCCAGCGG CTTCTTCCGC TTCATTCTCT ACCATACCAC TTGTGCATGC ATGTRATGTT 240 CTAATACCAA TTGAAGAACC GCTGTAGGTA CCTCCCTAAT AAGGATTTCT AAACCTATAG 300 TTAGTGTGAT CATGACTTTG GTCAAAGGCA AGTYTCCCAC CC 342 (2> INFORMATION FOR SEQ ID NO:38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 355 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: GATGACTTGG AGAATGCCGA AGAGGAAGGC CAGGAGAATG TCGAGATCCT CCCCTCTGGG 60 GAGCGACCGC AGCCAACCAG AAGCGAATCA CCACACCATA CATGACCAAG TACGAGCGAG 120 CCCGCGTGCT GGGCACCCGA GCGCTCCAGA TTGCGATGTG TGCCCCTGTG ATGGTGGAGC 180 TGGAGGGGGA GACAGATCCT CTGCTCATTG CCATGAAGGA ACTCAAGGCC CGAAAGATCC 240 CCATCATCAT TCGCCGTTAC CTGCCAGATG GGAGCTATGA AGACTGGGGG GGTKGACGAG 300 CTCATCATCA CCGACTTGAG CTGGAGTCAT CTTTCCTGMC CTTTGCCCCA TGCCC 355 (2) INFORMATION FOR SEQ ID NO:39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 303 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: GCCAAAAACA NYTCTGAACC CGTTTTGGGA AATAATGGGA TTCCTTGATC ACGGGACAAC 60 GAATCACCCT GAAGTTTTTC TCCAGTTTAC TCAGTCACAT AAGCCACCAG AGGCTAACCA 120 CACTGACAAC AAAAGCAAGT CCCAGGATTC CGGGGGCTAA TACCATGCTA GGCATTACTT 180 GGGAAGTTAT GAGTTGGTAT ACATCTGTGA ATTTGGTGGG AGGAGAAAAC TAACAGTAAA 240 TTTATCAAAG CCAGTGGTAC GTTCAGCGTT ATAAAAATTA CAAGGATCTG CTTCTCGGCG 300 ACT 303 (2) INFORMATION FOR SEQ ID NO:40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 178 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: GGTGTCGGGG GCTAGAGATA CACATGCCAG TNCTATACAT TTCTCAGCAC TGTGCTGTCG 60 ATTCACAGCA GTTCAATTGT TCATGCGATA TAAGCCAGTC ATGTGGCCCA AGTTATTCTG 120 TCGGCTGTGT TCTCTGCAGG AATCTGATGC AAGAAGGCCT GAAGGATGCA TGGCTTTT 178 (2) INFORMATION FOR SEQ ID NO:41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 322 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: TGCCTTTCTT TAGAAATTTA GGGCAGTGTG ATGCTTCCAG AGGTCTGTAC AAACACCAGC 60 TTTCATTGTG CTTGGGAGTT TCCATGCCTC TYCCTTCTCT TCGCTTAGTG CACGTTTCTG 120 CTTTTTATCA GTTTGACTGC CTGAGACTGA KTCCAACAAC CCAAACTGAA CGCTCAGCTC 180 CTCCKTTTCA AAGGAGGATG ACTTNTCTNA ACAACTATTT AGGTGAATTA TTKCKACAGT 240 TTATTAAAGC AATGGCTCTA AACAAATTCC ACTGGGGGTG ACAAAGTACA ATACAAAAGG 300 CGTACTCTGA GGGCTTGGGG GT 322 (2) INFORMATION FOR SEQ ID NO:42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 278 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: AAACTTTGGC ATTTTTATTC AGACACGTAT AAAAACAAAA CAAAAAACTT CAGTGATACA 60 ACAGACGTTT TCCCTTAGTT CCCCATCCAA GGGGACAGAG GTGTGCAGCT GAAGCTGGAY 120 CTTTTTTCTG TCCTACCTGG AAGCTGTCTC ACTGCTGGAT GAGAATGGCT TCTAAAAGTG 180 GATCTTGGGG ATCCTTGTGA ATTTGCCCTC GGATAAGGAG TGAAGWTCAT TTACGGCACA 240 TGTGGATTAT GGTTTACACA AAGATGTCCA GTTATTTT 278 (2) INFORMATION FOR SEQ ID NO:43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 225 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: AGATCAAAAG ATGAGAGAAG CTGAAACAGA ACCGCATGAG GGAAAGAGGA AAGTGGAATC 60 TCTGTGGCCC ATCTTCAGGA TCCACCACCA GAAAACCCGT TACATCTTCG CCTCTTTTAC 120 AAGCGGAAAG CCAGCAGCAG GATCTCTAGG AATATTAGTA TTAAAGAAGG CTATGCAGCA 180 TAAACCTGAT TTCAAAATGG TAAAAGCAAG GTTATGTGTA CTTGT 225 (2) INFORMATION FOR SEQ ID NO:45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 305 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: GGATTGCCAG GAGCTGTTCC AGGTTGGGGA GAGGCAGAGT GGACTATTTG AAATCCAGCC 60 TCAGGGGTCT CCGCCATTTT TGGTGAACTG CAAGATGACC TCAGATGGAG GCTGGACAGT 120 AATTCAGAGG CGCCACGATG GCTCAGTGGA CTTCAACCGG CCCTKGGTAG CCTACAAGGC 180 GGTGGTTTTG GGGGATCCCC ACGGCGAGTT CTGGCTTGGG TCTTGGAGAA AGGKGCATAG 240 CATCACGGGG GGACCGGAAC AGCCGMCTGG CCGTGCAAMC TGCGGGGACT GGGATGGGCA 300 AACGC 305 (2) INFORMATION FOR SEQ ID NO:46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 264 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: ATGAAATAGC ATATCTNNGC CTAATTAAAA GATTCCATTA CATTTACTTT TATCATTTAT 60 ACTGCCAAGG ATCAGTCACA AAAAATTCAA ATTATACATA TTATTCATGC TTTAATTTCA 120 TAAATAAGTA AATTAAAGCA AGCCAATATG TCTCTCTTCA TAACATAGGG AAAAATTACT 180 GTTTAGCATA ACAGNGTAAT AGGCAAAGTC TAGCCATACA GCAGCAGTTC ACGGTGTTGT 240 CAAGTTGGKA CAGGTTCCAT CGAT 264 (2) INFORMATION FOR SEQ ID NO:47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47: GATCTCTTCC AGCGTCAATG TACTGGGACA GCAAACACTC ACATTTGAAG TTCCTTCTGG 60 CCACCGGCTT CCCAGTACAT TGACGCTGGA AGAGATCATC TCAAATGGTT CTCCAGTGTC 120 AGGCTGGAGA TCTCCAGAAA TGGAGTCTAC TCCTGGGGTG GCTTGTATGG GAGCC 175 (2) INFORMATION FOR SEQ ID NO:48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48: GTCTGTCAGA GCNACCGGGC AGCTCAMRCC CACAGCGGCT CCTCATCCTC TGTGGTGGCA 60 TCCTCATTCC ACTCTCATCT GCCACCTKCT CAGGCGGGCC TCTAGCTTTC TCATGTACTC 120 TAGCAATTCC TGTTTCTCCT GCTGTAACTG CTCCTTTTCC TTCTGGAGCA CACGCAGGGC 180 TGACCGCAGC TGTGTCAGCT TCCGCTTACT TTMTGACAAC TGTACCAGGC TAGAATCCTT 240 TCTGCCTGGG TCAGCTTCAG TCTTTGAACA 270 (2) INFORMATION FOR SEQ ID NO:49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 359 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: CCCTGAAGAG TGGGTGGGAC AACCAGATGG GTGTAACCCC TTGTGGGGGA AAAGGAGTGA 60 GTTTACTTGG TAAAATAATA ATGGTAATGT CAGCAGCGTG GCTGGGGGAC TCAGTATGGT 120 CCCGGGAAAA GAGTTGGGGC AGTGAACTTC CCAGGCCGAC TGGCCTTGGG CTGGCAGCAG 180 GGAGGCTGCA GGGCGCCTAC CTMCTCTGCC ACGTCCCTGC CTAGGAAACC TATCCCAGGA 240 CACCCTGCTT TGGCCTGGAT AGCAGCCTAG GGATGAGCAT TTCTTTGAAA GCAATTAGGT 300 TATTCACCTG GTATTAAAAC TATTTACTGT TAAAAAATCT GTGACTTCAT GGARGTGGG 359 (2) INFORMATION FOR SEQ ID NO:50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 271 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50: CCAGGAAGGA CAGGAAGTGT CCTCTAATAC GCATAAGATC CAGTACAGGA GAGATGGGAA 60 GMGAGKCTCC AGGATGAAGG GGAAAARAGG CCGCATGCCA GTCACCTGGC ATCTNCCAGA 120 GAGGGYCAGY CTNCCCACTG AGACTGGGGC ACGAGTCCCG TCATCACCAT GCCCTCTGAC 180 TGTCGAACTG TCTTTTTACC TGACAAATAC TACACAGGTA TCGMTCGTGG CCATACTCTG 240 CTATCTAAAC CCAGGAACTG ATTAGATTGT T 271 (2) INFORMATION FOR SEQ ID NO:51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 226 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: CTCCAAGCAG TAAAGACTTG CAAAGCATTG CATTTTGATT AAACCTTGCT GGGCTGAAGG 60 GCAGGCAGAG CTGTGGTGGA CACTGGCAGG ACGCAGCACC CCCCGACTGG CCCTTGGCAG 120 GCTGCACCGG GCGCATGCGG GTGTGGGCCA GGGTTGCTTT AGGAAGCAGG TGGGAGTCTK 180 NCACGTGCAG KCGGTCCAGG AGKGYACCAK GCCTGGCAGG GCACTG 226 (2) INFORMATION FOR SEQ ID NO:52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 408 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52: GGTGGGGCAA GGTGGGGGTG AAGTGCACTC CTGCTGCATG AGTGGCAGGG CAGGGTGCAC 60 ACACACACGT GGGTMCTGGC TGGGTGAGGC AAGCAAAACC TGCCTGCACA TGGCAAAGGG 120 ATGTGGGAAG TATCCATGGG CNCCAGGGGA AGCTGCAGTT TGGGGAGGGA ATGGGTGGCA 180 CTGCTGCGTG TCTGTGGGGG CCACCCCACT GGGGGTCTCC AAGTGGTCAA GTTCCGTCTG 240 CCAGGTTAGA AGCTATGATG GGGGCTTCTA GGACACTNGA GGCTGACCTG AAAGCAAGGT 300 ACTTTTCACA CTGGGACCCT GCAAGAGGCC AACAAGATTA AGGGATGCTT CAGGTCAGAC 360 TTGGCCCTCT TCTTATGGGG CAAGACCTTC CCCGCAGAGT TCAGATCT 408 (2) INFORMATION FOR SEQ ID NO:53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 314 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53: TTCTGTGCAG GAGGACCACA TGGCAGTCCA GCAGACTGCA CATTTTTAAA AACTAGGTCT 60 TCCCAGGTAG TTTGAGGAGC ACCAGGGCAC ACTCAGGGAA GGGACATGTC AGTGTCTGAG 120 AGCTCACGGG AGGAAGGTGT AGTGACAACA TGGACCATGG TGGAGTGACT TTAGACGGCT 180 CTTGGGTNAG GAGAATCATC ATGTAACAAA GCATTAAATC ATTTGGAGAA ATTCAGAAAA 240 NTCGTAGATG TACATTCTAG CCCACTTACC AGGCCTACTA AACGTCAATC AGATATATTT 300 CAATTTGAAT TCGG 314 (2) INFORMATION FOR SEQ ID NO:54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 310 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54: AAGCCACCGC ACCTGGCCCA TTACATTTAT AATGTTATAA GGGGGTTGAG GGGTCGTCCA 60 CTGGAGCAGT GGTTCTCAAA CTCGTGTATG CATAGGAATT ACCTGAAGGG CTTGTTAAAA 120 CACAAACTGC AGGGCCCACC CCCAGAGTTT CTGGTTGGGG AGGTGTGGGC TGGGCTTGAG 180 GATGTGAATC TCTCACAAGC TCCCAGGTGA GGCTGCTGGT CTGTGGACCC ACTTCAAAGA 240 CCCAGTGAAT CAGAAGAGTC AGTGAGACTG GACAAATGAA CGCAAGACAG TCTTCAAAGG 300 AGACCAGAGG 310 (2) INFORMATION FOR SEQ ID NO:55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 252 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: TTTTTTTTTT TYCCGGGGAR GTCAAACATA CTTTTTCAAC ATAGGATKTC TGACAGGAGG 60 CCCTTGGMCA GGGTTCCCTG ACCTCTGYTT CAAACCCCAC TGGAAACAGA GCAAAGTCAT 120 CAMGAAAACC CAGGACACCA GGGCAGGGGG GCTGCACAAG GTCGGGTAGG TCACAGTGGG 180 CCAGCACACA GTGGCCCCGC CCAGGTCCAG CCCAGCCTGG GGGAGGGTGT GAGGGTTCCA 240 KGCAAGCTCA TT 252 (2) INFORMATION FOR SEQ ID NO:56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 188 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56: GTCAAGTCTA CCATCATTCT AGAAGGAAAA GGCATGGTGG GAATTCAGCA CCTGAACTTG 60 TATTTACACC AGCCTCGGCA TCTGGCAAGG RAATAGCGAT TGTTCATAGT GATGCAGAGA 120 GAGAACAGGA GGAKGAAGAA CAAATACACA CAAACAACTG ATCTAGGGAG ACTCCAARGA 180 TCCAACAG 188 (2) INFORMATION FOR SEQ ID NO:57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 304 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57: AATCAGCCTG CAAGCAAAAG ATAGGAATAT TCACCTACAG TGGGCACCTC CTTGAAGAAG 60 CTGATAGCTT TTACACAGTA TTAGATTGAA ATAATGGACA GAAACACATT CTTGTCAAGA 120 AAGGGGGAGA GAAGTCTGTT TGCAAGTTTC AAAGCAAAAA GCAAAAGTGA AATGATTTGA 180 GGATTTCTGT TCTAATTGGA GATGATTCTC TGGTTGTTAG AAATGGCAAA TATTGATGAT 240 TGTGTGCTAT TGATTGGTGC AGGATACTTG GTATACGAGT AAATACTTGA GACTCGTGTC 300 ACTT 304 (2) INFORMATION FOR SEQ ID NO:58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 261 base pairs (B) TYPE: nucleic acid (C)- STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58: CCAGAAGCTT CTTGCCTTCT CTGTGCTCTC AGTGGTTCCC TTCCCTGAAG TGCCTCCCTT 60 CTCATTAATT ATAGCCTGTG TCTGAACATT GTGAGCTATA AGAACCCTCA TATTAATGGT 120 TAAGGGACTG TTGGAAATGA TGTGATTTTA TTAAAAATGG GGTCTTTGTG GAGGAGTCAG 180 GAATGGTCAA AATGAGCTTC AGGTATGGGG CTTGCTCTRT GCTCCTGATA CCAAGGGTCT 240 GGCAAGCACA AAGGAAGGTG G 261 (2) INFORMATION FOR SEQ ID NO:59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 470 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59: AATACGTATT CTGAAGCCAC TATATCTGCA TATGTATCCC AGATTTGAAC AATTAAGTAA 60 AAAGATGGTG AATGATGAAA GCCAGTTTTC TGTCTGTAGA AGTGAGAGGT GACAGATAAC 120 CAAAGGAAGA AGGCTAGAAT GGATAGAGGA CAGTGCTTAA GTGTAGTTCC TGTTGCCTTT 180 AGTCTTATAG ACTTCATTTC CAAAGTTTCT TAGCACCCCC CTTCCCCCTT TGGTGAGGTT 240 GTTTCACATA TTTTCTAGAC AATTAGATTC TTTTGTCAAA GTCTGTGTTC CATCCGGAGA 300 GCCTCTGATC TCTTAAATGA TTTTTTAAAT TTACATACAT TAAGGTTCAC TCTGCTGTAA 360 AGGTCTGTGG GTTTTAATCC TGTCTCACAG TTTTTGCATA TGTTGGCCTT CTGCCTGGGA 420 ATACTCTCCC AGATATTCCC CATGACTGGC CCCTTATCTT CAATCAGATC 470 (2) INFORMATION FOR SEQ ID NO:60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 466 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60: GTGTTTCAAG GGAAGGCAAC TMCAAGTTTG TGCAGCTGAA TTTCTGTAAA GTTAAGACAG 60 ACTCAMCTTC TCATTCAATC TGGGGCAGTG GATAACCTTT CTGAATAGAC CCACTTGTTC 120 ACGGACAGGG ATAGAGGTTT GCCTTTCTTC TTTCCTTGAA TTTGGAGTGA GCACTAGGGA 180 GGGGAAGTGC ATGGGTGACA TGAAGAAGGT GAAGATGTAG TAAAAGCATC ATCCAGGTAC 240 ACATTAACGG TGCTGCAGAA TTTTCACAAT ACAACTGAGG GAGTCTGTAG TGGCAAAAGC 300 AATTACTGAG CACAAAAGCC AGTCCTCAAG GGCTGATTCC ACCTTCCCTG TCCAGGGACT 360 TTCTCAGCAA ACTTTGTTCA TGAGCAGTTG TTCGCTTTGA TGGTCTTAGC CAGTTTTTGG 420 TGCAGGGGTG TTCCTCTGGT ACTAGGGCTA GGGCAGCTGT TTAAAG 466 (2) INFORMATION FOR SEQ ID NO:61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 491 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61: GACACCCCTC CTGCCATGAA GAATGCCACT AGCTCTAAGC AGCTCCCACT GGAACCAGAG 60 AGCCCCTCAG GGCAGGTCGG GCCTAGGCCA GCCCCCCCGC AGGAAGAGTC CCCTTCCTCT 120 GAAGCAAAGA GCAGAGGACC CACCCCACCA GCCATGGGCC CACGGGATGC CAGACCTCCT 180 CGAAGGAGCA GCCAGCCATC TCCAACAGCA GTGCCAGCCT CCGACAGCCC TCCCACCAAG 240 CAAGAGGTGA AGAAGGCAGG AGAGAGACAC AAGCTGGCAA AGGAGCGGCG AGAAGAGCGT 300 GCCAAGTACC TGGCGGCCAA GGAAGGCAGT GTGGCTGGGA AGGAGGAGAA AGGCCAAGGT 360 GCTGCGGGAG GAAGCAAGCT CCATGGAGCG CCGCTGCCGG TTTTAGGGAG CAAACGTCTT 420 AAAGCCGAGC AACGCCGTTC AAGCCTTGGA GGAACGGCTA GCGGAAGAAG TTTGTGGAAA 480 ACAAGGGGCG T 491 (2) INFORMATION FOR SEQ ID NO:62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 478 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62: ATCATTGAGT ACGCAGAGCT CAAAACAGAC GTGTTCCAGA GCCTGAGGGA AGTGGGCAAT 60 GCATCCTCTT CTGCCTCCTC ATAGAGCAAG CTCTGTCTCA GGAGGAGGTC TGCGATTTGC 120 TCCATGCCGA CCCTTCCAAA ACATCTTGCC TAGAGTCTAC ATCAAAGAGG GGGAGCGCCT 180 GGAGGTCCGG ATGAAACGTC TGGAAGCCAA GTATGCCCCG CTCCACCTGG TCCCTCTGAT 240 CGAGCGGCTG GGGACCCTCA GCAAATCGCC ATTGCTCGCG AGGGTGACCT CCTGACCAAG 300 GAGCGGCTGT CTGTGGCTGT CCATGTTCGA GGTCATCCTG ACCCGATTCG GAGCTACCTT 360 CAGGACCCAT CTGGCGGGGC CACCGCCACC AATGCGTATG ACGTCGATGA GTTTTTGAGT 420 TCACTGCTGT GAGCGCATGA GTCGTGTACT GAATCCTGTG GACAACGGTT AAGTTACA 478 (2) INFORMATION FOR SEQ ID NO:63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 183 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63: CCTGGAAAGT GGGGGTGGGC CAGGGGGCCA GGCCCAGCAT GCACCCCCAT TTTTTTGGGG 60 GCTGATCCCT GCCCCAGCTC TGCTGATACC CGGGGCCACA GCGTCAGGCC GTTGGGGGTG 120 GAGKTAGAGG TGGGAGAGCA GGGGAGAGAG CCTKAGGAGC CACAATTGGG CAGACAGAAG 180 CGG 183 (2) INFORMATION FOR SEQ ID NO:64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 316 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64: GGATATTGCA CCTTACAGAC TTAGGGAGCC TTTACCAGAG ACGCCTAAAA CGCCCCAGGT 60 TCAGCCATTG TGCTGAATAG AGTGGAATAT AGAACCAGGG ACAGAGTATT TCATTTAACG 120 TTGATATATA CTTGCTAAGG AAACACTAAC AATACTGTAA CTTTGTTAAA GGACATAGTA 180 TTGAAATGGG AAATAGAGGT CAGGCTCACA TCATCTTAGT TTAATGCTGG GCAACTTTTT 240 CTGATTTCTG TAGTTCCCTG GAAAATGTGT CCTTCGTACC CATAAAGTGG TACAAATGCA 300 TTTGTAACCA TTTTTG 316 (2) INFORMATION FOR SEQ ID NO:66: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 411 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66: ATCTGGTCTA GAGAGGCGAC TCCAAGCTCT CTTGCTGGCT CCCAGCTGTG GGAATCCTTT 60 AGGCTTGTTC TCAACCTACA CGTTAAAAAT GCTTCTTGGT GTGTTTGGGG AGGGGGAGAG 120 GGAAACTGAG CTCTCTCTTG ACCTCCTCCA ACACCCTTGA CTTGCTTACC CAGCCATTTT 180 CAGTAGCTAC ACGGGTGGTC ACAGAACACT GGGCGGCACT CGGCACACAA CACAGAACCG 240 GGGCAGTCCA TGCAGGTGCG GGAACACATG TCGGACCCAG GGAGCAAGGA ACACGCCACC 300 CCGAGGAACA TGCAAACGGA GGAAGGATTC CCTTCAGATT CCAAGGATGC CACAACCCCG 360 ACGGGCGGCT TAGGGAGGCA CCGATTATCT AAGGAAAAAG GCCACTGTTT G 411 (2) INFORMATION FOR SEQ ID NO:67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 413 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ.ID NO:67: CTGCTCCTTA TGTTTTTATT TCCAAAGTTT AGAATTTCTT TGCTTCATAG TATTATTTTA 60 TTTTACTAAA TTACAGAGTA AGAAAAGCTT TTCATTTTAT CTGATTTTAT TCTTAGAACA 120 AAAATATTAC GATCTTCTAT ATTTTTGTTC TTTTGCCAAA AAGTGTAGGC AATTTTACAT 180 CATCTTTTTT CCCAATCAGT TTGTGATCCA ACTATAAAAA GGAGACATAG AATACTGAAT 240 AAATGAAACA GAAACTCCAA GGCCAAGAAG TGTCCATCTT GAAAGAGTGT TAGTGGCAAG 300 ATATGTGACT GCAGACTAGA TGTAGACAAA CCTGAGAAAA ACCAAGCATG GGGGAAAGGA 360 TYCCTATTTT AATAAATGGT GCTGGGGAAA ACTGGCTAGC CATATGTACT TTA 413 (2) INFORMATION FOR SEQ ID NO:68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 372 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68: GCACGGTTAA AAGACCAACG TGTGTGGNTC AAATATAAAG GCCACACCTT TCAGACCGAA 60 CCTACTCAAA GATCCTTTAC TTTGCAATAA TTTGAACTGG AGAACCAAAG ACGGGAGACG 120 AATGAAAGCA AAGATGCTCA AAGAACCAAA GGAAAGACCT GAAGGAATCC ACCTGCATAG 180 GCCACGCGTT CCACTCTGGG TCAAATGCTT CCACGATGCA GAAACCTTTT TTTAAAAAAG 240 TGCAAGTCTA ATTACCTACC AAGGGTAATA AAAAGCACAG CACAGGAATG ATTACAGCTG 300 ATGGTCAAAA AACAAACCAA AACCATTAAA AAAACAATCA GGCAGAAAAC AGGAGTTAAA 360 TGTTTACATA TG 372 (2) INFORMATION FOR SEQ ID NO:69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 389 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69: TCTAGAACCT GGACCCACCC AGCGCGTCCT TTCTTATCCC CGAGTGGATG GATGGATGGA 60 TGGATGGTAG GGATGTTAAT AATTTTAGTG GAACAAAGCC TGTGAAATGA TTGTACATAG 120 TGTTAATTTA TTGTAACGAA TGGCTAGTTT TTATTCTCGT CAAGGCACAA AACCAGTTCA 180 TGCTTAACCN TTTTTTCCTT TCCTTTCTTT GCTTTTCTTT CTCTCCTCTC ATACTTTCTC 240 TTCTCTCTCT TTTAATTTTC TTGTGAGATA ATATTCTAAG AGGCTCTAGA AACATGAAAT 300 ACTCAGTAGT GGATGGGTTT CCCACTTCTC CTCAATCCGT TGCATGAAAT AATTACTATG 360 GTGCCCTAAT GCACACAAAT AGCTAAGGG 389 (2) INFORMATION FOR SEQ ID NO:71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 329 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71: GAAAAAATGG GAGGGCAGCC ATGTATTAAT TGTACATCCA AGGAAACTGT GCCCCAGGGG 60 TCTTGTGTGT ATTTCTGAGA AGAGGGGTGA GAAAAGGCAC TGTGTCAACA TTTGCTTCTG 120 CCTGAACGTG CACCTCCCAG TGCTCCTCCA TCAATTAGGA GAACTGTCTT GAAGAATGCT 180 GCCTCAGCTT CTGAAGAGAA GACCCCAGGA CATGCATTAA TGAGAGGAGG GGAGTCACAG 240 CTGCAGAAGA ATAAAGCTCT CTGAGGGAGC CTGGGNGCCC CCAGTGGAGG CCTGGAGCTT 300 GTTGACCANN GCAGCAGGAG ACCCCTGCT 329 (2) INFORMATION FOR SEQ ID NO:72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 418 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72: CTGAGTTGCC TGAGGTCATT CACATGCTTC AGCACCAGTT CCCATCTGTT CAGGCAAATG 60 CAGCGGCCTA CCTGCAGCAC CTGTGCTTTG GTGACAACAA AGTGAAGATG GAGGTGTGTA 120 GGTTAGGGGG AATCAAGCAT CTGGTTGACC TTCTGGACCA CAGAGTTTTG GAAGTTCAGA 180 AGAATGCTTG TGGTGCCCTT CGAAACCTCG TTTTTGGCAA GTCTACAGAT GAAAATAAAA 240 TAGCAATGAA GAATGTTGGT GGGGATACCT GCCTTGTTGC GGCTGTTGAG AAAAATCTAT 300 TTGATGCAGA AGTAAGGGAG CTTGTTACAG GAGTCTTTGG AATTATCCCT CATGTGATGC 360 CTGTAAAAAT GACATTCATT CGAGATGCTC TCTCAACCTT AACAAACACT GTGATTGT 418 (2) INFORMATION FOR SEQ ID NO:73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 336 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73: CTGAATTTTT ATATGCTTCA CTTAGGCTTT CATTTGAGTA GACTCTAAAA ATTCTGCCTT 60 GCTTAAGTNC TAACACTGCC TCTCAGATTT CAGTTTTGGA CATTGCACAA CTAAGACCTT 120 TTAAACGCAT TTNCTTGCTA ACTCGGAAGA CACATAGTCT GCAGCAAGAC ATTCCTATAT 180 TGAAGAAATG AGAGAAAATT TTATGCTGCA TCAGGTGGAG AGCAAGGCTC AACGGTGGTT 240 GCATTAGTTC CCTCGGAAGT ATTGAAAAAN CTTTGAAATG GGAAGGAAAA TTTTTTGCAC 300 CTAATGTTCC TGAGGTACCC AGAATGTCTG GGGGTT 336 (2) INFORMATION FOR SEQ ID NO:74: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 402 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74: GTGCTCAGTA AATACAAATT GGATGGACTA GAGAGATAGC CCCGAGGACA CTGCCAAATA 60 AATAACAAAT TGTGCAAGCA GCAGGCCGCT GTAATTAGAC CAAGGAGGAC AGTCAGTTAT 120 TAATATCAGA CACGTGGCAG GGTTAACAGC CACTGAGGGT GGGTACAATG AAGAGAGTCA 180 CTTTCTGCAC CCTCAGGGAC TTCCCTTGTG ATGGCCTTCT AAAGAGGGCT GAACAGCACC 240 AAGTGCCCTC GCTGCCTCTG GTTCCTGCTG CCCTCCGCGT GCCTTGGGTG CCCCACAACT 300 AGGGCCCTGG GTCCCTCCCA TGTCCCCCTC CCTCCTACAA CCCCTCAGCC CCTTATCTGG 360 CCAGCCATTA TGATGCCTAT CAGTATGAGG CCAGATGAGA GT 402 (2) INFORMATION FOR SEQ ID NO:75: (i) SEQUENCE CHARACTERISTICS:" (A) LENGTH: 454 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear -1Q7- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75: GGACCCCGGG CCCGCGATGT GGCCCAGTAC CTGCTCTCAG ACAGCCTCTT CGTGTGGGTT 60 CTAGTAAATA CCGCTTGCTG TGTTTTGATG TTGGTGGCTA AGCTCATCCA GTGTATTGTG 120 TTTGGCCCTC TTCGAGTGAG TGAGAGACAG CATCTCAAAG ACANATTTTG GAATTTTATT 180 TTCTACAAGT TCATTTTCAT CTTTGGTGTG CTGAATGTCC AGACAGTGGA AGAGGTGGTC 240 ATGTGGTGCC TCTGGTTTGC CGGACTTGTC TTTCTGCACC TGATGGTTCA GCTCTGCAAG 300 GNTCGATTTG AATATCTTTC CTTCTCGNCC ACCACGGCGA TGAGCAGCCA CGGGTCGAGT 360 CCTGTCCCTG TTTGGTTGCC ATGCTGCTTT TCCTGCTGTG GACTTGCGGC CGTTTGCTCA 420 TTACCGGGTA CACCACGGAA TGCACACCTG GCTT 454 (2) INFORMATION FOR SEQ ID NO:76: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 313 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76: GCTTTGATAG CTAGTTGTCT AAAAGTGCTG NTTATTAAAT AATCCACCTN TTTCCCCACT 60 TAAAACATCC CTCTTACCAT ATACTAAATT CCNGTAGCCC TGGGTCTGTT TCTGGACTCT 120 CCCGTCTGTC TGACCCCCTC CAGGTCACAC TGAGTGAGGT AATGGTGGCG TGAGAATCCT 180 CTGGGAATCT GGCAGGNTCA CCCCNGAGCA GTCCACCCCN CAACTCATTA NCATCGTTCA 240 GAGTGGNCTG AGTGNTCTCA CACATTCACT CTGCCAAATG CACTTTAGGA ACTGTCAAAT 300 TCCAAAGTTT CAA 313 (2) INFORMATION FOR SEQ ID NO:77: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 446 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77: CTCAGCCGTA GCCCTAAGTC GTTTTTCCAA TTTAGGAAGC TCACAACGCA GATCTGCATT 60 GTCACGTACC AGCTGTTTGT GAACCTTTGT AAGCTGTTCC AGGTTGTTCT CAAGAAAGGA 120 AATCTTCTGC TTTTGGGAGT GAATCCCCCC ACTGTCTTCG GGCTCCATTT CTGCACTTTT 180 CTTGACTCGA GTCGTGACGT CTTGAACGAA CAGCTTGCGA AGGTTGTGGC SGGTCTGGAG 240 TTCCCGGGCA ACTGTCTCCT CCAGACCCTT GAGGTCCTGC TTGTGACTGC TCAATGTCGC 300 TCGTACAGAA ATGTCAGCTC CTGCAGCTTT GGTGCTCTTC TCGTGGTTCT TCGCTCTTTC 360 AGCTTTCTCG TAGTCAAGCC TGAAGGCTTC TCTAAGCTCT AACTGGAGCT TCTGATTTAA 420 GGTCTTTTGA GCTCATCAAA TGGTCT 446 (2) INFORMATION FOR SEQ ID NO:78: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 296 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78: AGCCGGTGGC GCAATGGAGA GAATGTGCCT GAGACAGAGC GCCTGGCTGG GGAGGAGGCA 60 GCCCTGGGNG CCGAGCTCTG TGAGGAGACC CCTGTGAATG ACAACTCATC CATCGTGGTG 120 CGCATCGCGC CCGAGGAGCG GCAGAAATAC GAGGAGGAGA TCCGCCGTCT CTATAAGCAG 180 CTTNACGACA AGGATGATGA AATCAACCAA CAAAGCCAAC TCATAGAGNA GCTCAAGCAG 240 CAAATNCTGG ACCAGGAAGA GCTGCTGGTG TNCACCCGAG GAGACAACGA GAAGGT 296 (2) INFORMATION FOR SEQ ID NO:79: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 285 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79: CCTTTCCTGC CTGGGAAGTG ATGACTCGCA GGTCGGGCTT GCGGCTGGGG GCTCCAAGCT 60 GGGTGCTGTG GGTAGGTGGG GGCGGAGACT TGGCAGGGAT GACCTTGTTT AGGCTGTTGC 120 CATTGGCCAC AGGGAGGAGG CCAGGGGAAG CCCGAGCACT GACGTAGCCA TTCCCAACAG 180 GGCTGGGGCA GGCTCCGTTA GCACTGTTCA GGTCACCNCC CAGCATGGCC CCCGCACTAG 240 CTGGCCGCTG GGGCAGGCCA GGAGACACAC TGTTCCTCTG TAGTG 285 (2) INFORMATION FOR SEQ ID NO:80: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 402 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80: ATGATTTCTT GCCTGTNATA ACCTATGCAC TCACAAAGAT GAACTCTCTG AGAGGGATGA 60 GCAAGAGCTT CAGGAAATCC GAAAGTATTT CTCCTTTCCT GTATTCTTTT TCAAAGTGCC 120 GAAACTGGGC TCGGAGATAA TAGACTCCTC AACCAGGAGA ATGGAGAGCG AAAGATCACC 180 GCTTTATCGC CAGCTAATTG ACCTGGGCTA TCTGAGCAGC AGTCACTGGA ACTGTGGGGC 240 TCCTGGCCAG GGATACTAAA GCTCAGAGCA TGTTGGTGGA ACAGAGTGAA AAGCTGAGAC 300 ACTTGAGCAC ATTTTCTCAC CAGGTGTTAC AGACTCGCCT GGTNGATGCA GCCAAGGCCC 360 TGAAACCTGG TGCACTGCCA CTGCCTTGAC ATCTTTTATT AA 402 (2) INFORMATION FOR SEQ ID NO:81: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 246 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81: CATTTTTAAT AGAGACGGGG TTTAACCATG TTGGCCAGGC TGGTCTTGAA CTCTTGATCT 60 CAGGTAATCC ACCCACTATG GCCTCCCAAA GTGCTGGGGT TACAGGTTTG AGCCTCTGTN 120 CCCGGCCCGG CCAAAGACTG CCTATTCTAA ACGTTGCTGA GGACGTGGAN CAATCACAGC 180 TCTCCTNTCT TTCCAGTGGG AGTTTAACAT GGCACAACCG CCTGAAAACC GTTTGGNGAT 240 TTCTGT 246 (2) INFORMATION FOR SEQ ID NO:82: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 394 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82: GGGAACCCTC AGCAAAATAT AATGGTACCG CTATTATCAG CCTTGTTCGA GGCCCAGGGA 60 TTTTGGGGGA GGTCACAGTG TTCTGGAGGA TATTCCCTCC TTCCGTGGGG GAATTTGCTG 120 AAACATCAGG NAAACTGACA ATGCGAGACG AACAGTCTGC AGTCATTGTA GTAATACAGG 180 CTTTGAACGA TGACATTCCC GAGGAAAAAA GCTTCTATGA GTTTCAGCTC ACTGCAGTCA 240 GTNAGGGAGG AGTTCTGAGT GAATCCAGCA GCACTNCCAA CATCACGGTG GTGGCCAGCG 300 ACTCTCCCTA TGGCCGATTT GCCTTTTNAC ATGAGGCAAC TTCGAGTGTC AGAAGCACAG 360 AGGGNTAACA TCACAATCAT CCGTTCCAGT GGAG 394 (2) INFORMATION FOR SEQ ID NO:83: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 308 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83: ATAAGACCAT TGGCAAAGGG AGAATTCATG AACTGAAAGA TCTGAAGTAA TTTCCCAGAA 60 TGTAATGTTA AGAAATAAGT TAAAAGGCAG AGCATAATGA GTCTAACATG TGTGATTGAA 120 GTCTTATAAG GMGAGAATTA AGAMCAGGCA ATATTTTAAA GGRATAATGG AGAAAATGGA 180 ATAATTGATG AAATATGTGA ATATATATAG GGACCATATG CATATGAMGG CCGGGGGTTA 240 AATAAAACGA AATCTACTTG TACATACTTT ATGGGATTCC TGCAGCCCGG GGGGATCCAC 300 TAGTTCTT 308 (2) INFORMATION FOR SEQ ID NO:84: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 313 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84: CTTTAACTTA ATGGCAATTA AAACTCACTG GCAAAAAAAA TCACTAGAGA TGTCAGTCCA 60 TTATCTTACC AAATAGTGTA TTTTTACCAT CTTTTACCTA CACCCTTGAG TAAGGTGGAA 120 TAGGTTAAAG TTACTGGCAT AATAACACTT CATTGAATTC ATGATAGTAT TTAACATGTT 180 AAAACTGTTT AGTTGAAAAG TTCACATGCA ATTTATAATT TAAAAATATG CTACATATAT 240 TTCATAAAAW TACAATAGGT CATACTARAC TTTGACTAAA ATTAAGAATG TKTTTCTKTC 300 ATAATAATGC AGG 313 (2) INFORMATION FOR SEQ ID NO:85: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 303 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85: TGCTCCGTTT ATTGCTCTAT TCAATGACCA CGAGCGAATT ATAAAAAGAC ACCAAATGTC 60 TCTGTCTGCC GTGGGATAAA TATTTAAAGT CAGCAATAAA GTCACGTGGC TCCAAGRTAA 120 TACATGTTGC CAAAGAGTCA TGCATGCCCT CCTGATGGGC TCTCAACACA CGTATGGWCA 180 TGGGAACACA CGCAGAGCAA CACGCAGTAT GAACTTSTGG GAAGGCTTTA CCACAGTGAC 240 ACAGTAAAAT GTCTCACGTA GATCTGRGCT GAGTCCCCAC CCAAACCTTG AGCTCCCCTT 300 CCA 303 (2) INFORMATION FOR SEQ ID NO:86: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 380 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86: AAAACAAACC AGCTTTAATA CCAATATAGT TCTCTCTTAA ATACCGTGTT TCCCAGGACA 60 AATGCAGGGG CAGGCTCTTG GCAGAAAGAG TAGAAAGGAA ATGTGGAACA AAATGGAATG 120 GATGGCCCAG GCCCAGGGTC CCTGCCTTGG GCACTAGGGA CTGGGCTGCC TCGGGGATGG 180 GGGAGTGACA GCAGCTCCCC CTGGTCCAGT TATTGCAGAG GCGTCGGGGG CTCCCCTCCC 240 TCCCCAGGCC TGAAACATTT CTCAGGATTA CTTCTGACCT TCAGCCCCAG CAGGGCCAGG 300 GCCTGGGCTC CTCTGGTCTA GGATGGGCCC CTTTGCCCAA AAGGGCCTTC AGCTAAGGCG 360 TTGGGTTGGG CGGGGAGCCC 380 (2) INFORMATION FOR SEQ ID NO:87: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 280 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87: GCCTTTGCTG CTTATTCGCA TCGATGGTGA AAGAGATGTC AGGAGCACTT CTCTGCTGAG 60 GTGGCTGAGA CGAAGAGGAC TCTGCTGCCA GCCTTGCCGC ATACCTGGCA ATTAGCCTGT 120 GTTCTTCATC AAGCCGGTTT GAACTCTCAA GCATGCTCCT GGTAATAAAA GGACTTCCTG 180 AGGAGGGAAC AGAGTGNGAG AACAGGGTGT CGTTCATGCT GGTTACAGGT CTGGGAGGCA 240 CGATGTGAGC CAAGTTGAGT GGCTTCTCAG GCTGATCTGG 280 (2) INFORMATION FOR SEQ ID NO:88: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 446 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88: CCTGCGTCTC TTACACCCYC TCCCACCCGA GGCTCCCCAG AGATAGCAGA GAATTCGAAG 60 AGGTCGCCGG GGACTGGAAA GAAGTCCCNG NAGGCCGCCT TCGCAGTCTA CACCCCAGCC 120 TGCTTCCCAG CCTACAYCCA GACCCAGCTC AGACCTTCGT GACCACCCCA TCCCTTTCTC 180 CGGCTGGCTG GGTCGGGGGC ATCCCTCTCT GTCGCTGGCT TCCAGAGGCA GGACAGGCCT 240 CCTGGTAAGC CCGCAAAGTT GCTGACCTCC TGACTTCGTC TGCCTTTTAT TAATATCTGT 300 ATTGCTGATA ACCGTGCTCT TGACTATGTG TCCCAGGTCA TGTCCCAGGT CATGGAGAAG 360- CCCGTGCCAC AGTGACCCTT CCCATACTTC TGGGGGGGCT GCTCTCCATC TGGATCGTAG 420 GAGGATATAG GTGTGTTCTG GACCAT 446 (2) INFORMATION FOR SEQ ID NO:89: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 384 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89: GTCCCTTCTG GGGACTCTRT TTCCCCATTT ATTGCTGCTG TGTCCCTNAC CAGTTCCTTG 60 CAGGATTCCC TCCTTTTAAA ATGCCCTTAA ATCTAGCTTT GCCTTGGAGA CCCCAGTGGG 120 TGCTGCTCCT GCCGTTTTCT TCCTGCCAAG CCTGAATCAA TGTTTCATCT CCAACCCTCT 180 GCCAGTTTGG CCCCTCAAAG CTTGGTGGCT CAAGACTGTW AGCCTGGCAG AGCCGCGNGG 240 TGAAGGGAGA AGCTCTTGGA GCAGGCAGGA TGCCACCGCT GCTTCAGCTT GCCTCCTCGC 300 CCAGCTACCC TTTGGCCCCA TTGGGCCCTC GTMTGCCTCT CCAGGATTGT ATGTTTCAAG 360 NCTTGTCCTG TGTTCCTTTG TCTG 384 (2) INFORMATION FOR SEQ ID NO:90: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 344 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90: TCAAGCTGGA AAGGGCTACT ACCTCATGCT GGAAAGGGCT ACTACCTCAA GCTGGAAAGG 60 GCTACTACCT CAAGCTGGAA AGGGCTACTA CCTCAAGCTG GAAAGGGCTA CTACCTCAAG 120 CTGGAAAGAG CTACTACCTC AAGCTGGAAA GGGCTACTAC CTCATGCTGG AAAGGGCTAC 180 TACCTCAAGC TGGAAAGAGC TACTACCTCA AGCTGGAAAG GGCTACTACC TCAAGCTGGA 240 AAGGGCTACT ACCTCAAGCT GGAAAGAGCT ACTACCTCCA AGCTGGAAAG GGCTACTACC 300 TCATGCTGGG AAAGGGCTAC TACCTCAAGC TGGACAGGGC TACT 344 (2) INFORMATION FOR SEQ ID NO:91: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 364 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91: GCCCCAGGGT GAGGGCTATG AGGGGTCAGG GGTCAGGTTC CCCAGGACCC TAGTCCTTGT 60 CCCCTTCCCT GGTGCTAAAT AAAAGTGAAT AAATACTAAA TAAATACAAC TGGGGCCCAG 120 GCCCTCCCTG CCTTCCCCCT CCCTCCTGTG ACCCGCAGCA GAGGGGGCAG TTTAGATGGA 180 GGGCTGTCTG TCAGCCCCTT CCATCCACTA ACCCATCACT GCCTCCCAGG GCAGGAAACC 240 AGGGCAGGGC CAGCCTGCGC ATTAGGGCAG AGAGGAGGGG CAGGTCTCAC GCCCACAGCC 300 CCTTCCCACT TGAGTCTTAG CATGAGGCAG CAACAGAAGC TCTCTCTTCC TCCCAGCTAA 360 GTCC 364 (2) INFORMATION FOR SEQ ID NO:92: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 218 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92: ATTTAATAGA AAATTAAAAT AATAAATAAT ATGAAACAGA CTGATAACGC TGAGCTGGGC 60 AGGCCCAGGC CAGTCTAGTA CAAAGTTAAG GAGGTAGGGA GGATGGTGGG GAGGAGGGGG 120 CGGACTACCC TGCAGGACGC GGGAGGCTGC TCAGACTGTG GTGATGTCAG GAAGGGCCGC 180 ACACTTTGGC ATGGACGATG CACTAAAAAA AGAGAAAG 218 (2) INFORMATION FOR SEQ ID NO:93: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 364 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93: GCTTTCAAGG GAACAAAGAA TCGGCCTGGC AGTGCCCTGG AGAAGGAGGT GGAGAGCATG 60 GGGGCCCATC TTAATGCCTA CAGNACCCGG GAGCACACAG CTTACTACAT CAAGGCGCTG 120 TCCAAGGATC TGCCGAAAGC TGTGGAGCTC CTGGGTGACA TTGTGCAGAA CTGTAGTCTG 180 GAAGACTCAC AGATTGAGAA GGAACGTGAT GTGATCCTGC GGGAGATGCA GGAGAATGAT 240 GCATCTATGC GAGATGTGGT CTTTAACTAC CTGCATGCCA CAGCATTCCA GGGGCACACC 300 TCTAGCCCAG GCTTTGGAGG GGCCCAGTGA GAATGTCAGG AAGCTGTCTC GTGCAGACTT 360 GACC 364 (2) INFORMATION FOR SEQ ID NO:94: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 423 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94: CTTCATACTA GAACTGTCTG CCATCTTTAT TTCTTTGTTT TCAGGAAAAT TGGAGAGAAA 60 AGTATTTCTT TTTTAAAAAT GATTATTATA CTTTAAGTTC TGGGATACAT GTGCAGAACG 120 TGCACGTTTG TTACATAAGT ATACACGTGC CATGGTGGTT TGCTGCACCC ATCAACCCGT 180 CATCTACATT AGGTATTTCT CCTAATGCTA TCCCTCCCCT AGCCCCCCAC CCTCCAACAG 240 GCTCCAGTGT GTGATGTTCC CCTCCCTGTG TCCATGTGTT CTCATTGTTC AACTCCCACT 300 TATGAGTGAG GGACATGCAG TGTTTGATTT TCTGTTCCTG TGTTACTTTG CTGAGAATGA 360 TGGCTTCCAG ATTCATCCAT GTCCTTGCAA AGGCATGAAC TCATCCTTTT TATGGCTGCA 420 TAG 423 (2) INFORMATION FOR SEQ ID NO:95: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 405 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95: AACAGCCCCC GATCTGCATA GCCTGTGAAA GCCCACGGGG ACATCAGTAA CCTTCTGCAG 60 CCACCATCCA ATGCCATTAC TGTNAAGTGA GACTTGGCCA CTGTAGCCTG GGCCTGCTGC 120 AGGAGCTCTT CAGAAAGGCA CATGAGGACC ACGGTTTGCC TCAGTTTCTG GTAAAACACA 180 AGGTCTGGAG TGCCCCTGCA AAGGGTATTG ATGGACTTCC TGCCAGTGAC AGAGCATGTC 240 TATTGCAAAC AATTCTCTCA GTTACGTTCA GCACTTAAGA ACGGCTAATG NCAATAGGAT 300 CTTTAGCAAC TTTTTCACAT CATAGAAGGT GCAATCGCTC ACTTGGGAAC ACTACTGAGA 360 GTGACTTCTC TTTTAAAATT GAGTAGCAGA TGAAAAATTA AAATT 405 (2) INFORMATION FOR SEQ ID NO:96: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 173 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96: GAAGACAATA CTGATGCCAG CTCTTTGTAA TTGTGAAATC TGTACCCAAA CCTCTGGATT 60 AGAATCTCCA GTTGTCTACT GTAAATACTG GAATTACAGC AAAGGATATG GGGACTGGGC 120 TGCTTTTCTG TATTGTACAA GCACTATTCT AGATATTAAA GAAATTTAAC CGC 173 (2) INFORMATION FOR SEQ ID NO:97: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 337 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97: ATGGCGCCCT ACAGCCTACT GGTGACTCGG CTGCAGAAAG CTCTGGGTGT GCGGCAGTAC 60 CATGTGGCCT CAGTCCTGTG CCAACGGGCC AAGGTGGCGA TGAGCCANTT TGAGCCCAAC 120 GAGTACATCC ATTATGACCT GCTAGAGAAG AACATTAACA TTGTTCGCAA ACGACTGAAC 180 CGGCCGCTGA CCCTCTCGGA GAAGNTTGTG TATGGACACC TGGATGACCC CGCCAGCCAG 240 GAAATTGAGC GAGGCAAGTC GTACCTGCGG CTGCGGNCGG ACCGTGTGGC CATGCAGGAT 300 GCGACGGSCC AGATTGGCCA TGCTCCAGTT CATCAAG 337 (2) INFORMATION FOR SEQ ID NO:98: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 212 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98: TGAAGCCCAA GNAGTNTGTG AAGACAGAGA ATGACCACAT CAACCTGAAG GTGGCCGGGC 60 AGGACGGCTC CGTGGTGCAG TTCAAGATCA AGAGGCACAC GCCGCTGAGC AAGCTGATGA 120 AGGCCTACTG AGAGAGGCAG GGCTTKTCAA KGAGGCAGAT CAGATTCAGK TTCGACGGGC 180 AGCCAATCAG TGAAACTGAC ACTCCAGCAC AG 212 (2) INFORMATION FOR SEQ ID NO:99: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 265 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99: CCTTTTAATA ATAATTCTGC TGTCTGCTGT GTACTAGAAC CCATGCCTAC TGCTTGGGGT 60 ATAATGTAGT AAATGTAGTA AAAACAATAT CCGCCGGGCG CGGTGGCTCA CGCCTGTAAT 120 TCCAGCACTT TGGGAGGCCA AGGAGGGCGG ATCACGAGGT CAGGAGAGCG AGACCATCCT 180 GGCTAACATG GTGAAACCCC GTCTCTACTA AAAATACCAA AAATTAGCCA GGCGTGGTGA 240 TGGACGCCTG TAGTCCCAGC TACTC 265 (2) INFORMATION FOR SEQ ID NO:100: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 333 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100: AAAATGCTCA CAGTGGTCTT CTCTGGCCGG TGAGCCTACA GCTGATCTTG TCAGAGACAA 60 ACGTTAGTTT TACTGAGTCA CCCAGAGCCC TGTGCTGGTG CCTGAGGGTT TGTTCCATGG 120 GACAGTCTCC ACAATTCCTC TGGGGAAGGG CCACAAATCC CACAGTGTGT CCCAAGAGGG 180 CTGGAGTAGG CGGAGTCCCC AGCAGCTGTG GCATGACCAG CCATCTCTCT CAAAACAATT 240 GTTAACAAGC CTTCTGCAAG TTAAGGTTCC ACATGGTAGC CGTGGTACAG AGGCATTTCT 300 CTAGGGTGGG AGAGGCTTGT GCTCTACACC AGG 333 (2) INFORMATION FOR SEQ ID NO:101: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 156 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101: CTCTGACTTT CCTGTGGNTT TAGAGCCAAG CTCAAGGTAG TAGGCCGTAG GGNCTTATTT 60 TATTTTCAAA CCCCCATCCT CAGAGCGCAG ATACATGCAG AGGCTTCTGC CAGGCTACCA 120 CGGGGCCTTA GTGGGAACAG GTTGAGACCA GCACTT 156 (2) INFORMATION FOR SEQ ID NO:102: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 331 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:102: CGAAAAGGGG NNNTATGGCC ATCTTTTATC AGAAAAAGTG ACAAAACGGG AATTTAAAAA 60 ATGAATTTTC NNTCTGACTT TATTTNNAAA TACACTTTCT TTTTTNNAAA ACCAATACAC 120 TTTCTTTGAG GATGACAGTA TTAGGAAATC CAATTNNACA AAAAATACTA CATCTAGTCT 180 GGGGTAGATA TATTTATTTT TGGTAACATA CATTAAGTGG CACTAATTAC ACAGTAACTA 240 TAAGGTAACT AACATGAAAC CACAGAACTG TAACTCTGCC ACAGCTGCAT GAACTTGGGC 300 TTTTCTGGTT GAGCCCATTT TCAAAAAACT G 331 (2) INFORMATION FOR SEQ ID NO:103: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 316 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103: AGCCACTGCG CCCCACCCCA TTTCGGTGTN ANCTCAGCTC ACTTCAACCT ACCCCTCCCA 60 AGTTCAAGTG ATTCTCCTAC CTCAGCCTCT TGAGTAGCTG GGATTACAGG GGTCTGCCAC 120 CACGCTGGGT GATTTTCCTA TTTTTAGTTG ACACTGCATT TCACCAGGTT GGCCAGGCTG 180 GTGTTGAACT CCTGACCTCA GCTGATCCAC CCGTCTCGGG GTCCCAAAGT GTTGGGATTA 240 CAGGTGTGAG CCACCACACC AGGCCCATAT TTTCTTTTAG ACATGCAGGC AATGTTGGTG 300 GGTTTGTCTG TTAAGA 316 (2) INFORMATION FOR SEQ ID NO:104: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 308 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104: GTTTTTCCTG CATCTATTGA GATAATCATG TGGTTTTTGT ATTTGGCTCT GTTTATATGC 60 TGGATTACAT TTATTGATTT GCGTATATTG AACCAGCCTT GCATCCCAGG GATGANGCCC 120 ACTNGATCAT GGTCGATAAG CTTTTTGATG TGCTGCTGGA TTCGTTTTGC CAGTATTTTA 180 TTGAGGATTT TTGCATCAAT GTTCATCAAG GATATTGGNC TAAAAGTGTG CTGTATTCAG 240 GAAACCCATC TCACGTGCAG AGACACACAT AGGCTCAAAA TAAAGGGATG GAGGAAGATC 300 TACCAAGC 308 (2) INFORMATION FOR SEQ ID NO:105: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 355 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105: GGCCTTCCTC AATATGTAGG CGCCACTTTT TCTCCCTGTG CCCTCACCTG GTCACCCCTC 60 TGTGCGCGAN ATCCCACTGT CTCTCTGGGT GTCCAAACTT CCTCTTCTTA GGAGGACACA 120 AGTCAGATTG GATTAGGGCC CACCCCAATG GCCTCATTTT AACTTAATCA CCTCCCTTTT 180 GTTTGGGCTT TTTAACTTAA TCACCTCTTT AAAGACCTTA TCTCCAACTA AGGTTTCATT 240 CTGAGGTATA CTGGAGGTTA AGACTTTAAA ACACGAATTT GGAGGGGACG TAATTCAGCC 300 CATAACAATA ACAATAATGA CATCTTACAA CTTACTGCCA CCACCAAGCT TGCTG 355 (2) INFORMATION FOR SEQ ID NO:106: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 355 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106: GGATGAGGTC GCCGGGATCG TGGCTGCACG CCACTGCAAG ACCAACATCG TCACAGCTTC 60 CGTGGACGCC ATTAATTTTC ATGACAAGAT CAGAAAAGGC TGCGTCATCA CCATCTCGGG 120 ACGCATGACC TTCACGAGCA ATAAGTCCAT GGAGATCGAG GTGTTGGTGG ACGCCGACCC 180 TGTTGTGGAC AGCTCTCAGA AGCGNTACCG GGCCGCCAGT GCCTTCTTCA CCTACGTGTC 240 GCTGAGCCAG GAAGGCAGGT CGCTGCCTGT GCCCCAGNTG GTGCCCGAGA CCGAGGACGA 300 GAAGAAGCGC TTTTAGGAAG GCAAAGGGCG GTACCTGCAG ATGAAGGCGA GGGAC 355 (2) INFORMATION FOR SEQ ID NO:107: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 273 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107: GTGTCTCTTT TAAAGAAAAC ATACTTTATT TTGGTCTAAA TTGTGAAAAT ACCCAAAACA 60 TTTGATAGAA ATTGAACTCT GTCAACAGTG TTATTTATAC TAAGATCAGG ACAGTTCCTT 120 GAGATCATAC TGTTTTATTA CTAAGTTTGG CCTTTGTTTT ACAAATGTAA TGTTCATATT 180 TATTTGAATT TTAAGATTGG TTAAATGTTA ATGAAAAGCA ATCCAATTGT TANTTTTTAG 240 TAGTGCCTTT TCTCTGTATG CCTTAATTTT ATT 273 (2) INFORMATION FOR SEQ ID NO:108: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 359 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:108: ATTTTATTTC CTTACATCGA AGAAAATGTT AAAGAGTATC TGCAGACACA TTGGGAAGAA 60 GAGGAGTGCC AGCAGGATGT CAGTCTTTTG AGGAAACAGG CTGAAGAGGA CGCCCACCTG 120 GATGGGGCTG TTCCTATCCC TGCAGCATCT GGGAATGGAG TGGATGATCT GCAACAGATG 180 ATCCAGGCCG TGGTAGATAA TGTGTGCTGG CAGATGTCCC TGGNTCGAAA GACCACTGCA 240 CTCAAACAGC TGCAGGGCCA CATGTGGAGG GCGGCATTCA CAGCTGGGCG CATGAAAGCA 300 GAGTTCTTTG CAGATGTAGT TCCAGCAGTC AGGTAAGTGG AGAGAGGCCG GGATGAAGG 359 (2) INFORMATION FOR SEQ ID NO:109: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 360 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:109: TTTATNAAAG CAGTTAAACT TAGCATTAAA TAACACTCTT TAAATGGTAC ACCTATGAAG 60 CAAGAGTTAA ATATAAACCC AGTCTAATCC TGTACACTTG TGATTAATTG TGACAATCTT 120 AAGTTGCTCA CTTCTTTCCC ATTTACCAAT TCAGAGAAAG CCCGTTTCCT GTTTTCTCCT 180 CACCACTTTG CCTTGGCATC ACACCAACCC TGCCTCGGGC TTCAGCTGCA GATCCTCCCC 240 AGCCCCTCCT CCCAGCTGGG CTGACTCCAG TCCCAGCCCC AGTCTCCACC AACTGAGCAG 300 CGTACGCAGG GTTGTGTCTG GCTTCCAGCA TCTACCAACC CTTCAGAGCA ACTTCCAACA 360 (2) INFORMATION FOR SEQ ID NO:110: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 364 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:110: TCTCAGAGGG GCTCTGGGGG TCATTCAAGG GGGACTTCTA GCTTCTCTCT GGAACCCTTT 60 GTCCAGAGCA AAGCCAGGTT TCCAAGGTCC CCACGGCAAG GCTGTTGGGT GCTGGCAGCA 120 AGAGGTACAC AGCAGTTCTC CCAGCTCACA GCAGTGACCT CAGATCTCCA GCAGCAAGGG 180 CCGCACTCTC GTGCCCACAA GGGCCTTGCA GAAATNCTCC GGTCCCTGGG NCTCCCCCGG 240 CAGGAGGGGC GGGGCTCCTG CCTGCAGTGA GGCCACAGCA CTAAGCGGCT TCAGTCACAT 300 GCTTTTCAGG TGAATCACTC CAAATTCAGT GAGGAGGGCC ACGACAAGGA AGTTCAGGTA 360 GAAG 364 (2) INFORMATION FOR SEQ ID NO:111: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 455 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:111: TTTTTTTTTT TATATTTTAA ATGGAATTTA TTCTATCAAC TGCCTGAGAG GACACAATGG 60 GGGAGGGGCT TCGGACCACA GCAGGAGCCC CGACTGCCCA CCTGAGGGCA GGGAGAGCCT 120 GACCCCATTG GCCCAGGCCC TGGCTCTGTA ACCATTAACC TCTTCCCCCA ACTAACACCA 180 ATGAAAACAC CATTCCACGT GACTGGGCTG TGTGTTTGCC TCTGTGACAT GGGGACCCCT 240 t GACCCTAGGG GTCTCGCCTG AGCCAGACCT GAGGGACCCA CCCGCGTAGG ATGGAGGAAG 300 GTTTAGGCCT CCCTTTTGCC AGCCAACGCC GGGGGGTGGG GCAGACCCTG GGAGTGGGCC 360 TTACAGACCA GCCACAGGTA TTTCTTAGGC AATTTGACAC ATTTTATTAC AAAACCAGTC 420 TACATTCATT CCTAAAAGGG TCATTTTCAG TAAAA 455 (2) INFORMATION FOR SEQ ID NO:112: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 398 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:112: CTGATCTGAC AGGAGGTGTA GGTCAGGCAG TAATGGAAGT SATGGGGAAC AGCTGTAAAT 60 ACAGATAAAG CTTTACTCAC TCGCCCACCC ACTGCTCATC TCCTGCTGTA CTGCCCAGTT 120 CCTAACAGAC AGCAGACAGC TACTGGTCTG TSGCCCAAGG GTTGGGGACC CCTGACATAG 180 ACTAAACAAT TCACAATGTT TATATTAAAC AACTTATTCC AAGTTTCCAT TTTAGACTCT 240 GGAACATCTG ACATGGTGAA TCCACAGGTA GTAAATSGGA AGGGAGATAA CAGACAACTT 300 GACGGCCGTG GAAGACGCAC TGGGCGGGCA CTGGTGACGG GTCTCGGGAC AGACTTCACA 360 TCTCCAGACT GGCACAGTGG GCTCACACCT GCCTCCCA 398 (2) INFORMATION FOR SEQ ID NO:113: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 444 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:113: ATCAGTGTCA GTGTCTAACA GAAGGGTCTG TTAAGGATGC TTCTGATTTA ACCAAAAGAT 60 TAAGCTTCAG AAACAATCTA ACATACTCAA AGGAGCACCA AATTATCAAC CGGCTACAAG 120 GATGCAAAGG ACCTAAACAA CAGATGTCAA AGGGCTTGTA AAAACTGGAG CCAGCAACCA 180 TTCCACTTGA AGGAATCCAT CTCAGGGAAA TGCTGGAATC CACACACAAA AGCAGGTGTG 240 CAAATAATCA CTGCAGCACG CCTTCTAATA GTGAACAACA GAGGCAATCC AAATATCCTT 300 CAACAGGGAA CTGAGTAAAT ACCAACTATG GGCATATCCA CATAAGGCTC TCTGCAGTCA 360 TTAAAAAGGA TTGCACTTAC ATGCATGTCT GCCATGGAGG TCTTTCAGGC CAATGGTTCC 420 ACTCGGAAGG GCAACCACCA ATTA 444 (2) INFORMATION FOR SEQ ID NO:114: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 472 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:114: TCGGGCCCCA ACGGAGACCT GGGGATGCCG GTGGAGGCGG GAGCGGAAGG CGAGGAGGAC 60 GGCTTCGGGG AAGCAGAATA CGCTGCCATC AACTCCATGC TGGACCAGAT CAACTCCTGT 120 CTGGACCACC TGGAGGAGAA GAATGACCAC CTCCACGNCC GCCTCCAGGA GCTGCTGGAG 180 TCCAACCGGC AGACACGCCT GGAGTTCCAG CAGCAGCTCG GGGAGGCCCC CAGTGATGCC 240 AGCCCCTAGG CTCCAAGAGC CCCCAACCGG GACCCAACCC TGCCTCCCTG GGGCTAAGCT 300 CTGGCCTGGG GCACTCACCC CCTGGCTTAG ACAACTTCTC AAGGGCTTGG CCTTCAGGGG 360 ACCCTTGTGG GTCTTGCCTT GCTGGGGCCA CCTTTTCTTG CTTGGGGCTT CCCCTTTGGC 420 CTACCTTGGG GCCAAGCCCC TACCAACTTT GGATTGCCTT CTTGGGGGCC AA 472 (2) INFORMATION FOR SEQ ID NO:115: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 293 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:115: CTNGGGGCCA TGTGGCTGAT TTCCATCACC TTCCTTCCAT TKGCTACGGC GACATGGTGC 60 CCCACACCTA CTGCGGGAAG GGTGTGTGCC TKCTCACTGG CATCATGAGA GCTGGCTTTA 120 CCGCGCTCGT GGTGGCTGTG GTRGCTCRCA AGCTGGAGCT CACCAAGGCT GAGAAGCACG 180 TGCACAACTT CATGATTGAC ACTCAGCTCA CCAAGCGGGT AAAAAACGAG GCTGCTAACG 240 TTCTCAGGGA GACGTTGGCT CATCTACAAA CATACCAGAG CTGGTGAAAG AAG 293 (2) INFORMATION FOR SEQ ID NO:116: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 448 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:116: TTTGAAAATT TAGAGGATAT TTATTTCTCA GGAAGGTGCA CAACAGCTGG CAGGCACTGC 60 TTTCCCTGCT CTAGGGGATT CCTCTCTCCT TTTCCAAGAA ATCCCCTCTC TTCTTAGAAG 120 TGCCCATGGG AGGCTGGGAT GTGAAAAGAA ACCATACACA ACACTCCAGA GCCTTAAAAA 180 AATAAAGCAA CAACCTCCTC CACACGAATA CACTTACAAA ATAAATAGAC GGATAAAAGA 240 GAGGCCACGT GCCTCCCATC CCGGCTGTAG GGCTGCTTGG GGATAGTGGG GCTGGGTGGC 300 TCGGTCCCAC TTCTCCCAGC CAGGATGATC CAAAGGCTAA ATGGGATGGA AGGGCCCTGG 360 CTTTCAGAGA GAGGGTGGGG CAGGCCTCTC CTGGTACTCA GCAGGGAGGA CACTGGGGCA 420 CGGGTAGGGG TCCAAGGGCC ACTTAATA 448 (2) INFORMATION FOR SEQ ID NO:117: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 551 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117: GAGACGGAGG CTCGCTCTGT CCCCCAGGCT GGAGTGCAGT GGCGAGATCT CAGCTCACTG 60 CAAGCTCCGC CTCCCGGGTT CACGCCATTC TCCTGCCTCA GCCTCCCGAG TAGCTGGGAG 120 CCAGCGCGCC CAGCCTAAAA AACTTTTCAA GTCAATATTA CTACGATTTA ACATTAGAGT 180 GTGGACATGT GATTTAATCG CTATAGCTAA AATACGTCAA ATATACGTTG TCATGTGCTT 240 GAACATGATG CTAACCCTGA CAGGATGAAG GAAAGTAATA TTCTTTCAGT GTAGTTCAGG 300 AGAGCATTTG TTTTCTTTTC TACCAATTAA CCCATCATTG CTTTTAAACA ACCATCTGAA 360 GGAGCAGAGA GGCAGGGTAG AAGACAGAAG GGGGTCTATG TGGGTACTAA AGATGTTTCT 420 GTTTTGTAAT ATTGTGTGTG TGTGGGTTTA TGGTTTGCTT AAGGGATCAA AACCTGGAAA 480 AAATGGGATT CCAGGAATGG CTCTGTTATT TTTGCTGGGT TCCAGCTTGT AATGCCTACT 540 GCCTTGGTTC A 551 (2) INFORMATION FOR SEQ ID NO:118: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 426 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:118: CCCCACCCCA AAATCAAAAC TGAAGGTAGT GTCAGTGTAT ATATGGNGTC CCTTGTGCTG 60 AAAGTCAAAG CAGCTTCATT TTGGGGCCTC AAGAGCTCCA GCTCTGGGCT CTTCACCTCT 120 AAGCCCATGG GCAGTGCCCG CCCAGTGGTG TGTATAGATC GGAGGCTGAG GGCCTCACCC 180 TTAGCTGAGC TGTCGCGTGC TGGGGAGCCT GTGCAGGAGG GTACAAGTAG GAAAGTGCCA 240 TCTGCATGGG AAGAAAAATG CAGCGTCCTT GGTAGTGCGG ATGGGGTCCA GGAGACCCAG 300 GGAGCTTGCC CAGAGGGACC TGAGTGGCAT TCCTGTAGGA AAGCAGCCCA GATCTTGGGG 360 CCGTAACGGA TGTTCTGGAA GTTTTGACTT TGAACCACCA GGTCCCATTG TTAACAAGCT 420 TCTTGA 426 (2) INFORMATION FOR SEQ ID NO:119: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 434 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119: TTTTTCGGTT AAAAAGGCCC AAAACTTTAT TTAGTTTTCA GGGAAATATA AGATGCATGT 60 AAACATAAAA TACAAAACAA AACCCAAATC TTACAGTCTA GAAGCATGCC AAGACAGAGC 120 ATTTTCTGCA GACCAAAGAG TCCCGTCAAA GTGATAAAGG ACACCTGGAA AGTGGCAGGC 180 CAAGGGGCTG GTCCCTTCCC CAAGGGCACT GCATTTTTGT GATGAGATTA AAAACAAACC 240 AACTCCACTA TTAAAAATGC TAGAAACATG GGATAGTTTA GCACCACCAT TGATTCTGGC 300 AAATATTTCA GCACTCACAT CGACTGCACT GAGTTTAATG TCCTTTCTCC AGTTTCTCTG 360 CTGAGGAGGG AAGGAGGGAA ACCTGGGCGG AAGGGGCTCC TCCTGACCCC ACAGGGCCAC 420 TAGGAGCTTG GAGG 434 (2) INFORMATION FOR SEQ ID NO:120: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 276 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120: AGGAAGTGTT AGCAAATGCT ACCATGTGGA ACACTCAACT TTATTTGCTT TATTTATATA 60 TTTAACAATT CTAAAGTATT TACTTCTTGC TTTGACAAAA AATGAAAAAT ATAGGGGCAC 120 TGACTGACTC CTCTTTAGGA GAAAAGGGTT ATATGTACAG CTATGGAGAG TTACGGTTCC 180 CCCTTTAACA AAGGCAAATA TTAATAAAAA AGGGCTTCAT CGGTCAAAAA AGGGCTAAGA 240 GCTGCAAGCA TTTATTCACA CTGTACATCG GGCCCC 276 (2) INFORMATION FOR SEQ ID NO:121: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 554 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:121: ATTTCTTTCC TTAATCATAT CTGATGCTGG GATGTGGGTA ACCCCAAACT GAAGGCAGCT 60 GCTAAATCTC AAATGCTAAA AAAATACTGC AATTTTGACA TCAGTGAGTC AGATCAATAC 120 ATCCTCTGGG GCTGATTTTG CTTCACAGTT AGGATGAGCC ATCTCTTAAG CTGCAGGCTC 180 AAATGGGATT AACTGAACTC TATACCTGGG ATGGGCCATG GACTGAGCTG TCCATGCAGA 240 AGGACCAGGC TGTCCATGCC TTCCCTGCCC TTTTACTCAC CACTGCACAG CAGCCCCAGT 300 GGGCCTACTG CACATGTCTA GGAGAAATCA CTCTAAGAAA ACCAACAGGA ACAGGCTTTA 360 GGCAACAAGA GACGTCTCAC TGCATCTCCT CCCACGTCAG AACTTGAGTA CTGGGTCTTT 420 GCAGCTCAGA GCATTCCTCC CTTCCCTTTC CTGCCCGAAA GGCCTGCCTT TTCCTGAGAC 480 ATATGGCACT CCATGCTGCA AGTTTCAAGC AGATGCAGGT TCTTATGGGG CTTTTTGCTC 540 AAAGAGCTTT GGTT 554 (2) INFORMATION FOR SEQ ID NO:122: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 238 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:122: CACCTAAGCA GGTAGACATC CGCAAAGTCA GATGCTTTCC AACATGACAC CTGAACATCT 60 TCCTTTATGC AACACCCAAA CATCTTGGCA TCCCCACCCC AGGAAGTGCG GGGAGGAGGT 120 TATGATCCCT GGGCGCTTCG GCAGAATGGA GAGCTGAGGT GTCCCTCCCC TGCTAGTCAC 180 CTACCAGGTG TCTGAGCAGC TGCATGCTCC CTGGCTCAAG TGGGCACTGT ACCTTTTG 238 (2) INFORMATION FOR SEQ ID NO:123: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 244 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:123: ATCCAGGCTT TCATTTCTAG CCAACCCTCA AACACCACCA ACTACAAAGA AAATTTAAAA 60 GTCTAATTTG TAACCTTCAG ATAAGTATAA ATTAGTTTTT TCTAGGCTTT CATTATTTGG 120 CTTCTTATAC AATCTATCTT GTAAAGTACA TTCCTCTAAA TTTACATTAT CTAAAATTAA 180 GGCTAAGCAT TATTTAAATC ANTTAATCAT ACAATATTTT ATGGCAATAT GCACATATTT 240 -12.5- ATAA 244 (2) INFORMATION FOR SEQ ID NO:124: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 330 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:124: CTCAGCGTAT CATAGGCGTG CTCACCCTCC TCCCCACGCT CCCGCCCCGC AGGCAGGTGG 60 TGTAGGATAG AGTGGTGCAT GAAAGGGGGG AAGCCCGAGG GGCCCGCTGG GAAGGGTGCT 120 GCCCCGTAAA GGGCATCCCA CTGGCACTGT GCCTCANCTG CCGCTTTCTG CTTCAGCTCA 180 GCCAGTCGCC GCCGCTGCTC TTCAATCACT TGTTGTCCCT TCTGCTGCAG AGCTAGTTGG 240 CGCTTTGGTC TCGATGTCCT GCAGTGTGGC TGCCAGGTTG CAAGGAAGGC TGCCCGGTGC 300 CATTCTGGGG GTGAGTAGGA GCGCTCTTTT 330 (2) INFORMATION FOR SEQ ID NO:125: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 281 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125: CCTCTCTCCC TTCGGTTCTC CATTTACCGA GCCACAGTAT TTCTTAAAGC TCGTTGGCAG 60 CCTGCACCCT GCTTATTCTT GGGAGACACG AGTTTGCATC CTATTACAAC CCATAGTTTT 120 TGCATAACCA TGGTGAGAGG AACCATCCTT CCCAATCCCA ACCTCAACCA AAGCTTAGAA 180 AAAGTGCCAT CNTTAACCTT TCAGAATCAC TCATAAGTAA ATCCTATAGC AGTCTCTGCT 240 AATGCAAATT TCAATGTGTG CCCGCTTATT AGGTGACTTT T 281 (2) INFORMATION FOR SEQ ID NO:126: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 266 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:126: CTTTTAATGA TGTGGTTCTG GTGGGATTTA TAAAGGGAGA TGGACCCCTG GNAAGATGCT 60 TTCCTMAACC ACAACCCACA CATTGGGTCA CCATTTCCTC TTCCTCCTCC TTCTGTGGGT 120 GGCCGGAGAC CTGTAGGACC TTCCCTCCCT TTAGGGTTCT GTAAGGCCCC TTNTCAGTCC 180 TCAGAGTCCA TTCTTCTCTT GTGCTGAGGG CCTGCAGTGG GGACCATATA CTTCTGGTGC 240 TCTTAGTTTG CTGTCGCGTC TGTTTT 266 (2) INFORMATION FOR SEQ ID NO:127: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 435 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:127: GTCTGGTTCT ATTCATTTTG TAGTTGCGAG AAAAGGAATG AACCGTGACT ATGGCAATTC 60 ACCGTGACGT GTGATAATTT AGTTTGCTAT GAGTTTTCAC TCTTAGGTAA AACCTAGTTA 120 TCCTAATTAA TAATTAGTTA TGGATGATAT AGTAATTTTT TTTTTTTTTG ACTGCGTCTC 180 ACTGTCATTC GGGCTGGAGT ACAGTGGCTG ATCACAGTTC GGTGCAGCCT CGACCTCCCT 240 GGGCTCAGTG ATTCTCCTGC CTCAGCTTCC CAAGTGGCTG GGGATTATGG GCATGCACCA 300 TCAATGTCTG GCTAATGTTT GGTGTGTTTT TTTATAAAGC CAAGGGTTTT GCCCATGNTT 360 CAAGACCCCG GGGCTGGTCC TTGAACCTCT TTGGGGCTTC AGGCAAGTCC TCCCACCTTC 420 GGGCCTTCCC AAAGT 435 (2) INFORMATION FOR SEQ ID NO:128: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 471 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:128: TTCCCTTCCC AAGGACTCGA CCTGAGAACC GCCATGTACT CGGAGATCCA GAGGGAGCGG 60 GCAGACATTG GGGGCCTGAT GGCCCGGCCA GAATACAGAG AGTGGAATCC GGAGCTCATC 120 AAGCCCAAGA AGCTGCTGAA CCCCGTGAAG GCCTCTCGGA GTCACCAGGA GCTCCACCGG 180 GAGCTGCTCA TGAACCACAG AAGGGGCCTT GGTGTGGACA GCAAGCCAGA GCTGCAGCGT 240 GTCCTAGAGC ACCGCCGGCG GAACCAGCTC ATCAAGAAGA AGAAGGAGGA GCTGGAAGCC 300 AAAGCGGCTG CAGTGCCCCT TTGAGCAGGA GCTGCTGAGA CGGCAGCAGA GGCTGAACCA 360 GCTGGAAAAA CCACCAGAGA AGGAAGAGGT TCACGCCCCC GAGTTTATTA AGTCAAGGGA 420 AACCTTCGGA GATTTCCACA CTGACCAGCG AGAGAGAGAG CTTTAGGGCC A 471 (2) INFORMATION FOR SEQ ID NO:129: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 186 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:129: GCCTTTAACA TCCTCTGCCA ATRACTGGCC TCAAATCACC AGTGGAACCT TTTCAAAAAA 60 TACACCATTG GCTCTATGTA GTTCTACTGA TCTRAAATAT CCACGTGTGG GCCAGGAGCA 120 CTGGCTCATG CCTGTAATCC CAGCATCTTG GGAGAGCGAG GAAGGAGGAT CATTTRAGCC 180 CAGGAG 186 (2) INFORMATION FOR SEQ ID NO:130: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 307 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:130: ATAAAATACT TAGGAATATA CCTAACCAAG AAGGTGAAAA ACCTCTCCAA GGAAAACTAT 60 GAAACACTGC TGAAAGAAAT CATAGACTAC ACAAATACAT TTCATGCTCA AGGATGGGTA 120 GAATCAATAT TGTGAAAATG GCCATACTGC CAAAAGGGAT CTWCAAATTC AACGGTATCC 180 CCATYAAATA CCACCATCMT TCTTTACAGG NTTCGGAAAA GGAATTCTAA AATTCATATG 240 GGACCCAAGA CGGGGGCCGC ATAGCCCATG GCCGGCTTAG SAAWAAGGGA CAAATCTGGG 300 AGGCCTT 307 (2) INFORMATION FOR SEQ ID NO:131: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 184 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:131: CCAGGTTGGA TGGAGTGCAA TGGCACGATC TCGGCTCACT GCAACCTCCC AGGTTCAAGC 60 AATTATCCTG TCTCAGCCTC CTGAGTAGCC GGGATTACAG GCACGTGCCA CCACACCCAG 120 CCAATTTTTG TATTTTTAGT AGAGACGGGG TTTCACCGTG TTAGCCAGGA TGGTCTCAAT 180 CTCC 184 (2) INFORMATION FOR SEQ ID NO:132: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:132: GCNGGAGGGC GTCGAGGGCC AGGAGCTATT CTACACGCCC GAAATGGCTG ACCCCAAGTC 60 AGAACTMTTC GMGNAGACAG CCAGGAGCAT TGAGAGCACC CTGGACGACC TCTTCCGGAA 120 TTCAGACGTC AAGAAGGATT TCCGGAGTGT CCGCTTGCGG GACCTGGGGC CCGGCAAATC 180 CTTCCGNNNC ATTGTGGATG TCCACTTTAA CCCCACCACA GCCTTCAGGG CACCCGACGT 240 GGCCCGGGCC CTGCTCCGGT AGATCCAGGT 270 (2) INFORMATION FOR SEQ ID NO:133: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 529 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:133: CTTGCAGTAC ATAGCATTGT TATTACTGAT AGCTTTATAA ATCTGCCAAA TAACATAGAA 60 TGTAGCCTCA AAAGGATGGT CGAGGGTTCG CAATCTTTCT TTCTCCACCC AGTGGTGTGG 120 AGCAACTCTG TGCCTTAAAG AGGGCACCAT GGAAAGAAAC AAAAAGGAAT CTCTTTCAAA 180 ATGCTGGAAA TTAGGCTTAG CTCACTACTT TCAGGATAAA GACAACTGCA TCTAATTAAG 240 TCCACTCCAC ATTTCTTTGG ACTCTAAGTA TTCTGCACCT GAAGGCTAAA TTGAACTGGC 300 TCAGCCCTAT CTTTTTTGCC ACATCTTTAA TTACAAATCT ATTTCTTCTT CCTTTCATTT 360 ACTTCTCTTC TCTTAAGTAA GAAATGTGGG AAATGAGACT GGCAGTTTGG TTTGTTTGCA 420 TGTGGGTGTC CATTAGGCGT CTCATCCTAT GGCCCTTTTT GGAAATGTTG CCTTCCTACT 480 ACACACCTGG GAGGTTTCCC CAAGGCTCAA CCTTTTTGCT TCAGGTAAA 529 (2) INFORMATION FOR SEQ ID NO:134: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 437 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:134: GACGGTGGCG ACGCGTGCAC CGGGGATGTG TCCTGCCACC AGAGGAGGTG TGCGTGGCGG 60 GGAGCAGAGG GGCTTTGTTT CCCAGGTGAA GGTGCGGCTT CTTCACTCTT AGAGGTGCGT 120 GTGTGGGTGG GGGTGCTTGC TGTTGAGGTT TATGCCTGTA ACTGACAGCT GTCCCCCAAG 180 CCATGCTGGC AGTGTGTAGG TGTCGTGCCG GCCACCGCAG AGGAATCCTC TGGGCTTCTG 240 TGGTTCAAGT GGGGCCCAGC GCAGAGCTCC ATGAGTTGCT GAGCAGCCAG CCCTTCAGCA 300 TCTCCTGGGT TTTGGCAGCA GGAGGCGTCC CCTTGTGCAA TTCAGGGGGC CGTGGGGGCT 360 GGGGGCACTC GTAGCAAGGT AAAGGAGCCC CTGCTCAGGC CCTTGTTTGC TCCCCTTTCT 420 TGCAAGAGGG GTAGACG 437 (2) INFORMATION FOR SEQ ID NO:135: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 534 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:135: GGCATTGTTC TGGTGGGTGT GTCACGCTCC CAGAAGACTG AATTTATGGT AGGATCACTC 60 GCAAGGCCTT GTGAAGGAGT CTTACCTAAA ACAAAAGAAA TATCAGGGAC TTTTGTTGAC 120 TATTTACAAC TCAGTTTTAC ATTTAAATTC AGGCAGTGTT AATATGCCAA GGTAGGGAAT 180 GTGCCTTTTT CAGAGTTGGC CAGGAGCTCC TGGCTGGGAC ACGGAGAGGC AGGTGTGGCG 240 TAAGGCCTCA CTCCCGGCTG TGAAGGTCTC TGATCACACA GAAGCAGCCC TGCCCAGCCT 300 GGGTCATTTG CTGTCCGCTT TTCTCTGTGA CCACAAGCAG CCCTGAACAA CCAGTATGTG 360 TCTTCTTTCT CCAGATAGTG AAAAAGGGTG TCCAGATAAA CCCACCTAAG TGAAATGGGC 420 CATCCTCTAA ACTGGGGTAC CTCACTGCAC AGGTTCTAGG TAGGCTTTCC ACTTAATCTA 480 ACTTGAGGCC TACAGGTACC CTGTAAAGTT AGTGGGGCTT GTCCTTGATT GTGG 534 (2) INFORMATION FOR SEQ ID NO:136: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 279 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:136: CAGTTTGGAC AAAGTAGCAT AGTGACTTTN TTCCTACANT GACTTTCGGA GAAGTTNGCA 60 GTTTCTGGCA AAGTGACGCT GGGCTGTTTG AAAAAGGCAA GCTTAGCCTA GGCTGCCATC 120 TTAAAACATT TCGAGGCTGT AGCTTCCTCA GGATCCTTTG CCTGTGGTCT GGTGGCCGGC 180 AGTGCCCCGT CTAACAGCTT TTAACTCTGC ACTTAGTGCC TGAGCACCTA TGGCTGTGAG 240 AGATGCTAGA TACAGAACCC TGTCCTGTAC CACGTGGGG 279 (2) INFORMATION FOR SEQ ID NO:137: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 518 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:137: CAAATATTTA ATGGAGATCT TCCTTGTTGG TCTGTTATAT GTCTATCCGT TTCTGGGTGG 60— TTTAGGAGAA TCTGTACTAT TTCAGCATGT CCTCCTCCAG CAGCAAAATG AAGAGGAGAA 120 CTAAGTTGTC CATTTAAAAG GTTTGGATTG CACTTTCCTT TCTCTAACAA TATGCGAGTG 180 GCCTCAACTT TTCCATACCA GCATGCATAA TGAATGGGTG CCCAGTGGTC ACTATCTAAC 240 TGGTTGACTG AAAATCTTTC ACTGAGAAGA CGGCTTAGTA ATTCTGAATC TCCTTCACAG 300 GCGCTTCGGT GGAGAGGAAA ATCATCTACC CACTGTCGTT CCTTGTCTTC TGTGACACTG 360 CTCATGCTTC TCTGCCAGTT TTTCCTGTTT AGGGTATTTG GATTTTTGAG TAGTCTGGAG 420 CTCCTAGACC CAAGTATGGA TTTATTACCC ACTTATCTAC CCGATTTGTA TACTGAGGAT 480 CCTATCCAAC AAAGGGTGTA AATCCAGGAT CCGCCTTC 518 (2) INFORMATION FOR SEQ ID NO:138: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 266 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:138: GATTGCAGGC ATGANCCACT GCGCCCAGTC GAGTGGTAAT ATGTTMAAAG GAAACCTTTT 60 TCTGAGCAGG TCTCAAAAGA GAGGTTAAAA TACTGAGTAG ACCATMCTGT AAACAGATGT 120 MCTGTTATYC GGGCTTTCAT ATTCCATTTA TAAAGCACAG GCAGAGCTCA GAGTAGATTT 180 AAYGTAACTC TGAAGGGCAC TAGGATTTTC AGAATGGTAA ATAAGCATTG GCTTCACCTT 240 AAATYCAAAT CTGCATTGGG CTTGTA 266 (2) INFORMATION FOR SEQ ID NO:139: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 341 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:139: ACCTCGCTCA CCGCTCTGAC CACCGACAGG CAGAGCAAAG GATGCGGGAG TTGCCTCTGC 60 TGCCCATCTA AGGGGACGTA GGCAGAGAAG CAAAGGCCTC TGCTCTCCCT CCATCCATCC 120 CGGTGTGCTG GCCCCAACGG AACAGGAGTC CTTCAACTAT TGCCTGCCAG AGACCCAATT 180 TTAGGGACTG TAGTCTGCAT CTGGATGAGC TGGGCTGTAG ATTGAAGTCT CAGAAGCAGG 240 GAAGGTTGGA AGGGGTAGGG TCCCAGAGCC CATGGAGTTA TTGCTGAGAA GATATGCAGG 300 GGACACATTT CCCAGGGGCA GAGTAGAAGC CCTGGGCCTT G 341 (2) INFORMATION FOR SEQ ID NO:140: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 234 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140: GTGAAGGGAG TTGCAGAATC AAATTGCTAC ATAGGCCAAA CAAAAAAGAA GGCTTTTTCA 60 AAAAACATTA AATTCACATG CAGTCTCAGA GACTATTTAG GCAAAGTTCA AGTTAGGAGC 120 TTTTAGGATG TGGGANTAAA ACTTTAATKG GAGGGGAGGG CTTGCTTCTG GAGAAGGAAG 180 AAGCCAGACT TGTTAGACAG TACTCTTAAC TCCTAGCCCA GCCTAGCGTG CCCT 234 (2) INFORMATION FOR SEQ ID NO:141: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 354 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141: CAACTCAGGT TAGCAACTGC AGGAAAACTT TCTTCATTTT CACTGAATTT TAAAGAGAGA 60 ATCCTGTCTC TATTTCTCAG AGAAACTTAG GTGAAAAGTA AAAGAGAGGC AAAATCTCTT 120 TCCTTCATGA GATACTTTTA TTTTTATCTC TTTCTCTACT CATGTGCTTA ACTGGTGAAA 180 TGATTCTGTA GAAATAGATC CTTCTGATTC TGCATCTCAT TTCCTTATGG CAACTACAAC 240 AGGAGGAATC CAGCTGGAAA TGCCACTAAC CCCACATCCA GCACCTGAGA GAGGAAGCCA 300 GTCGGAGCGC CGTGCTGGGC TCACTCACTC TGGGCCTGCG CACTGGGGTT GTGG 354 (2) INFORMATION FOR SEQ ID NO:142: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 373 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142: GTTTTTGCAA CACTTTTTTT TTAAGTTATT GGGTGCAAAA TCCCAAACCA GGATATGTGT 60 ATGTCTGTGT GTTTATGTTT TTNATTTGAC CCTCCCCTCT TTCAACCTAC CCCCTTTTAT 120 ATCTAATGTA GAAAAAGCGA AATTGAATCT GGAAAGCAAA CTGTTGTATA TAGTTGCGGT 180 AACAATCATG AAGAGAGAGC CGGGCTGTCC AGTTGTTTTT GAGACAGAGT CTCACTCTGT 240 TGCCCAGGCT GGAGTGCAGT AGCATGATCT TGGCTCACTG CAACCTCCCC CTCCCTGGGT 300 TTAGGCGATT CTCCTGCCTC AGCCCTCCCA AAGTAGCTGG GATTACAGAC CCGTACCACC 360 ACAACTGGGC TAA 373 (2) INFORMATION FOR SEQ ID NO:143: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 262 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:143: CCGCACCTCG GCCAGAGGCG GCTGCAGCAG CTGCTMCCTT TTCCCTGCCG CCGCCTCTCC 60 AGTCCCTTTT TTAATTACCA CTCCAMCTGC TGGGAACGGG CGAGAAAGAG GAGGAGGCGA 120 GAAACTCCCA CCGACCCACA GAGGGAGCAT GATTTCGGCA ACTTCACCTA TCATTCTGAA 180 ATGGGACCCC AAAATTTTGG AAATCCGGAC GCTAACAGTG GAAAGGCTGT TGGAGCCACT 240 TGTTACACAG GTGACTACAC TT 262 (2) INFORMATION FOR SEQ ID NO:144: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 384 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:144: GGAAAAGCGG GACCCAAACA GTGGTGCTGG GGAAATTTTT CCCTGTCCCC TTTGGAAGGC 60 TGAGTGGGTG ATGCAGCACA GGAACAAGGC TTGGACGTCA GAGGTCTCAT CTTCACTGTN 120 ACAAAGCATA AAGGACTTGG GGTTGAGCGT GTGTNTGGGC TCAAGTGACC ATGCAAGTCC 180 TGTCACCTCC TTCCTAAGAC CCCATCCTTC TCCCAAGTCC TCCACAAGAG CTACCTTCTT 240 CAAAACAATA ACAGAAACAC ATCAAGCTTG GGCGTCACTG AATTCAAGTT CTGATTTCTC 300 CCGTCACCCC AGCAACAGTG CCCAGTTTGA TTGTGACACT TTGACCCAGC ACTTGGTTTT 360 GAATGTTCTT TTCGGCTTGT ACCG 384 (2) INFORMATION FOR SEQ ID NO:145: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 324 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:145: CTACATGGAA TCATAAGTKT TCCTAAAAAA GGAAGACAGA TTTGAAGACA GAGGAGGAAG 60 GTGATGTGAT GATGGAAACA AGGGGAGAAA ACGCAATGTG ATGTGGCCAC GAACCAAGTA 120 ATGAGGACAG CCTACAGAAG CTGGTCAAGG CAAGGAAACA GATTCTCCTC TAAAGTCCCT 180 GGAGAGGGCC TGGCCATGCT GACACCTTGA TTTTKTCCCA GCAGAAACTC ATTTTGGATT 240 TCTGGCCTCC CAGAAAAGTA AGGGGGTAAT GTGCTGTTTT ATGTCAGGTT TKGGGTAATT 300 TGTTTATTGC AGCCATCGGG AAGG 324 (2) INFORMATION FOR SEQ ID NO:146: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 355 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:146: TTTGCCTCCT TCCTTCCTTA TCCAAGCAAG GGTGTGGTGA CAATGACCTG ATCGGGGTTT 60 AACGCCGGCT CTGTCTGCTC ACCAGACCTG GGGTGCTGAG CTCTGACCAG CCTGGGCAGC 120 CCAACCCACA GGAACTGCGG TTTCATAGCT GGGTCTTCAG GAAGGGGTGG AGGCTTTGGG 180 AGTGGCAGCT CCCCGCCTCC CACCACCCCA AGCCAGAGAA TGGGGCAAAC TTGTATGCAT 240 GGCTTATCTC TAAATTACTA ATCTGCTTCG GACCAGACTC ATCTCTACAG TATAGAGTTA 300 GAGTTATTGC TTCTATGACA GGTGTTCCAG AAGCCCTGGG TGGCTTTAAA GTCTG 355 (2) INFORMATION FOR SEQ ID NO:147: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 337 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:147: CAGTTTTCTG AGTTCCCGTG TGCTAGACTG GCCAGAAGAG AGGGTCTGGG GCCTGGTCAC 60 TCGGCCACTC TCTCCTGTTT CTGGCCTCTT CTCCCTTCAC TCCCGTCCAG TCTGGTTTTG 120 AGAGCAGGGG CTGTTCTACA GCACCTCAGG GAAGGGAGGA GAGATACCTG CTGCTTCCAT 180 TGCTTTTCCC TTCCTGGAGT CGATGCCTTT CTAAGGGTTG GAGCTGCTCC TTGCAGGGGC 240 GGGTCAGTTT CCCAGGCCAT GCCGGGGGTG GCCATCTATG CTAGGGCTGG AAGCTGAGGC 300 TGGCCGCCAA CTGTGGGGCT GGGGTGGGGG TGGGTGG 337 (2) INFORMATION FOR SEQ ID NO:148: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 278 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:148: GGAATCAGAT GCTCAGGTGT CCAAGCAGGG ATAAGGACAG GCAAAATAAA TAACCCGCCC 60 AACCCCCATC GTCACTCTGC TGCAACACGA CACAAAGGTT TAAAGATCTG GGCCCAAAGA 120 CTCTGGGACC CTTCAAGCAA GTCAGGTGGA AGAAGGTTTC CCCACCCCCC ACCAGGCCTG 180 TTTGTCCCAG GTTGCCCTAG GATGGAGGCA GTTCAGACCC TGGGTCACTG ATGCTTGATA 240 GGAAGATCTT TGATATCAAT GGCCTAAGCT CTGCTCAT 278 (2) INFORMATION FOR SEQ ID NO:149: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 368 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:149: TTTTTTTTTT GTTTTCAACA AACTTTACTA AATAACCCTG GAAAGGCAAT GAACGATCTG 60 ACAATTTAAG CTCTAATGAT TTAAAGCTCA GCTAGAAGAA AGTGAGGCAT GACATATACT 120 GTCAACGGAG GGTGAAGGAG GCAGATTTCT GGAAATGCAA TGATCCCACA CATTTGCTTC 180 AAGGAGAAAC CTGCAGACAT ATTTTCAGGT CTTGCTAAGT AACAACTGTT TATTTGTAAT 240 CAATACATTT GGGGAAAGTC TGCTATGTAG CTAAGGTCAC TGTGACCACA GACCAACAGA 300 TGGAAAGGAA AAAGGCACTG GACCAGCAAG GAAAAATACA TCCCCATCCT CAAAAGAATT 360 TTAAGGTG 368 (2) INFORMATION FOR SEQ ID NO:150: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 367 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:150: TTGTGAAATG GGCCTGGGTA GATAAGGAAA AGAACCTCCA AGAGGTTAAG TGATTTGCGG 60 ATTTGCCTAA ATTATACAGA AGAGTCAGCA CCAGTGCCCA GGCCTTCTGA TTCTTAGTGC 120 AGTAAACACT AAGCACCATC ATTCCATTTC ACCACACTCC TGTCTTGCTG TTGTCCTCAG 180 CTAAGAAAGC CTACCCCTGA GTTACCCTCT TCCATCTTAG AGCCTTCCTG CTCGCTGTCT 240 GCCCCCCTGC GATGGGGACT TCTTTGGCCC TTCTCACCCA GCCCAGCCTC TGCCCGTTTT 300 CCTTCTCCTT TCCACTGCGG CTGAGCTCTT TTCTCCTTCC GAGAAGCCTT TCCTTCATCT 360 TTCCTGG 367 (2) INFORMATION FOR SEQ ID NO:151: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 366 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double -13.5- (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:151: CCCAGCGGGC CGCCTCCCTC CTCTCTCCTC CATAGGTGGG GGTTGTGGGC CTTCTTTTTT 60 TTTTTGTCTT GGAGGGCAGT TAAACTTCTC CATTTGCCTC TCTCTTCACA CCCAAATGCC 120 AAAGGACACT TTTCCTTTCT TTTGTGGGTA GTTGCAAAAA AAAAAAATTC CTATGGGTTA 180 CTGCCACTTT TAAATACTTT GTAACTTAAA GGCAAAGTAG TATGTCACTG TTTCTTTTCC 240 CTGTAGTTTA CTTTTGAGGT TAAACATCTT TCCATGTCTT TATTGGTCAA ATACAGTTCC 300 TYCTTTTGTA CAATGTTAAT CCTAATATGG ACCATTTTTC CTAATGGGAT TACCGATTTT 360 TTTAAA 366 (2) INFORMATION FOR SEQ ID NO:152: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 269 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:152: GTTATTCTGG CAAGTGCTTT CAGGGCCCTC CAGGGTTTGG CTGGTCACCA TGGAGGGGGG 60 GTTCAGGTGC TGAATTTAGG GACCCCAGCA TCTCACAGGT TTCCCCTTCC ATCTTTCCCA 120 GTGGCACTGT GTCTGAGCAG GTGTGCCCAG GTGAGGTTGT ATCCACTGTG TCTGAGCAGG 180 TGTGCCCAGG TGAGGTTGTA TCCACTGTGT GTGAGCAGGT GTGGCTGTTG CAGGTGGAAG 240 TGGGGATATN TGGGCACCTG GGTGCCATT 269 (2) INFORMATION FOR SEQ ID NO:153: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 260 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:153: TTTCAGGATT TTATTTAAAA TTTATTGTAA TGGGGTCCGC GCAAAAGGAA GGGGTGGAGG 60 GTGGGGTACA TGCAGGGGAC ACAGGAACAN GATCCACATG GCCAGGGNCA CAACTTCTTC 120 TGTCGTGGGG AAGAGGGATG AAAAGACAAG ACCAGGGCTA NGAGCTGGGG TGGAAGAGGG 180 GAGGGGNAAC ACTGGCTGCA TTCCCCNAAC CCCANGANGC ACCTATAGGC CCTGGACCCA 240 TGGGTCACCC TGGGCCCTAG 260 (2) INFORMATION FOR SEQ ID NO:154: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 405 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:154: TGGAACTTGT GAGTGGGGAC CCATGATGTA TGGGTCTCAC CTGACTTGAG GTGAATTTTG 60 GAGTGAAGGG CCCTGAGGTC AGCTCCCAGG TCGGTCGTGC TGGGCCAGGC CTGGTTTTCA 120 CAGGGGCTGA AGGATCCCAG TCCACCTGTG TGCATGTCAG GGCTCGGCCG GGAAGAAGCC 180 AGCAAAGTCC CCCGTGTCCC TTGCTGAGTA TTCTGTCACA GACAAGCCTC CATTAAAGCC 240 ACAGCAGTGC TACCCACCAC ACACACCTTG CTGGCCCGGC CACCACTGCT GGCTTCAGCC 300 CCTTNAGCAG CCCATGGNTT AGCAGACCCT CAGATGTAGG TCAGTGGCCT TANCTGTNTC 360 TATCCATGCT GTTAAACTCC CTGCCTCCAA CTGGGGGTCA CCAGT 405 (2) INFORMATION FOR SEQ ID NO:155: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 400 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:155: CCATGATCTT ATTTATTACA TCTAGTTTTT CTTTATACCT CTAAAAAAAA GTGCCTTTTA 60 GATTTACAGC TTGTGCTTCT AAAGCAAAGG TTAAAACATC ATGCCCCAAA GGAAAACAAG 120 GTAAAAAGGA AGCTGCCATA TAAGCTCTTA AAANTTGTAT GTTAGAAGGT TCTAAAATCT 180 CTTCAGCACT GGTTGGTTGG TAGATTGTAC GACACTGACA TGGTGCTTGG GAGGGTCATT 240 TATCTGATGG TTGGAGCAGC ACCATGGGAA AGCTGCCCAG ATGGTCTACT GAAGTCCTTG 300 GCTGTGCACA GAATGGGCCC AAGGGCCAGN AATTCATGAG TCCGGGGAAC TTTGGNGGTC 360 CTTACTCAAT CTCCTTAGTG CTAAAGNTTC AGAGTCTCAA 400 (2) INFORMATION FOR SEQ ID NO:156: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 443 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:156: GTCCTCTGGA TTGCTTCGTT GGTTGCGAAC TTTAAGAATG GCAAACTGTG ATTGGNTCCG 60 ATTAAGACAA GCTTTGTAGT TTTCTTCGTG TAAACACCAA ATCCCGCCTG GGCCATGAGG 120 TAGCAGAAGT GGGCCGCATC CAAGAGGCCC CTTGAAGCCA GAGTGTCGCC CATGGTAGCC 180 ATCGTCCTGG ACTCGACGTC CATGTTGTTG TTCAAGTTGG ACAAGACCAT GGCGAGGTGC 240 GGCCTCCAAT CTCCCCATTT CTCGTCTCCA CAGCACGTGG ACGCGGCAGG CATCCGTCCG 300 GACATGAGCT GGTAGACTGT CTTCAGAGGG TCGTTGATTK GGGAGGCTTT TTAGCAAACC 360 TKGGTCATGA CTCGGGCGTG TGTCCGGCTG TTCCATCTTA CTTGCAAGTA GCAGAGCGTG 420 ACCCCACAAG GCCATTCTTA ATT 443 (2) INFORMATION FOR SEQ ID NO:157: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 383 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:157: ATTGGAAAGG GTTTTAAACG GAGTCGGAAC CTGAGTAGAT TTCCAAATTT TACAGCCAGG 60 ACTACAGAAG TGCATCATTC TAGAATGTGT AGACCTGAGT AGCTTATACA CTACAGAGCA 120 CTTTGCTTAT TTGAAAGTAA TTCAGCAACA GGTCACTTTG GGATATAACC TGAACCTTTT 180 TTTGGAGTGG GGTGGGTAGA CTACAGTAGA CACAAGGGCT GGACATGCAG ATGCTTAGGG 240 GATTAGCGTT TTTCATAATT TGTTCTGTTT GTCAGTTCAT TCCTGTGTGT TCTTACCTCT 300 ACAAAGGTAC ATTACACATT TTARGTTTTT TAGTGACCTT TAACCATGTT ACTTGAAGCA 360 TTTTGGAATA TAAAGCTATT TTA 383 (2) INFORMATION FOR SEQ ID NO:158: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 241 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:158: TGGTSTGTGG CTCAGCTGCA GCGGCASGTA AGTGGGTSTC CAGGGGAGTG GACAAGCAAT 60 TCTCCTGTCA TTTGCAACTT TCTTCAGGAA CTCAGATAAA GAACACTTGG ATAACGATGA 120 TCCCTGTAGA GGGATTTCAT CTGTACCATC ACACATGGAA GAGGAGTTTC TAGGTCAGGA 180 AAGGCAGCTN CTAAGCTAAA GGTTTCTTGG TCCCTTNGTC CTGGCATGCC TTAAGGAGGG 240 G 241 (2) INFORMATION FOR SEQ ID NO:159: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 224 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:159: CTGTCAGTAA TGGCTCACTA AAGGGCCAGC AGTTTAAATT ACACAGGTTG CACTAAAAGC 60 TGCAGCTTTG GCCAGGCAAG GTGGATCACG CCTATAATCC CAACACTTTG GGAGGCCGAG 120 GCGGGCAAAT CACCTGAGGT CAGGAGTTCA AGACCAGCCT GGCCAATATG GTGAAACCTA 180 AGCCTCTACT AAAATTACAG AAATTAGCCG GTCGTGGTGG CACA 224 (2) INFORMATION FOR SEQ ID NO:160: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 377 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:160: GGAGGCTGAG GCGGGCGGAT CACGAGGTTA GGAGATGGAG ACCATCCTGG CTAACACAGT 60 GAAACCCTGT CTGTACTAAA GATACAGAAA ACTGGCCGGG CGTGGTGGTG GGTGCCTGTA 120 GTCCCAGCTA CTTGGGAACT CGGGAGGCTG AGGCAGGAGA ATGACCTGAA CCCGGGAGGC 180 GGAGCTTGCA GTGAGCAGAG ATTGCGCCAT TGCACTCCAG CCTGGGCGAC AGAGTAAGAC 240 TGTCTCCAAA AAAAAAAAAA ATAATAATCA AAGCTCTTGG ATTTATAGTT TGGTCCCCAG 300 CCTTGTTTTG ATCTTTCCTT TATCCTGTTT TATTGCCATT TACCACGTCC TTTTGGAAAC 360 ATCCCTTTCA ACTGCTG 377 (2) INFORMATION FOR SEQ ID NO:161: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 273 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:161: GCAGCGGCGC CGGGCGAGGA GGCGGCAGGG GCGAGGAGGG GGCGGCGGGT GGCGACCCGC 60 AGGAGGCCAA GCCCCAGGAG GCCGCTGTCG CGCCAGAGAA GCCGCCCGCC AGCGACGAGA 120 CCAAGGCCGC CGAGGAGCCC AGCAAGGTGG AGGAGAAAAA GGCCGAGGAG GCCGTGGCCA 180 GCTCCGCGCT GCTAGGCCCC CTTCGCGCGG GCCCGGCGCG CCCCCGGAGC AAGGAGGCAG 240 CCCCCGCGGA GGAGCCCGCG GNCGCCGCAG ACT 273 (2) INFORMATION FOR SEQ ID NO:162: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 286 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:162: TTTTGGTCAA ATAAATCAGA GTACTACAAT CATCAAACAT CTGATTCATT TAACATGTGA 60 GCATCTATAC CTGCCCATTT GTGTGAATAT TCAGTATATA TCTCATACCT ATTCTCATGC 120 CTTCATTTAT TGTGGTTATG GCTGTAGATA TGGAAAAAAC AGTAGCTGAG ACATTTTTAT 180 TATGAACTAT ATTATACCTT AATCAATCAG TCAGAAAATG CTTAGGAAGA AGAAATGCAT 240 GATTGTAAAT GCATGATTTC AACATGCTAC CCGGCCAACA AAGTTG 286 (2) INFORMATION FOR SEQ ID NO:163: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 342 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163: TGCCCAAGGA AGACAGAACA TGGAGAACCG TCAAGGCAGG AACCCCACAG ACTGTCCCTT 60 CCAGCCCACA CTCTGCCACC TCCTGGCCCT GTCCCAATTC TGAGCCAAGG CCTCCCCGAG 120 GCAGAAGTTG CCTGGTCCTC TGTCCCCACA GTGACCTGAC TGGGGGTGAG GGAGAAGGAG 180 GAGAGAGCCC ATGTGTGGTG TGTGTGCCCC TGAGAACTTC GTGGTGACTG CCTTTGGGAG 240 CCCGCAAGTG GCCAGAGGCA GGGGTAGCTG AGTTCCTGGG AGACCCCTTT TTTTCCCCCA 300 RGTTCCCCAG AGGGCAACGC CATCAGTAGC AGTGTGGTGT TT 342 (2) INFORMATION FOR SEQ ID NO:164: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 392 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:164: ATTACCCGGG CCCCGCCTCC CTAAAACAGA TCTACGGACC TTAACCGACG CCATGCTGAG 60 GCTCATTCCA TCCCTGCRGA CGTATGCAGA GCCGCTCACT GCTGCCATGG TGGAGTTCTA 120 CACCATGTTA GGAGGAATTC ACCCAGGATA CACAACCTCA CTATATCTAT TCACCCCGTG 180 AAATGACTAG GTGGGTGAGA GGCATCTTTG AAGCGCTGAG ACCTCTGGAG ACCCTGCCTG 240 TTGAAGGCCT CCTTCGGATT TGGGCACATG AAGCTCTGCG TCTCTTCCCA GATAGACTCG 300 TAGGGGATGA GGAGAGGCGT TGGGACTGAA TGAGAAGATC GACACGGTTG CTCTTGAAGG 360 CACTTTCCCT AACCTTCGGC AGAGAGGAGG GC 392 (2) INFORMATION FOR SEQ ID NO:165: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 406 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:165: GTTATAATTA TCTTGTTTTA TTATTTATTG TTTATCTCTT ACTGTGTATA ATGTAGAAAT 60 TAAACTTTAC CATAGGTATA TACATATTGG AAAAAGCATC TTATATACAG GGTTTGTTAC 120 TATCTGTGGT TTCAGGCATC CACTGGGGGT CTTGGAACAT ATCCCTTGCA GATAAGAGGG 180 AACTGCTGTA TCCATAGAAT AAAAACACCC CATCTTGAAG ATAGGAGGTT CTGTAAATTG 240 GGATGGGGTC AGGGAATCTG AATTTTAAAA GTTTCCCATG TGATTTGATG CCCAGCCAAG 300 GGCTGGGGAC CACTGTCTTG AAATATAATG CTGAGGAAGA TACTGTCTTT GGATTTTCCT 360 GGTAATTCCG AGTGCAAATT CTCAGGCTGG AACCTTATGG GCCTTG 406 (2) INFORMATION FOR SEQ ID NO:166: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 453 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:166: GAAAACTTTG CCATGGGTCA GTTTTATTGG AAGTTCATTT TCCTGAATGT TTGGAAGAAA 60 GTCTAGTGAC TCAGGATAGC ATTTCTAATT TCACAGAGTT ATTTTTCCGT TATGAAACAC 120 AGATTGCCTT TGAGGTCTCC TGTTTCTACT ACTGCCCCTC ACTTTTATGT GGGCCTCCTC 180 TTTCCTTTGT TTCTGGAGAA CCTTTTCCTG TTCAATTCTG TTTTAATTTT CAGCAGTTTT 240 TTTTCTGTGT GAGTGAGGCT GTTTCCTAGC AGGGAGGTCT GGTTGGTCAT TTTCAAGTTC 300 ATCAGGGCTT CATCAGGGCT TGTCCACTTC AACCCTTACG CTATAGGNCC CTNTGCACCA 360 TCTGCANTCT TCAAAATGTG CCCACTGGTT CGTTCCCATG GANGGCTTGT TGGTAATTTG 420 GGCTTTTAGG GGGGGCCATG GAAGGAGCAA ATC 453 (2) INFORMATION FOR SEQ ID N0:167: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 285 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:167: TTTACTCTTA AAACTGTTAC AACAGAATCA TGGACTGACA CAGGTAATGG CTGAGCCATA 60 AGCAAATCGA GAAGTACAGA AATGTCCCAC CCCAAACAGC TGCGGAGTAC ACATCACACA 120 GGGCCTCTGG TCCCGGCCTT CTCAGGTGCT CTGGAGTGGA GGATCCTTTG AGGGAACTCT 180 GACCACTCCT GTTGTCTACC TAGAGAGCAC GCCACTTGGG CCACCTACCC CCAACCTTTG 240 GCCAAAGGAG TGAAAGGACC TGGAACCTGT CGTCAACCTC AGCAT 285 (2) INFORMATION FOR SEQ ID NO:168: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 327 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:168: CTAGAGGGCA CTCTGTATAC CCGTCAGCTC CTGGAGCCAT TCATTCTATG CTGGGCAGAC 60 AGGCTGTGAG AGGACATGGG GGACGGTGGA AAGGNTCCAA AGACGAAGCT GTNGTTTATC 120 CTTGTTGGTT TTACACAGGG AATGATGAAA CATTGAAGGG GTTTAATAAG CTTTTCCTAA 180 AACATTTTCC CCCTAAACAG GCTGGCACTA TGTCGAAGCT GCCCAAATTT GAGATTGATT 240 TACCAGCTGC GNCTAAGTCA ACTAAACCCA NGCCTTTCCG AAAGAGACAT CGCAANTGGC 300 TTACCCAANG TANTGTCCCG TTTTCAG 327 (2) INFORMATION FOR SEQ ID NO:169: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 346 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:169: GGTGCTATGG AGAGCCGGCC GTCCTCCAGG GGTGAGCTGG GGAGGCTTCT GCGGTTCTGG 60 AGTCCCGGCG ATGGCGCCAG TTCCCCAGCA AACCCCCTCC AGAGCTGCCC CCGGATGCAC 120 AGACAAGGAG GGGGCTTGGG AGTGACTTGA GGCTGTGACG GGRTCGCCCT CGGTGTGGGC 180 AAGTGAGTCC TCTGTGGCCA AGAGGTCAGA GTCGTCCCTG AGGCTGAGTC GAACACAGAC 240 CCGTGGCCCT CATAAAATTA AACATAAAAG CACAAAAATG GGCGCAACCA GACAGCATTG 300 GCTTTCAGAC AGGCAGGGAC ACGGGGGCCC CTTCGTGTTG ACCTGT 346 (2) INFORMATION FOR SEQ ID NO:170: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 398 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:170: TTGACCTCAA CTTACTGAGC AATGCCGTAG CTATGGAATA GAAGCATTTG TTGCACTCTT 60 TTTGTGAGCC AGGCCCTGTA GGAGGGATTG TGGATGGCAA AACCTCAGGT TCTGCCCAAA 120 TCCTCCCCTT GGGGGCTGGA GGGTCTCTAG TTAATTGGCA TTCCGGTGCT TAAGGCCACT 180 TTTGGGTAGA GGTTTGGCAA GGATGGAGTG TCCAGACCTA TGATCCTCTA AGAACTTTAC 240 CTTTTAAAAA CAGCCACCCA AATGGTGGTG GCGTGGGGAG CAGGTGGTGG TGAAGGGACT 300 GGGGGTGTCT GGCCATKGCC ACGTACCAGA GGAGACTCTG TGAGCCCTCT CCCTGCCTGA 360 GGGACACTTA ACTTTTATAG CACTACATAG GGTCAACG 398 (2) INFORMATION FOR SEQ ID NO:171: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 321 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:171: AGACAGCATC TGGCTCTGTC ACCCAGGCTG GAGTGCAGTG GCGCAATCTC GGTTCACTGC 60 AACCTCTGCC TTCCAGGTTC AAGTGATTCT CCTGCCTCAG CCTCCCAAAT AGCTGGGATT 120 ACAGGCATGT GCCACCATAC CCAGCTAATT TTTGTATTTT CAGCAGAGAC GGGGTTTCAC 180 CATGTTGGCC AGACTGGTCT CGAACTTCTG ACCTCAAATG ATCTGCCCAT CTAGGCCTCC 240 AAAAGTGCTG GGATTATAGG TGTGAGCCAC TGCGCCTGGC CCTTGGGTAA ACACTTCAAA 300 TGCAMCCAAC CATTAAAGGT A 321 (2) INFORMATION FOR SEQ ID NO:172: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 293 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:172: GAAACTTATA GTCTTGCCTC CCAACCTTCT GAACACTCCA GTAGAAAAAT CTTCTCGCCT 60 ACCTTTATCA CCCCACGACC TACTAGCATT TCTTACTCTC AAAAAAAATC TTTTCTGAAA 120 AATCAAGACA GAGTGCAAAC AATCAGCATA ATTTTATTAT GACARAACTT TTAAATTTTA 180 TCCCCCTCTC TGAGAGKTCT GCTAGGACTC CTTCAGATAA GTGAAAAAGA AAKTTTTTAA 240 AATTTATTCT CAAATCCGAA TTCCAATCTG TATAAAAAGG GCGATTCTCC CTC 293 (2) INFORMATION FOR SEQ ID NO:173: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 282 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:173: GCTTGGTCCC GTTCCTCAGG AAAAGGATGG ACCTTCTCTT CTTCTCAGAT GGTCCCTTCC 60 ATTCCCCTGA AACCTGCATG AGAGCTCCTA ACATGTTTCT CCAATGCAAT CAAGCCTAGA 120 CTCCAAATGT CCTCCCAGCT CACCTCCATC TATGCATCTC ATCTCTGGAT TTGGTGATCA 180 GACTCTATAT TGACAGTAGG ATCTCAAACC CTGCATCCAT CCTTCCTCCA GCAAGCCCTG 240 CTAGCCACAT GAGGAACAAG TTTCCGTGTC TTCATGACTT CC 282 (2) INFORMATION FOR SEQ ID NO:174: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 353 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:174: CAAGAGGTGG GAGAGGTAGG GGGCAACTAC AGCTCCCCAC CAGCCCCACC AGGGGGAATG 60 GACCCCTCCC TGCCTCCTGC CCAAGTGGCT CCCCCTGTAT TATGGGGGGG ACTTTGTGCA 120 AACTCTGCCC CGAGGGGGTG GGGAGGGTGG AGGGTGAGTG TGAAATGGCA GCGGTTGGGG 180 CTGGCAGCTG TGCTACTGGG CACTGGGGGG CTTGTAGGGC TCCAGGAGGA GGGCCGAGAA 240 GGTGTTGACC TTGTCTGCCC CCCGCACCTC ATGGGGTAAC AGCGGCAMTT TCACGATGTG 300 GAAGTTCTTC ATACAGGTCC TCCAATCTGG TCCAGATACT TGGCCTGGGT TCT 353 (2) INFORMATION FOR SEQ ID NO:175: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 394 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:175: GCCCATGCCC TTGTGTACAT AATCTCTAAT ATTTATATAT ATTGATATAG AATTCTCTCT 60 ATAATATATG TCATAGAATC TCTCTTGGGC CTGGCGTGGG AATGTGACAT TAAGAAAACA 120 TGCTAAGACT GGCCAGAAAA ATGGATATTT CCCAGACCTG GAGGATGGTG TGTGGGATGT 180 ATAGGTGAGG TCGTGGAGAA GATAATAAAC TCATTCCCCA AGATACCCTC TTCAACACAA 240 GGACAAGAAG GAAGGTGTGT GGTGGGGGAG GGGACAATGG AGGGGGAGGA GTGGAAGATT 300 TGGATTTTCA TTTAATAAAG TCAATTGAAA AATGAAAGTG CACCCCCCCT CCAAAAAACA 360 GGAGATTCAT TTAGCAAGAG CCGTTTCATT CACA 394 (2) INFORMATION FOR SEQ ID NO:177: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 381 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:177: ATTGGGACGG GCCCCCCTCT GAGGCGACGG ATCGATAAGC TTGATATCGA ATTCCTTGAT 60 NTTTTCTAGT GTTATGGTTT TCTCCCACTC CAATAACTWT TCATACCTKT GGTCTKAGTT 120 TTTCCATCTA TAAAATCATG TGCTAAATAA TTAACTATCA TCTCTATCAT TGTCAGACTA 180 CACAAAGCTT CCAGCCTGGG CAACAGGAAC CCTGTCTCTA AAAAAAATAC AAACATTAGC 240 CAGGTGTGGT GGTATGCGCC TGTATTCCCA GCTACTTGGG AGGCTGAGGT GGTAGGACTA 300 CTTGGGCTTT AGAGGTCAAG GCTGCAAGTG AGCTGTGATT GCGCCACTGC ACTCCAGCCT 360 GGGCAACAGG GCAAGACCCT G 381 (2) INFORMATION FOR SEQ ID NO:178: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 443 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:178: GATTTTATTC AAACACAGGC AAGAACAATG ACCTTCAGAG CTGGGTAAAA ATAATAAGTT 60 AAAAGCATGG TTAGAATTTT AGACAATCAG ATAAAAAGTT TGAAGGAAGT GATTTCCCCT 120 TCCTCTCCTA ATTGATTAAT TCAACACAGC ATAAAAATAA TTTGTATCTA TAAAATATCC 180 TTGTTCCCAC ACAAATGAAC TGGAGGTGGC CCTAGGATTT CCTTGACTAT GCACAATGCA 240 CACAATCTAC ATGTCCCTCC TCCCCAACTT TTAAGGCAAA AATGGTCCTG CATCTTCAGG 300 CAGAGGGTGG GCTCATGCCA GCAGTCAGCT GTGGTCAAGG ACACTGGGGG TGCGTTTYCT 360 CCACCGAAAG ATGCCTGCTT TGGGTCCACT TTGGGCGCGG GATCCCATTT TATTTTCTAG 420 CCTGTGCCTC ACCACAGGGA AAA 443 (2) INFORMATION FOR SEQ ID NO:179: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 325 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:179: TGGGGGACCA GCATTGCTCC CAGCTGAGGG CGCCGTCTTC CTCACCACGT ACCGGGTCAT 60 CTTCACGGGG ATGCCCACGG ACCCCCTGGT TGGGGAGCAG GTGGTGGTCC GCTCCTTCCC 120 GGTGGCTGCG CTGACCAAGG AGAAGCGCAT CAMCKTCCAG ACCCCTGTGG ACCAGCTCTT 180 GCAGGACGGG CTCOAGCTGC GCTCCTGCAC ATTCCAGCTG CTGAAAATGG CCTTTGACGA 240 GGAGGTGGGG TCTTACAGCG CCGAGCTCTT TCCGTAAGCA GCTGCATAAG CTGCGGNTAC 300 CCGCCGGACA ATCATGGCCA ACTTT 325 (2) INFORMATION FOR SEQ ID NO:180: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 213 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:180: GAGCATGCCC CCGGAGTCCC CAAGATCCTG GTGGGGAACC GCCTGCACCT GGCGTTCAAG 60 CGGCAGGTGC CCACGGAGCA GGCCCAGGCC TACGCCGAGC GCCTGGNCGT GACCTTTTTT 120 TAGGTCAGCC CTCTTTGCAA TTTCAACATC ACAGAGTCGT TCACGGAGCT GGCCAGGTTC 180 GTNCTGCTGC GGCATGGGAT GGACCGGCTC TTG 213 (2) INFORMATION FOR SEQ ID NO:181: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 219 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:181: AGCTTTATCA CATTATACAC AAACATAGAA AACAGTGTTT CAGAAGAGAA GCAAAGGCCA 60 TTGGCTTCAA ATATTTATGC AACAATGAAA ATGTTCTCAG CCCTTAAATG AGCACTTGTG 120 ACTTGTCCAA CAGTGAGATA ACTAGTCAAT GGAAGAGTTC AACACTAGAG CATGTATCTC 180 AGTCTGTTCT CATATTGCTA TAAAGGGCTS CCTCAGACT 219 (2) INFORMATION FOR SEQ ID NO:182: (i) SEQUENCE CHARACTERISTIcjs: (A) LENGTH: 451 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:182: GTCTTACTCT GTTACCCAGG CTGGAATGCA GTGGTGTGAT CATAGCTCAT TGCAACCTCT 60 GCCCTCTAGG CTCAAGTGAT CCTCCCACCT CAGCCTCCCG AGTAGCTGGG ACTACACGTA 120 CATGCCACCA TGCCCAGCTA ATTTTTGTAT TTTTGGTAGA GACGGGGTTT TGCCATGTTG 180 ACTAGGCTGG TCTTGAACTC GTGAGCTCAA GTGATCTGCC TGCCTCGGCC TCCCAAAGTG 240 CTGGGATTAC AAGCGTGAGT CATGGTGCCT GGCCTAGTTT GCTCTTATTT TTTTTCCATC 300 TTTGCAGTTT CTAGGCCACT GGGAACAGGC TGCAGAGCTC AGAGTCCACA GCTGTGAGGC 360 TCCATGTTGC ACCATCAAAA AATAAGGTGA CGAGAGTCCT GGGTTTCCCA GTGTCACGGC 420 AAGAGGGGTT ACTGCTCACG GGTACACACA G 451 (2) INFORMATION FOR SEQ ID NO:183: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 444 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:183: CCAAGTTGAC CCGCCGAACC ACCGACAGGA AGAGTGAGTT CCTGAAAACT CTGAAGGATG 60 ACCGGAATGG AGACTTCTCA GAGAATAGAG ACTGTGACAA GCTGGAAGAT TTGGAGGACA 120 ACAGCACACC TGAACCAAAG GAAAATGGGG AGGAAGGCTG TCATCAAAAT GGTCTTGCCC 180 TCCCTGTAGT GGAAGAAGGG GAGGTTCTCT CACACTCTCT AGAAGCAGAG CACAGGTTAT 240 TGAAAGCTAT GGGTTGGCAG GAATATCCTG AAAATGATGA GAATTGCCTT CCCCTCACAG 300 AGGATGAGCT CAAAGAGTTC CACATGAAGA CAGAGCAGCT GAGAAGAAAT GGCTTTGGGA 360 AGAATGGCTT CTTGCAGAGC CGCAGTTCCA GTCTGTTCTC CCCTTGGAGA GCACTTGCAA 420 GCAGAGTTTG AGGCTCAGCA CCGA 444 (2) INFORMATION FOR SEQ ID NO:184: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 399 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:184: GGCAGAAAGA GGAAGGAGAC AGTGCCAGGA GGAAGAAGGA AGGAGTCCCT TAGCTCTCTT 60 CATTGTCCCC TTTACTTCCT GCTATCTTCT TCTCCTCTTC TTCTCTCTCT TGCCTNTATG 120 CCTGTATTTC TGGCAATATG ACAGGCCTGC CTACCCAAGA TCAGAACTCC AAAACCACTC 180 CCACCCCTGA AGGTCGGGAG GGTCTTAGCA GCCCTGGGTG GCTGCCTGTG CTCAGGTCCT 240 CAGCTCCATG GGAAATAAAA ATGGCACCCT GAATCTCTAG GATTTTGTCA CTTTGGAGTC 300 ACAGCAAAGT TCTCTTCCTC TTGTCCCCCC GTTTGCTGCT CCTTGGGTTA TAGGACATGG 360 TAAATATTTA TTACTTTCAG GGAACCAGTA TTTTATTAG 399 (2) INFORMATION FOR SEQ ID NO:185: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 263 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:185: CAGAGACACT GGCCCAGCTA TTTTCAGCAG GGACAGAGTC GAGGCTCACT GGGGATGGCT 60 TCAGAGGACA CTGAGGCCCC TCTCAGGGAG GGCAAGGCAC AGATACCCCA AATTCCACCC 120 CACGTCCCAA AGGTCTCCCA GCGGGGCTGT CCAGTCCATG TCAGCAGAAG GCTCTTGGGC 180 GTGTGAGGGA GGGTCTTGGA GAACTAAGCG AAGGAGGCAA ACGCCAGGGC CCCTTGCAGG 240 TCAAGGCACC ATGTGCACCA CTT 263 (2) INFORMATION FOR SEQ ID NO:186: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 343 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:186: GTTCCAATAG CTGGTTTTAT TCTCAGCACA AAAGGGCCCT GTGTAAAAAC CAGAAGGATT 60 TTGTAAAATA TCAAAATGAA TATTTGGCCT GGAGGTTGGA AAGTGAAGCA AGGCTGGACA 120 TAGAAAAAAA CTGATCAGTA GTTATTCAGG ATATTATTTA GGATAAATGA AATAGGAACT 180 TAGGGGCATC TCTTACTTTT CTACAGGTTC TTATCTGGGT CAATGAAGAA ATTGTGTTTA 240 TCTTGCTGCC CTTGCATCAG GTTTTTTGCA CTAATGGAAA AAAGCCGGCC GAAAAACAAA 300 ACCCAATCCT TTCAGTCCTA GCTTTTACAT CTTGCCCTTG CAA 343 (2) INFORMATION FOR SEQ ID NO:187: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 229 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:187: GGTGCGGCTC CACCCCTTCC ACGTCATCCG CATCAACAAG ATGTTGTCCT GTGCTGGGGC 60 TGACAGGCTN CAAACAGGCA TGCGAGGTGC CTTTGGAAAG CCCCAGGGCA CTGTGGCCAG 120 GGTTCACATT GGCCAAGTTA TCATGTCCAT CCGCACCAAG CTGCAGAACA AGGAGCATGT 180 GATTGAGGCC CTGCGCAGGG CCAAGTTCAA GTTTCCTGGC CGCCAGAAG 229 (2) INFORMATION FOR SEQ ID NO:188: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 284 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:188: CCAGCAACTC AAATTCACCA CCTCGGACTC CTGCGACCGC ATCAAAGACG AATTTCAGCT 60 ACTGCAAGCT CAGTACCACA GCCTCAAGCT CGAWTGTNAC AAGTTGGCCA GTGAGAAGTC 120 AGAGATGCAG CKTCACTATK TGATGTACTA CGAGAKGTCC TACGGCTTGA CCATCGAGAT 180 GCACAAACAG GCTGAGACCG TCAAAAGGCT GACGGGATTT GTGCCCAGGT CCTGCCCTAC 240 CTTTCCCAAG GAGCACCAGC AGCAGGTTTT TGGGGGCCAT TGAG 284 (2) INFORMATION FOR SEQ ID NO:189: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 215 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:189: GGAAGGATGA GAAACAGATT TCTGCTCACT TCATGGGCTG RCCTRGRATT GACGATGGTR 60 CAAACCCAAG ATTATCCTCA TGTAATTTAT GAAGATTATG GAACTGCAGC GCATGACATC 120 GGGGACACCA CGAACAGAAG TAATGCAATC CCTTCCACAG ACGTCACTGA TACAACCGGT 180 CGGGCACATC TCKCGGCCTA TGCTGCCGGT GGTGC 215 (2) INFORMATION FOR SEQ ID NO:190: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 153 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:190: TTTCATATGG AAAGAGCTAG TACAATCACA TATTTGAAAG GAGAAACAAT AGGTACTGAA 60 CCGGAGGGAA AGGGCGAGGG TGAGTGTGCC AGCACCGGCC TGGTGAATCC ACGATTCGGT 120 TTCCCATCCA AGGGTAAGTT TCCCAAAATA CCG 153 (2) INFORMATION FOR SEQ ID NO:191: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 316 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:191: GTATTTATAC ATTTATTTAT ATATGTATAT TTACTTCAGA NGAAACGAAC ATTTCGGGGA 60 CAGGAAGCAA GCAGGCCCGG GGCTGCTTCC CTCACTGCCC ACCTCAGAGT CAGAGTTGGC 120 ACATGACAAA TACCAAGCTC AGGGTGAAGA ACTGGGAGTT AACTGGGAAG TAGGGKGCGC 180 TCTATGCACA CGCAGGCTTC TAAGGGTGCA CGGTATGGGC AGKKGGTTTG CACTGGGAGG 240 CCCTATGTAC AGCTTGAAAG CTAGGGGTGA GATTAGCCCA GTGACTACAG GAACATACGT 300 CAAAGTTGAG AGAAGA 316 (2) INFORMATION FOR SEQ ID NO:192: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 360 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:192: GTGGTTTTTG GTTATATGCA GCTTTTGACT AGCATGTATT GTGTCTTTTT CTCCTCTATG 60 AATAATTTTA TATTTCATGC TACTTCTTGA AAGTTTACTC TTTGATGCTC TAAGAGAACA 120 GCCAGATGGT TTATATGAAT AANCTTTATC TGCAGGATGG TGGATTGGTA AATNAGGAGA 180 ATGTTGTTTG AGATATCAAG ATTTATGTCT GGGAACTAAA ATATATAATG CCAAATGTGT 240 TTTTGTCAAT TACTAGAGAA TTCTGTGCAA ACATATCATC TCTTCACATG CTGCACACTT 300 TGCTTTTTGT TAAACAGCAG GTAGTAGACA GACCAATACC AGTTTCGCGT TAAGGCTTTT 360 (2) INFORMATION FOR SEQ ID NO:193: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 397 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:193: GAAAAGACCA AGGAGATGGT GAAGACAGCA GAAGCCCAGA AGCAGCAACT GAAGGAGGAG 60 CAGGGGAGGT CAGCAAGGAA CGGGAGAGTG GGGATGGAGA GGCTGAGGGA GACCAGAGNA 120 CTGGAGGGTA CTATTTAGAA GAGGACACCC TCTCTGAAGG TTCAGGTGTA GCGTCCCTGG 180 AGGTTGACTG TGCCAAAGAG GGCAATCCTC ACTCTTCTGA GATGGAAGAG GTAGCCCCAC 240 AGCCACCTCA GCCAGAGGAG ATGGAGCCTG AGGGGCAGCC CAGTCCAGAC GGCTGTCTAT 300 GCCCCTKTTC TCTTGGCCTG GGTTGGCGTG GGGCATGCGT CTAGCTTTCA CTCTGGTTCA 360 GGTCCAACAG GGTCCGTTCT GTGCCTTTGG TGCCCCC 397 (2) INFORMATION FOR SEQ ID NO:194: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 225 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:194: GATTATTGGC TTTGCTTTCA TAACATGTAT TTTTAAGTAT TTACTCTCTT AATGGCCCTC 60 GTGTCTATTT TATACATCAT ATCTCTTAAT TCTCTAGATG GAACACTGAA GGACAGGAAT 120 TAAGTAAGTG ACTGGCCATG CAAGGGTTGG AAATTTTACT GTATCCCTTC CTCRGTAGAA 180 GTTATGTTAA ACATTCAAGC AACCACATAT CTAACAGAGG AGTTT 225 (2) INFORMATION FOR SEQ ID NO:195: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 294 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:195: ATTACTAGAT ATTTGTATGT TAAATTATGT GGGTTTTCAA ATTTGTGGAG AATAAGTAAT 60 AGTGACATTA GTTTAAGGAC AGTGTTTCAT CAGGGCATTA TTTTAATGAA TCTTATATTT 120 AAATGTCTGT TTCAGGAATT CATGTGAATC TTTCTTTTTA TAGAGGACCC ACAGGCATGA 180 NTTATTTACT CCTCCGGTGA TAGGTTCTCA CCCTGATGAA AGCGGAAGCA AATTCCAGGT 240 TAGAACATTA TNCTAGTTAT GTAGGGGGGT ATAAAGTGTG TAAGTTTAAT ATTT 294 (2) INFORMATION FOR SEQ ID NO:196: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 233 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:196: TTATTTTTCT CTAAATTTTA AAATAGAAGA CTTTAATGGA AAACATTTAG TACCATCATG 60 TCAMCCTGAA TGCCAGCAAT ACCTCGACTT TTACACACGC AGGAAGCCTA GTAAAAGCCC 120 CGTCAGTAGT ACACATTTCT CTATGGTCCT TCAACAGTTT TTCATATACA AAATTTTCTG 180 CTATTTTTGC TTTTGCAAAC AGCAATAACT TTTGGGTTTC CCATATGACC ACC 233 (2) INFORMATION FOR SEQ ID NO:197: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 230 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:197: AAGATATCTA CCTGGAGTAG CTGTGCAGCC CCGCCCTCTG CTTCCCCCAG CCCTCAGGCC 60 AGTGCCAGGA CAGCTGGCTG CTGACAGGAT GTGGCACTGC TTGAGGAGGG GCACCTGCCA 120 CCGCCAGAGG ACAAGGAAGT GGGGGCCGCT GGCCAGGGTA GGGAAGGKTG GGGCAATGGG 180 GAGAGGCAAA TGCAGTTTAT TGTAATATAT GGAATTAGAT TCATCTATGG 230 (2) INFORMATION FOR SEQ ID NO:198: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 118 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:198: TTCTCCTGGG GAAAGGGCTG TTGCTGAAGT GGCCGGTTTT TTTAAGCATC GACATTTGCA 60 TCCAAAGGTT CAAGCAGCCG CCTCAGGTTC CARAGGCTTC CACCTGATGG CTGCACTT 118 (2) INFORMATION FOR SEQ ID NO:199: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 268 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:199: TAAATGATGG AGTTAAATGA TGTTGTCAGT GCCTATTTAA AAAACTACTC TTCCCCTTCT 60 CTATGAGTTC TACTTTGGTA AATATTAATA TTTAACCAGT TAGTAAAACT AACACCACTA 120 TTTCAATTCT CTTTTGTGCA TAGTAAGTAA ATTTTGCTTT ACTTACTTTA TAAAAAAATA 180 CTTTACATTT TATAAAGCAG GTTTTAGAAA AACGGTTTAC AAGAAAGTTT GCCTCCATTT 240 CACTGCCAAT TTAAGCACAG GGGAAAAT 268 (2) INFORMATION FOR SEQ ID NO:200: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 422 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:200: CCAGTGAGTT TGTGAAAAGC AACAGGGGTA NGACAGGTTC AAGGAAGGAC ACAGACAGTG 60 CCCTGTTTTA GGTTCCAAAT TTCTTCTTTT TAATGGGTGG TGGGAGCTGA GCAATGATGT 120 CATTTGGAAG GGGCAATGAC TTGTCAATNA TGCAGAACAT GTAGGCATCA TGGAGAAGGA 180 TGTGCATCGG TCTCTTGGGA TGAAAACTGA TGTGTGTGAT AGGAGTATCC CTTTGGAGCC 240 AAAGGTGGTG AAAGCCCTGC TTCTGGACAG TCCGGCTCCA ATCTGTATAC TGTTTGTCTG 300 GGATGCTGTA CTCAAATACC TGCTGGTCCG AATGAGCGAT GACAAGGTTG TTTGGTATTG 360 GGGGCAATAG CCATAGCAGT CACTTGGGAA ATTGTAAGCA GGCACCGTGC AGTGAAGTTT 420 TA 422 (2) INFORMATION FOR SEQ ID NO:201: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 273 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:201: ACTCCACGCT GATGAACCCG ACGTCCATTT CTCCAAGAAA TTCCTGAACG TCTTCATGAG 60 TGGCCGCTCC CGCTCCTCCA GTGCTGAGTC CTTCGGGCTG TTCTCCTGCA TCATCAACGG 120 GGAGGAGCAG GAGCAGACCC ACCGGGCCAT ATTCAGGTTT GTGCCTCGAC ACGAAGACGA 180 ACTTTGAGCT GGAAGTGGAT GACCCTCTGC TAGTGGAGTC CAGGCCCCCA GACTACTTGT 240 TACGAGGGCT ACAACATGTG CACTGGGTGC CCG 273 (2) INFORMATION FOR SEQ ID NO:202: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 436 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:202: GGACTCCAAC CCCCCAGGAG GCCGAATGCT GAGCTTGGCA ATGGTGGCCT GGATGGAGCT 60 GATGGGCACA TCCCCACCGA GGACCAGGTC CTGGGAGTCC TGAGGAAGGT GGTTCTTCTG 120 GCTGATGCTT GCACTGGCCA AGGGTTTGCA TGGAGGAGGC ACACCATGGC GCTGCAGGAC 180 CTGCTCCACG TGTCTCACCA CTGCCTCATA GCAGAACCTG AGGTGCAGCT TCTCCTGCAG 240 CATGTGCTTT CTCTGCTGCC GCATGCGCCG CACCAGCTGA GGCAGCTCAG GGATTCCKTT 300 CCCAGCCTCC ACCTCCTGCA CAGCTGCATA GAGCAGTGCA AAGGCTCCCG TGCGGCCCAC 360 ACCAGAGCTG CAGTGCACAA TGATGGGCGT TTGCAGGGGC CGTGATGCAA GGTAATTTGC 420 GTGCACCTCC TGGGTT 436 (2) INFORMATION FOR SEQ ID NO: 03: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 336 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:203: CTGCATGTNT TGGGGACACT TACGCCAAGG CGCCGCGTTC TCATTAGGAG CTGGGACCAG 60 AAGTGAATAA GCCAGGTTCC TGTCTCAGGG AGCTCCATAG CAGGACTCAG AACCACACAC 120 GGCCCTCTAG GCATTTKTGA AGCTCTGTGC TTCATTTTTT TTGCTTTGCC TCTAGTTTTG 180 CCTTTGCAGT ACCAATGCAG CCAGCCCATG TKTCCCCTCT ATGTGGAATG TTAACGATAT 240 TCCCACTGTT TCTGGTGTCC TTTCTGTAAT CAGAGCTGCC GTGACCATTC CAGTTCAGGC 300 ATCCTGGTGG CCTGGCTTTC TCTGGGGCAT AGAGCT 336 (2) INFORMATION FOR SEQ ID NO:204: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 393 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:204: GGAATCAGAT GCTCAGGTGT CCAAGCAGGG ATAAGGACAG GCAAAATAAA TAACCCCCCA 60 ACCCCCATCG TCACTCTGCT GCAACACGAC ACAAAGGTTT AAAGATCTGG GCCCAAAGAC 120 TCTGGGTCCC TTCAAGCAAG CTCAGGTGGA AGGAGGTTTC CCCACCCCCC ACCAGGCCTG 180 TTTGCCCCAG GTTGCCCTAG GATGGAGGCA GTTCAGACCC TGGGTCACTG AAGCTGATAG 240 GAAGAACTNC GATATCAATG GCCTAAGCCT GCTGTNTGCC CAAGGGAGCC AAGGGCAAGA 300 GCCAAAGGGC CAATTTAAAG GACGTGGACC TGGGGGGCCA GAGGAGGCAC CACAGCCGAG 360 GGGAGCCACG CCCTGGGCCG GCAGGGCACA TGG 393 (2) INFORMATION FOR SEQ ID NO:205: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 390 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:205: GAGGAAGAGG ATGACCTGAG TGAGCTGCCA CCGCTGGAGG ACATGGGACA ACCCCCGGCG 60 GAGGAGGCTG AGCAGCCTGG GGCCCTGGCC CGAGAGTTCC TTGCTGCCAT GGAGCCCGAG 120 CCCGCCCCAG CCCCGGCCCC AGAAGAGTGG CTGGACATTC TGGGGAACGG GCTGTTGAGG 180 AAGAAGACGC TGGTCCCAGG GCCGCCAGGT TCGAGCCGCC CGGTCAAGGG CCAGGTGGTC 240 ACCGTACATC TNCAGACGTC GCTGGAGAAT GGCACACGGG TGCAGGAGGA GCCGGAGCTG 300 GTGTTCACTC TGGGTGACTG TNACGTCATC CAGGCCC1GG TTCTCAGTGT CCCACTCATG 360 GACGTNGGGG AGACGGCCAT GGTCACTTCT 390 (2) INFORMATION FOR SEQ ID NO:206: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 172 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:206: CTTTACTGTG GGTGTGGGTG TCACTGTCAC TGCCACAGCC ACTNGGAGGG ACACACAGCT 60 TTAACCCCTR TTTGCTTAGG NGAAGGGTGG GGGCATTCAG GGTTATAAAA CTAACTATAT 120 ACACAGAAGG TCCTAGGKAG AAAGCCACCC TGAGCACACA TGTCTAGGCA CA 172 (2) INFORMATION FOR SEQ ID NO:207: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 215 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:207: AAGGCAATTA GAAGATTTAT TGAATATTGG TTAAAAGTAG ATTGACAATG ACATTAAAGA 60 ATAAAGTGTA ATTTATTTGG TGCTACTTTG TGAATGCTTC CAAGTACAAA TCATCTCACA 120 ATACCATATA CAACATACTT TCAATCACAA CTCAAATATA AAATAACCTA CAAAATCACA 180 TTGCTATAAT CAATATACAA TAATTGTATT TTTAA 215 (2) INFORMATION FOR SEQ ID NO:208: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 444 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:208: GGAGTTCTCT TGTCCACGGA GAGCAGTGTT GCAGTGTATG GAATGCTAAA TCTTACCCCA 60 AAGGGCAAGC AGGCTCCAGG TGGCCATGAG CTGAGTTGTG ACTTCTGGGA ACTAATTGGG 120 TTGGCCCCTG CTGGAGGAGC TGACAACCTG ATCAATGAGG AGTCTGACGT TGATGTCCAG 180 CTCAACAACA GACACATGAT GATCCGAGGA GAAAACATGT CCAAAATCCT AAAAGCACGA 240 TCCATGGTCA CCAGGTGCTT TAGAGATCAC TTCTTTGATA GGGGGTACTA TGAAGTTACT 300 CCTCCAACAT TAGTGCAAAC ACAAGTAGAA GGTGGGTGCC ACACTCTTCA AGCTTTGACT 360 ATTTTGGGGG AAGAGGCATT TTGACTCAAT CCTCTCAGTT GTACTTGAGA CCTTCCTCCC 420 AGCCTGGGAG ATGTTTTTTG TATT 444 (2) INFORMATION FOR SEQ ID NO:209: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 338 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:209: GCAGATCACT TGAGGTCAGG AGTTCGAGAT CAGCCTATAT ATGCAAGTAC ACACACAGGC 60 ACTCGCACGC ATGCATGCTC ATGCAACACA CATGTACACT CTACATGTAC AGCTCACATA 120 TGCATCCATA CACATGTGCA TGCTCACCCA TACACCAGCC ACACACAAGT ACTCATACGC 180 ATACATGGCC ACACACAAAG TACACACACG TACACCATAT GCATATGTAT GCACTCATAC 240 ACTCATACAT ATGTGCCCCC TCAGAGAAGT ACACAAGTGC ATGCGCATCA CACATGCATA 300 CGTGCTCATG CATACACACG GGACATTTCA TACACACG 338 (2) INFORMATION FOR SEQ ID NO:210: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 371 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:210: GAGGAAGTAG AGCCTNAGGA GGCTGAAGAA GGCATCTCTG AGCAACCCTG CCCAGCTTGA 60 CACAGAGGTG GTGGAAGACT CCTTGAGGCA AGCGTAAAAG TCAGCATGCT GCAAGGGGAC 120 TGTAGATTTA ATGATGCGTT TTCAAGGGTA CACACCAAAA CAATATGTCA ACTTCCCTTT 180 GGCCTGCAGT TTGTACCAAA TCCTTAATTT TTCCTGAATG AGCAAGCTTC TCTTAAAAGA 240 TGCTCTCTAG TCATTTTGGG TCTCATGGCA GTAAGCCTCA TGTTATACTA AGGGGGAGTC 300 TTCCAGGTGT GACAATCAGG TTATTGGAAA AACAAAACGT GGTTTTGGGA TCTGTTTGGG 360 AGACTGGGGA T 371 (2) INFORMATION FOR SEQ ID NO:211: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 295 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:211: CCTCCCAACG TGTTGACATT ACAGGCGTGA GCACACGCAC CCAGCCCATC TAGCATAATG 60 TTTTGCATAG TTGTCAGCAG ATAAATATTG AATGACAAAA CTCAGATGGA GGAAAAAGAA 120 CAAAATAACC TAGTTCTCAG AAAGATTTAA TGAGCAAATG GGAAAATGTC AAAAAGATTT 180 ACAGACAGGG GCATCTTAGA GTCACTGGAA TCACACAGGC CTTCCCTCAG CTTGAGGGGC 240 TGCCTGGAGG TGGGGGTGGG GGTACACCTC CTCAGTGGGG AGAGACTTGC CAAAT 295 (2) INFORMATION FOR SEQ ID NO:212: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 370 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:212: TGGCCGATAT GAGGGGGGTG GGACTGGGCC CCGCGCTGCC CCCGCCGCCT CCCTATGTCA 60 TTCTCGAGGA GGGGGGGATC CGCGCATACT TCACGCTCGG TGCTGAGTGT CCCGGCTGGG 120 ATTCTACCAT CGAGTCGGGG TATGGGGAGG CGCCCCCGCC ACGGAGAGCC TGGAAGCACT 180 CCCCACTCCT GAGGCCTCGG GGGGGAGCCT GGAAATCGAT TTTCAGGTTG TACAGTCGAG 240 CAGTTTTGGT GGAAGAGGGG GGCCCTAGAA ACCCTGTAGC GCAATGGGGT TGGGCGCCCC 300 AAAGGTTAAG TTTGAACCCG AAGAGCAAAG GAAGAGGCGA TCATCATAAG TGGAGGATTA 360 GGATTAGGAT 370 (2) INFORMATION FOR SEQ ID NO:213: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 302 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:213: ATCTGTGGAA TAATCTGCGG GCTAACACGG ATAACTCAGT ATAAGAACCA CCCAGTTGAT 60 GTCTATTGTG GCTTTTTAAT AGGAGGAGGA ATTGCACTGT ACTTGGGCTT GTATGCTGTG 120 GGGAATTTCC TGCCCANTGA TGAGAGTATG TTTCAGCACA GAGACGCCCT CAGGTCTCTT 180 GACAGACCTC AATCAAGATC CCAACCGACT TTTTATCTGC TAAAAATGGG TAGCAGCAGT 240 GTATGGGAAT TTTCTCATAC AGAAGGGCAT CCCTCAAACC GGAAACCACA GAGATGCTAG 300 GT 302 (2) INFORMATION FOR SEQ ID NO:214: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 354 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:214: ATGGATGAGT GGGCACCCCG CACAGGGCTG CAGGGTGGAA AACGCTCGAC GGCCAGGTGG 60 TGACTTGGGG GCAGAGAGCG CAGTGTNGTA GGGGAGGAGA GGTGGTGTCC CTGCTGCCTG 120 GGAGCCAGCC TGCCTGTNCT GTGGGCAGAG CAAGGCACTT TCTGCTGCCG GTGCTTCCAG 180 GGCCTAAGCA GCCGCTGCAC ACTCACCAGC GCAAGGCTCC TCTGCAGGGA ACGAGGGCTG 240 CTACCCATTT CACAGATGAG GGCAAGCAAG GACTTGCCCA GGGTTGCCCA NAGCAAGTGC 300 GTAACAGGCC CTGAGAAGAG NGCCAGTGAG CTCATCCTGA GTTAATTATG GGCT 354 (2) INFORMATION FOR SEQ ID NO:215: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 260 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:215: TGGTTCAAAG TCTAGGCCCT CTTNAGAGCT GGCTGATTCA GCTTGCCAAC AGTGACATCA 60 GGGTGAGGCT TCCTCTGTCC ACAGCATTAG CTGCGAATAT CCTCATGGTC ACAAGATGGC 120 TGCCAGTGGC CGTCAGGGTG TGTGCTTCCT TGTTCACATC CAGTGGAAGA GTGACAGCCT 180 GCTCCCCTTA GCTCTCTGAC ACCANTGTGA AGGTGCCANG AACTTACTAG CAGGNCTTTC 240 CTCATGACCC ATTCAACAGG 260 (2) INFORMATION FOR SEQ ID NO:216: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 232 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:216: CTTGGACAAG ATCTGGGATA ATTCTCTGGA TTACCTGGCA GAGACTTTTK TTCTCTTCCC 60 TTACTGTCTC CCAAATAAAC AGTCTCTCAC TCTGTTGTGA GCCACCTGAA GCTGTGATAT 120 TTCCAACGAC TGTAGGAGGA AAAAATTAAG GGGAGAGAGG AAAACAAAAC CAACCAACCC 180 CTAANATCAT TTNTTTATTG TACATAACGA CCTCATTCTC CTGTATATGC GG 232 (2) INFORMATION FOR SEQ ID NO:218: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 219 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:218: CTGCAACCAT CCATACCTTT TNCCCGTGGC TGCTATGGAG TCCCCCAAAC TCCCCAGTGG 60 GGCTTATGAG GGTGGGGCAC TTATTANGTN GTCTGGGAAG CTCATGCTGC TCCAGAAGAT 120 GCTGCGAAGC TGAAAGGAGC AAGGACACCG AGTGCTCAAT NTTCTCGCAG ATGACCAANA 180 TGTTAGCCTT GCTTGAGGGC TTTCTTAGNC TATGAGGCT 219 (2) INFORMATION FOR SEQ ID NO:219: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 390 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:219: GATAGGTAGC AGAGACCAAG GCGCAGGGTG CTTCAGATGA GCAAGAGAAC CCAGTCGAAC 60 CAGATACCCC AGGTGGGCCG GAGGGACCCC AGACCTTCAG AGGGCTGCCC TGGTGTTCTC 120 CACAGTGCAG TCCCTCTGTA TTCCCAGAGT GGGATCGGGG CTTTCAGCCC ACCCTGATGC 180 CTGCCCTCCA GGATGGCTGG TTTAGTCTGG GTCCATGTCC CAGACCCCTC TATTCTGCTC 240 CAGGACAGCA GGACTTCAGG TCTTTCCTGG GGGTGGATAT AGGAGAAAAT TTCTGCCTGG 300 CACACACCTG GGCTCCAACC ACTTGCCAAG TGATTCACTC TTAGGCCCAG GGGGAACACA 360 ATGACTATCA TTACTGATGC AGACCTGGCT 390 (2) INFORMATION FOR SEQ ID NO:220: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 382 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:220: TTTTTGTTTT GTTTTAATAT TTTTGATATT CTCTTTGCAT TGAAATGGTA TAAATGAATC 60 CATTTAAAAA GTGGTTAAGG ATTTGTTTAG CTGGTGTGAT AATAATTTTT AAAGTTGCAC 120 ATTGCCCAAG GCTTTTTTTG TGTGTTTTTA TTGTTGTTTG TACATTTGAA AAATATTCTT 180 TGAATAACCT TGCAGTACTA TATTTCAATT TCTTTATAAA TTTAAGTGCA TTTTAACTCA 240 TAATTGTACA CTATAATATA AGCCTAAGTT TTTATTCATA AGTTTTATTG ANGTTCTGAT 300 CGGTCCCCTT CAGAAATCTT TTTATATTAT CCTTCAAGTT ACTTTCTTAT TTATATTGTA 360 TGTGCATTTT ATCCATTAAT GT 382 (2) INFORMATION FOR SEQ ID NO:221: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 314 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:221: GACTTTGGTT TATTTAAAAA ACAAGCCAAA AAAAAAAAAA AAAAACCCCA ACTTTATATA 60 CAAAGTCAAA CTGAAACCAC GGWTTATGGA AAGAGGCAAG AWTTATGGGT AACAGGGGAG 120 AAGGCTGGGC CAGAGCCAAT ACCACATTCT GAACACAGGA GCCACGGGAA AGAGGTGCTG 180 GTTTCTTCTG GCAAGACCGG GGTGACTGGA ACGCAGTGGT CCTACTGGCA AACCCAGCCC 240 AACACTGAGC TCTTTCTAGC ATGGACTCCA TTCCCGTGAT TGGCCAAGGG AGACCCTTCC 300 CCCAGGAGGC CTGT 314 (2) INFORMATION FOR SEQ ID NO:222: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 342 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:222: TTCCTTCTCT GCGGCGGCAC GTCGCNAGCA GCCTGCTTCG CCCCGTCGTC AACTTTGAGC 60 TGGAGGAGAA GCAACTTTGG CAGTGGCCGC GGGGTGGGAA TCCCGCTTCT CCTCGGCAGC 120 AGTAGGCTCG CAAGTCGCTG GGGTTAGGTG GGGCAAGAGT TTCGCCGGCG CATCAGCGCT 180 TGCTTCGGAC TGTTTGCAAC GTGTTTCCAG CGAGCTGGGA GCGGGGGTTG TGACTGCGAG 240 TCGTCTGGGG GAGGGGGACT TGTTTTTCTT TTCCTCTAGA GACCTCGGCT TTCAACTGGA 300 TCAAACGTTG TCGAAAGGAT GTAAATAGGC AAGAGCAAAC TG 342 (2) INFORMATION FOR SEQ ID NO:223: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 376 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:223: GTGATGGCTG CCTTGAGGGG GACCATCATG TCGGAGACGC ATTGGTGCAG GTCTCACCCC 60 ACAGCCCATG CCCAGCCTCC TGCAGACTCA GGTCATCCAG CTGGTCGATG GCTCTTTGCA 120 TACCTGGTGC CTTCTCCTCT CGGGCTTGGC AGGCTTCTCT GGGGGCTTCT CAGATGACTC 180 TTTTGCCTTC TTCTCTGTCT TGGCTAACTC CTTGGCCAGC TCTGAACGTG CCTCCTTGGC 240 TCCCTCTTCT ACCACCTCCT CCCGTTTGGC CAACTTGCTC ACGGCCGTCT TGGTAGTGGC 300 TTTGAGGCTC TCCTTGCTAT CAGCCCGCTG TTTGATTTTG CTGGGCTTGA GGTTGGTAAG 360 GCACAGCCCC AAGAAG 376 (2) INFORMATION FOR SEQ ID NO:224: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 445 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:224: GTTGATAGAC ATTGGCATTG GGGTTGCTTC CACCTTTTGG CTGTCATGAA TAATATTGCT 60 ATGAACACTA ATGTACAATT CTTTGCCTGA ACGTAAATGT TTTCATTTCT CTTGGGTATT 120 TATCTAGAAA TGAAATTGCT GTATGTTAAC CCTTTGTTTA ACCTCTTGAG GAACTGGCAG 180 ACTTTTCCAA AGCAGCTGCA CCATTTTAAA TTCTAACCAG CAGTGTTTGA GGGTTCCAAT 240 TTCTCTATAT CCTTGGTAAC ACTTGTTATC TGCCCTTTTG GTTAGAGACA TCCTAGTGAG 300 TGTGAAGTGG CATCTCACTG TGGTTTTGAT GTGCATTTCC CTGATAGCTA ATTGTGTGGA 360 TCCCTTTTGC TTTTAGTGGA ATGAAATATC TGGTAGTCTC GTATGCCAAA CTAAAGCTAA 420 AATTAAAATG ACTCTGCATG ATGGA 445 (2) INFORMATION FOR SEQ ID NO:225: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 403 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:225: TGCTCTCGGG ACAGTTTCCC GGGCAGCTCC TGGCCAGCTT CCAGCCCAGA GTCCTCAAGT 60 CCAGGGCACC TTGGGCCCAG CGCAGGCAGA ATCCGAGGTG GTCCTGGCTC TACCCTGGGC 120 CTCCTACTCC CCAGCACCCC TGGAGGAGGC AGGGGCTCCC CGCCGCCGAG GCTGCCTGCC 180 CTAGGCCCAC CTCTGCATGC TGCTCATGGG GCCACCCTGC CTCCTGGGCC CTCACTCTGC 240 CTAGGGGAGC TGGGCCAGGC ACTAGCCTTT GCCCAGGGAG GTGGGCCTCA GGCTGCCCAG 300 GTGCCTGCAC CCCAGCCGGG CTTCTCTGGG GCCTCCCCGT CGTCAAGCCT ATATCCTGTC 360 TGTCCCCACC CCAGCTGTCC CTTGCCAGGG GACTGGCATA AAA 403 (2) INFORMATION FOR SEQ ID NO:226: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 440 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:226: GTGCCTTAAG GAGAGAGATT GTGTTCTTCC TCTCTCAGGG GTGATAACTC AGGAAGCCTC 60 TGGGTTGGGA AGACCATCAG TTCTTTTGTC TTAGGTTTCT TTTCCTGTCC CTCTTCCATC 120 CCCAAGATGT GACCCCATAA AAATTTTTCC TGAGTTGGCC AGGCATGGTG GCTCACGCCT 180 GTAATCCCAA CACTTTGGGA GGCTGAGGCG GGCGGATCAC GAGGTCAGGA GTTCGAGACC 240 AGCCTGACCA ACATGGTGAA AACCCCATCT CTACTAAGGA TACAAAAATT AGCCGGGTGT 300 GGTGGCACAC ACCAGTAAGT CCCAGCTGCT CAGGAGGCTG AGGCAGGAGA TTTGCTTGAA 360 CCTGGGAGGC AGAGGTTGCA AGTTAGGCCG GGATTGCGCC GTTTGTACTC CAGCCTGGGC 420 AAGCAGAGCA AGACCATCTA 440 (2) INFORMATION FOR SEQ ID NO:227: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 426 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:227: GACCAAGAAG TTCCGGTTCG AGGAGCCCGT GGTTCTGCCT GACCTGGACG ACCAGACAGN 60 CCACCGGCAG TGGACTCAGC AGCACCTGGA TGCCGCTGAC CTGCGCATGT YTGCCATGGC 120 CCCCACACCG CCCCAGGGTG AGGTTGACGC CGACTGCATG GACGTCAATG TCCGCGGGCC 180 TGATGGCTTC ACCCCGCTCA TGATCGCCTC CTGCAGCGGG GGCGGCCTGG AGACGGGCAA 240 CAGCGAGGAA GAGGAGGACG CGCCGGCCGT CATCTCCGAC TTCATCTACC AGGGCGCCAC 300 TTGCCACAAC CAGACAGACC GCACGGGCGA GACCGCTTTG CACCTGGCCG CCGTTACTTA 360 CGCTCTGATG CCGCAAGGGC TCTTGAGGCC AGCGAAGATG CCAACATCAG GCAACATGGG 420 CCGAAC 426 (2) INFORMATION FOR SEQ ID NO:228: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 278 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:228: CAGGACCAGG AGAAGATCCT GGAAGATGCA GTGGATGAGT GGACGGGCTT TAACAACAAG 60 GTTAAAAAGG CCACTGAGAT TGTTTTAGAA AACCAACAGC AAAACACTGA CAAGGTACAT 120 AAATACAGAT TGGACATTTT AGGGTAAATT CACTGTATTT CCTACTTGCT TGTAGGAAAC 180 CGAGTAAAGT GGAAAAGCTG TCCTGATCAT ATGGCATGCA CACCAGACTG CAAAAGGNCG 240 TCCACACTAT TTAACAGGAC TGTGGCAAAA TAGCTTTA 278 (2) INFORMATION FOR SEQ ID NO:229: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 425 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:229: TTTTTGTTCC CAAGCCTTTG TGACTGACTT TAAATCCTCT CACCTGCAGA ACAGAGATGG 60 CTTCAAAGTG GGGAGTGAGG GAGTGAGCGA GGACCCTGGG CTGAGACCTG TTTTTCTTCC 120 ATTTCTGCTG TGGCTTCCCA CAGCTCCCTG GTTCCACACC AGGCCCTGCT CTGCCGCAGA 180 AAATGGATTC CCAGGCCACA GAGCTGTCAG GCCTTTGACT TTGCAGAGAC CAAGCACCCC 240 AGAGGCTGTG CGACASGGCT AGTCCCTGGT GGGCCGGTCT GGGGCATGGG GGGCAGGGAG 300 ACTKGGAGAT GGGGAGGGCG TTGAGAATCC GGGGGGTCCT GGATACTTGA CAAATTGGCT 360 CAGGTCTTAG CTYTGGYTGC CCCACTGATT GTGTTGCTTG GCAAGGTGCA AGTYTTCGGC 420 TGTTC 425 (2) INFORMATION FOR SEQ ID NO:230: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 382 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:230: TTGGAGGATG TGCTGCCCCT CCTGCAGCAG GCCGACGAGC TGCACAGGGG TGATGAGCAA 60 GGCAAGCGGG AGGGCTTCCA GCTGCTGCTC AACAACAAGC TGGTGTATGG AAGCCGGCAG 120 GACTTTCTCT GGCGCCTGGC CCGAGCCTAC AGTGACATGT GTGAGCTCAC TGAGGAGGTG 180 AGCCAGAAGA AGTCATATGC CCTAGATGGA AAAGAAGAAG CAGAGGCTGC TCTGGAGAAG 240 GGGGATGAGA GTTCTGACTG TCACCTGTGG TATGCGGTGC TTTGTGGTCA GCTGGCTGAG 300 CATGAGAGCA TCCAGAGGCG CATCCAGAGT KGCTTTAGCT TCAAAGGAGC ATKTTGACAA 360 AGCCATTKCT CTTCAGCCAG GA 382 (2) INFORMATION FOR SEQ ID NO:231: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 398 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:231: GAGGCTGGAG AATCGYTTGA ACCCAGGAGG CGGAGGTTGC AGTGAGCCGA GATGGCGCCA 60 TTGCACTCCA GCCTGGGCCA GAGCAAGGTT CCTTCTCAAA AAACTTGGAA ATCTGTTGGG 120 AAGTAGGGGG AGGGCAAGGT TAAAACCTAT GCAGGTGTGT CAATTAGACT TGTTCCAACT 180 TGAGAACCTG AATTTTGCAT GTAATTGAAA TGTTCCAGAA CAAGTCTGGC AGTTTCATAA 240 GGGAGTTTTT AGATGCCAAT ACATTGCAGA TAACCATATT GGTTACATTA GGGGAATGAG 300 CATGGGATAG GTGCCTCCCA GTTGGTAGGA TAGCATGAGG AGGTTTCAAA AGTAACCSCT 360 TTAAGGGTTA TGTCCAGTAT TTGCTAAGTA ACCAAGGT 398 (2) INFORMATION FOR SEQ ID NO:232: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 272 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:232: GGGGCTGCAG ACTGAGTTAT TTTATTTCGC TATTTCCAGT TTGAAGCTAC TATCATGGGC 60 GTTTAGAGTT ATACAAATGA CACTTACAAA AAATAAAAGA CCAAGACACC CAGAGTGAGA 120 TGCATGTTGG GGACGGGGGA GGCTGGCAGC AGGGGGGCCC CGGCGGYTCA CCCCAGGGCT 180 CCCGGAGGGG CGACGCCTGG CTTCATCCAC CCGGGAGGCC CAGGGAGCAC CAATCACAGC 240 AGGGGCTCTG GCCCAGGTGT CGGCAGCCCA GG 272 (2) INFORMATION FOR SEQ ID NO:233: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 364 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:233: ATTTTACAGT TTTATTTTTA AATCATTTAC ACATATTCAT ACAAAGAAAA ATAAATTTCA 60 GGATGGAATC CTGGGGACCA TGGTAGTTTA AAAAAAAAAA TCTCTCTGAT CATTAGCTAC 120 TAAAGACANG GCAAGAGGCT TAGCAGTCAT TTCTGGGGGT TAGTGTATCT CCCCATGCAG 180 GGGACAACTG NGAAGAATCC AAGCTGCTCC CTCATCTTCC TTCGATCTAG ATGGGGGAAG 240 GGGATTTTCC AATGCTCTCC CCTAGAAACA TTTCAAGAAG TACAGCAAAG GCTTATGGTA 300 ACACTGGAAC CTATTTGCTA GAAATCTGGC AAGATTGCAC TTTCTGAACC CAATTTTCCT 360 ATAA 364 (2) INFORMATION FOR SEQ ID NO:234: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 217 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:234: GGCCAGGAGC CAGAGGGCCC CGGGGCCACC CCTGCCGGGG AACGTGATGA CCAGAGTCCA 60 GACAGTGTCC CAGAGAGGCC GCGGCCCGCA GACCGGAGGC TCTGTCTGCC CTNCGTGGAC 120 GCCTCGCCAC TCCCAGGGAG GACGGCCTGC CCGTCGCTGC AGGAGGCCAC GCGGCTCATC 180 CAGGAGGAAT TTGCCTTCGA TGGCTACCTG GACAATG 217 (2) INFORMATION FOR SEQ ID NO:235: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 221 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:235: AACTTTAAAG TTAGGATTTT AAAATATTTG TAACTGGCTA AATTTTAAAG TCGTGACAAA 60 TAATTACTTA GGTTCAGAAA TATACACACA CTTACTCTTT AGCCAGTTTC TTTCAAGGTN 120 TTACTGTCCC ATCAGATATC TAGCCATTTK CCTTTGCAAA TTACATACCT TCTTAAGAGT 180 GTATTTTTAA GATTATTACT TATGCTTTAT GATGATATAG T 221 (2) INFORMATION FOR SEQ ID NO:236: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 221 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:236: ATAAATGGGT TTCTCACTCC TTAGGGACAC GATTGGAAAC AATACATCCC ATGAACACAG 60 GTGAATGTCC CTGGTTATCC CTGAGCTGGG CAGTTTCACA CAATCANTTT TNCTCTGAGG 120 CCAAAGTCTG TGGTTTGATC ATCTTAGCAG CTTCCAGAAC AGAAAGTAGG TTTACTTTGT 180 CTCCAAANTC TNATTCTCGG TGCTCAAAGA AGAATGACCT G 221 (2) INFORMATION FOR SEQ ID NO:237: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 251 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:237: GACATCTTTC TAAGATTCTC TGTGGGAAAA TGACTGTCAA TANAATGCGG GTTTCTGGGC 60 CATTCGTCTT ACTTTCATTT TTTGATTACA AATTTCTCTT GACGCACACA ATTATGTCTG 120 CTAATCCTCT TCTTCCTAGA GAGAGAAACT GTGCTCCTTC AGTGTTGCTG CCATAAAGGG 180 GTTTTGGGAA TCGATTGTAA AAGTCCCAGG TTCTAAATTA ACTAAATGTG TACAGAAATG 240 AACGTGTAAG T 251 (2) INFORMATION FOR SEQ ID NO:238: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 327 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:238: GTTCGTGGCT GTCACAATAA TGCTGTGATA ATGCTGTGGT TTCCCAGCAG GGAGGTGGGA 60 GCGGGGAGGG GGCTGCAGCC TGATGAGAGC CAGCTGAAGG AAGAGCTGCC TCTCCCTTCC 120 TAAGCCCCTT CCCAAGGTCT GCCCCACCGC CCAAACCAAA GACCACTCCG AACAAAGTGA 180 GGATGTGGAT GCTCTTGCTG GGTCCGCTGT TCCGCAGAGG GAAAGAAAGG GTAGCTGCAC 240 TGACCCCACT GTCCCCATAT ACAAGGGTTK GGGGGCAAGA GCATGTGGCT ACTCCCAGCA 300 AGGGRAAAAT GGGAGGAGCA GTAGAAA 327 (2) INFORMATION FOR SEQ ID NO:239: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 285 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:239: ATTATTAGTT TATGGTGCTT TAAACCTATC AAAATAGTTG TAAGTAAATG GATTTCTTGT 60 NCTCCCAATA ACAATTCTCT GAGCTAGGAT AGATGTCTTT CTGGCCATTT TACAGGTGAT 120 GACACTGACA TAGGGACTGA GTGGGTAGCT TAAGTNCCAT GGTTACCAGG AGCAGGACCN 180 ACGTTTCCTG NCTCCCAGTC TCATCCTGTT TTCCACTGAC CAGGTTGGTT GCTCCCTTGG 240 AAAGCAGTCC CTGAGAGTTG ACTTAGAAGT TCAGGGNGAA GAGGT 285 (2) INFORMATION FOR SEQ ID NO:240: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 349 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:240: TTTTGCCATG TTGGACAGGC TGATCTCAAA CTCCTGGCCT CAAATRATCT GCCCAGCTTG 60 GMCTCCCAAA GYGCTGGGAT TACAGATRTG AGCCACTGCA CCCAGCCTGA CATGCCATAG 120 TTTCAGCATT TTCTTGGGCA ATGATCCAAG CTGAAGGCTG GTCTGAGGGA TCTSAAGAAG 180 CGTATGAGTT GGAAGAGAGG GACAGAAAGG AAGAAGACAT GTGAAGAGAG AAAAGGAAGG 240 AAGCTAGCAG AGGAATGCCC TCCAATAGAG ACTGCTGCCT GAAGCTCAGC CCCTCTGAAG 300 ATAGGTAGGC CAGGCTGGCT TAGCTGAGGC AGTGGGTTAG ACCAGCCCT 349 (2) INFORMATION FOR SEQ ID NO:241: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 233 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:241: GTGCAGCGGT CTGCCTTCAT CTTTTAATGG CCGGTGCGGT ACAGTTAGTG GACAGACGGG 60 GGATGGGACA CAGCAGGGGT GAAACAGGGC AGTCACAGCC GGGGCCGGGG ATCTGGAAGC 120 GGGGGCGGTC CTCCCCCTGG AAACACCGTN TCTGGAAGGA CACCCTTAGG ATCCCCTGAC 180 CTCARGGTGC CACCCACACG GGCCTGGTGT TCTGGGAGGC CCGGCTKGAG TGA 233 (2) INFORMATION FOR SEQ ID NO:242: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 372 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:242: ATATGTACTA CATTTGGTGG AATACGCATG TACAATTCTT CAAAAATAGT AAAGAGCAAA 60 ACAAACAAAA AATAGTAGAA GCACTGGAGA AATACACTAT GGCATAAACT AGTTACGGGT 120 GGGATGTCAC ATGGACCATA TCTACACTCT GTGGCAACCT TCTTACCTGA CTCCAAAGGA 180 TCAGATAATC AAACAGGAAA TTATGGTAGG AAATCAGAAA ATTGAAGTAT GCATTCATAT 240 CCTAAGCATT TTATTTTAGC TCAAAATATA AAAATATTCA TCAGTTAGCC AAGCTTTTGN 300 GATGAGAGAT CATAGCCTCC TCTTTGATAG GGGGTTTCTT GGGTTTCCTT GATTTCATGT 360 TTCAGAGTTT TT 372 (2) INFORMATION FOR SEQ ID NO:243: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 256 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:243: CTCACACATT CATACCCAAG GAAGAGGCAA ACACACTCAA GTCCAGAGTT CCCAGTGGTG 60 CCGCCCAGAC CTACTGTCCC GGGGGTGTTA TGGCTGTCCC TCGGCTTCCC CAGAGCAGCC 120 AGGACAGCCT GCACCGNCTN CCAGACTCTC GCAGGAAGGG GAGCTCTGCC CTGGGGAGGA 180 AACTNACAGG CTGGGAGACA AGACTCCCAT CGCAGGGACA TGCACAGCAG CAGCCACAGC 240 CCCGCGGACG GGGCAT 256 (2) INFORMATION FOR SEQ ID NO:244: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 220 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:244: CAAATGGCAG TTCTCGAGAA TCGACGAGGA ACTTAAATCT GGACTCAGGG TTTCAGTGCG 60 GTCTCCGACT CCCACCACCC CGCCCCTCCG NCTGTCTCGC CGCCAGGNGT GACCTCCACG 120 CGAAGGAATC TTCTTCGGAT GGGTGCACCT TGCCAANAGG TGTGGCACCT GGNGGACTAG 180 GAGGCGCCTC CANACTAAGG GCGCTCANTG CGGCGTTCTT 220 (2) INFORMATION FOR SEQ ID NO:245: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 239 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:245: TTCATGCTCA TGTAACCTTC TTAATAGTGC CTTGTCTGCT GGGTTTGTAG CTGTAAGAGT 60 TCTGCAAACT GGCCCTATAA AAATATTGAT GCTGTCCATT AAAATGAATC TCTCTCTCTC 120 ACTCAGTCTC TCTCTCTGTC TGTCTCTCTT TCTTCTCTCT CCTGCCATGT GTGTGTCTCT 180 CTCTACTCCT CTGATTTTGN CCTCTCTCTC TATTCTGCTA CTCTCTCTCC TCTCCTCCG 239 (2) INFORMATION FOR SEQ ID NO:246: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 269 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:246: GGTTTCACCA GCGTTTAATG TGCTCTGATG TTGACCGTCC CTCTNAGTNT TCTGGGGAGG 60 AGGGGGTGGG GCGGAGGGTC AGGAAAGCAG GCTCAGCTTC CAGGGTCAGG GAGTTGTGGG 120 CCCAGAGGGG CTGTCACAGT GGATGCACCC TGCCCCCTCC CTCGCCAGAC CCGAGGGTAG 180 GGCAGAGGCA CCTCCTCGNC AGCCTNTGGG CTGCACCCAC AGGGAATNGA GGGGAGGGGC 240 ACCATTACCA CTGGACCCAC CAAAGACCC 269 (2) INFORMATION FOR SEQ ID NO:247: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 297 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:247: CTATTCAAAG TTTACTGACC TCCCCAGCCA GGCAGGCCAA CCCTTCCGAG CAGGGGAAAT 60 GTCCATCTAG CTGCCCTCTG CTGGGTTGCA GCCTATGCCA TGAGAGGGTA CTGGAAGCAG 120 GAGGGAGCCC TGGCTAGGGC AGGCCTTAAA CGCAAGGGAA GCTGAGCAGA GATCTGCACA 180 CTCAACCCCA TTTGATATTC TTCTCCTCCT CAGTCATGGC CAGCGTGTTG GTGACTAGAC 240 CGGTGCCAAT AGTCCGGTTG CCATCTCGCA GGGTGAAAAG ATGGCCTTTC TCTTAAG 297 (2) INFORMATION FOR SEQ ID NO:248: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 281 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:248: ACAACAAGCA CACCAACTAT ACCATGGAGC ACATCCGCGT GGGCTGGGAG CAGCTGCTCA 60 CCACCATTGC CCGCACCATC AACGAGGTGG AGAACCAGAT CCTCACCCGC GACGCCAAGG 120 GCATCAGCCA GGAGCAGATG CAGGAGTTCC GGGCGTCCTT CAACCACTTC GACAAGGATC 180 ATGGCGGGGC GCTGGGGCCC GAGGAGTTCA AGGCCTGCCT CATCAGCCTG GGCTACGACG 240 TGGAGANCGA CCGGCAGGGT GAGGNCGAAG TTCAACCGCA T 281 (2) INFORMATION FOR SEQ ID NO:249: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 383 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:249: AGCGCATCCA CACCGGGGAG CGGCCCTACC CCTGCTCCTA CTGTGGCAGG AGCTTCCGCT 60 ACAAACAGAC ACTCAAGGNC CACCTCCGTT CAGGCCACAA TGGAGGCTGT GGGGGTGATA 120 GTGACCCATC AGGTCAGCCA CCCAACCCAC CAGGTCCCCT CATAACTGGG CTTGAAACTT 180 CTGGCCTGGG TGTCAACACT GAAGGTCTAG AGACCAACCA GTGGTATTGG GGAAGGGAGT 240 CGAGGGGGAG TTTTGTAAAT CCAAATCTCT GTGGNTTCAT GCTTTGTATA TGCTCACAGC 300 AGGGCACAAT AATCCAAGAG AAGGTCTGTG AGCCCCNATC CAACACCCAC AGTAATTATA 360 ATCTTGGCAC ATCAATGGAA TTT 383 (2) INFORMATION FOR SEQ ID NO:250: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 397 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:250: GTATCCTACG TTACAACAAT AATATCATGG GAGAAATAGA AATAGCCTAG TTTGCTTCCA 60 ATAGAAACTG CTTTTAACAT GGGCTGTATA TAAAAATATT AAAGAGAAAC AAAACTGTAC 120 ATTTCCTCAT TGCTCCGCTA CAGACAACCC ATGTCATAAC CTTGTTGCAA ATATTTTTCT 180 CCTATAGCAG TAAGTACAGC ATTAGAAGGT GATTAGAGAG TCTGTTGATG AAACACAAAT 240 GTATGTTTTT ATTGATTTTT ACTTTAGAAC ACTACAGAGT TCCTGGGACC GGGGTGAANG 300 GCATTTAGCT GGGGTGGTTT GTGTGGGGGT TAAATACCTT CCCACTTGCA AGTGACTTGC 360 CTGTNCCCGC TGCGGGAATC CTGTTNCTTG GGTGGGA 397 (2) INFORMATION FOR SEQ ID NO:251: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 276 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:251: GGCCATAAAA GAAAGAGCCT GTTACCTATC CATAAACCCC CAAAAGGATG AGACGCTAGA 60 GACAGAGAAA GCTCAGTACT ACCTGCCTGA TGGCAGCACC ATTGAGATTG GTCCTNCCCG 120 ATTCCGGGNC CCTGAGTTGC TCTTCAGGNC NGATTTGATT GGAGAGGNGA GTNAAGGCAT 180 CCACGAGGTC CTGGTGTTCG CCATTCAGAA GTCANGACAT GGACCTGCGG CGCACGCTTT 240 TCTCTAACAT TGTCCTCTCA GGGAGGGNTC TACCCT 276 (2) INFORMATION FOR SEQ ID NO:252: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 314 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:252: CCTGAACAGT CTGTTTCATT TGACTGTTTG GGGGTCTCCC AGTTTAAGCA AGATATTTAA 60 GCCTTATTTC TCTTGGCATG CTTGGATTCC CCAGTAAAAA AAACTCCTGC CCTGGGCTGA 120 CAATCAAAGT TCTGGGAACT AATATGGATA AGCAAGCTGG AAATGGAGAA GGCTATTCAC 180 TGTGCCTGGG TCCTACTGTT TTCTGGNTGG GAACTGCTTT TCCATTAGGC CTGGTGTGCC 240 CTGGAAGGGA NGAGCCTCTT GCAGAGACTA CAATCTTGGA TGGGTCCTTT GCCAAGTTTG 300 AAGGTAGGAA CCCA 314 (2) INFORMATION FOR SEQ ID NO:253: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 293 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:253: GAACACTCTG CTCCAGCCAA GGTGGTGAGG GCAGCTGTTC CTAAACAGCG CAAAGGCAGC 60 AAGCCACAGT CCCACAAGCC TCAGCCTACC CGTAAACTGC CACCCAAGAA GGACATGAAG 120 GAACAGGAGA AAGGAGAAGG GAGTGATAGT AAGGAGAGTC CAAAAACCAA ATCAGATGAA 180 TCAGGGGAGG AAAAGAATGG AGATGAGGAT TGCCAGCGAG GCGGGCAGTA GAAGAAAGGA 240 AACAANCACA AGTGGGTTCC ATTACAAATA GACATGAAGC CTGAAGTGCC CAG 293 (2) INFORMATION FOR SEQ ID NO:254: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 413 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:254: CTTTTTCTTA ATATATTAAT ATTTACCAAG GCAAGACAGT GATTTATGGA CATTTAAATT 60 AGTTTAGCTT TGTTCTGCTG TTCTAAAACA TTGTGTACTG TCTGATAGAC TTTTAAAAAA 120 CAGTGCTTTT CCAGGATGAT TTATGATATG CAGTATTGTT TATAGATGCC CATGGCTTAA 180 CCTTGAAAAG TCAATTAAGT GACACAATTA AGAGAGATAT GAATAGTGGT AGAAAAAGCA 240 TGTACTCTGG ATAAGTGGGG GTAAATCTAG TATTTGTTAT TCCTGTCAGT AATATTGTCA 300 NTAGTATTTT TTAGAAGGTT TAATTTTTTT ATGGGTTATA AATTCATGTC ACTCTTCTGC 360 AATGGGTACC ATCAGTGGGA ATGCNGGAAT TATCCATGCT TTGGGGGTTA AAA 413 (2) INFORMATION FOR SEQ ID NO:255: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 376 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:255: GGGTCCAGGG GAGAATCAAT ATATCTAGTA TAGTTTATAT TTGTACCTTC TCTCCTTAAG 60 AGTTACAGTG AGTGACTCTA CTCCTCAAAT GGAGCACCTC TCTCCAGGAG AGTAAGAAGA 120 TCACATAAAT AGAAAGTGAG CTTTGGACTC TAACAGACAT AGGTTCATAT TCAACTCTGC 180 TACTTAATAT CCATATTGGT TTGAGTTATT TAACCTTGAC AATCCACACT GTAAAATGGG 240 TAAATAATAA ATACCCTCCT CTCAGAAGTG TTACAAAGTT TATATGAAAT AATGTGCTTA 300 AAAAGCTGGG TACATAGTAG GAGCTTAGTC ATTGTTTATT TTCTCCCTCA TACCCATACA 360 TGNTTCATTC CTACTG 376 (2) INFORMATION FOR SEQ ID NO:256: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 241 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:256: GTAGAGATGG GCTCACTATK TTGCCCAGGC TGGTCCTGAA CTCCTGAGGT AGGAGGATCG 60 CTTGAGCCTG GGAGACAGAG GTTGCAGTGA GCCGAGATCA CGCCACTGCA CTCCTGCCTG 120 GGTGACACAG TGAGACTCTG TCTTAAACAA AACAAAACAA AAAAAGGCCA GGCGCAGGGG 180 CTCACACCTG GTAATCCCAG CACTTTGGGA GGCCAAGGTG GGTGGATCAC CTGAGGTCAG 240 G 241 (2) INFORMATION FOR SEQ ID NO:257: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 406 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:257: CAAGGGTGTC CTTCGCCAGA TCACTGTTAA TGATTTGCCT GTGGGACGCT CCGTGGATGA 60 GGCTCTGCGG CTGGTCCGAT TAAGAAAACC AAGAGAGGCC GGGCACGGTG ACTCACGCCT 120 GTAATCCCAG CACTTTGGGA GGCCGAGGTG GCGGATCATG AGGTCAGGAG ATTGAGACCA 180 TCCTGGCTAA CACAGTGAAA CCCCGTCTCT ACTAAAAATA CAAAAAAATT AGCTGGGCAT 240 GGTGGCACGC GATTGTAGTC CCAGCTACTA GAGAGGCTAA GGCAGGTGAA TCGCTTGAAT 300 CCAGGAGGTG GGGGTTTCAA TGAGNCCGAG ATCGTACCAC TGCACTCCAG CCTGGGGCAA 360 CAGAGTANGA CTTCGTAACC CCCAACCAAC CCNCCAACCC CCCGCC 406 (2) INFORMATION FOR SEQ ID NO:258: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 157 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:258: GAAAAGAAGG AAGGAAAGAG GGGAGGGAGG GAGGAAAGGA GAGAGGGAGG GAAAGAAGGA 60 GAAAATGCTG GAGCAAAGGA GGTTGGTTAC ATGATTTCTC TAATGGCAAT GAGCTGCTTT 120 CTGGATGAAA TACAGAATCA GAGCGAGACT CCGTCTC 157 (2) INFORMATION FOR SEQ ID NO:259: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 361 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:259: AAGCAGATAT AAATGGGACC ACTGTGAATC AAAGGGGAAA AATTCCAGGA AAAAAAAATT 60 CCAATAGCTT CACAGTTTAA CTGAGGTTTT GGAAAAACTT AAGTGAATTC AGCTGATGTT 120 TGAAATATCT GTCTACATTT AATTAGATGT GTTGTATTTA CCAAGGAGGC ACAAATATGT 180 AGTTCTGTAG ATTTTAATAC TAACTTTTCC AGTAAGAAAA ATAATACCAG GTGATTTCAA 240 AAAGGGCAGT GATCTATAAA CACTCAAAAT GCATCTTTGA ACAGGGGAGC AGAAATAGCT 300 AATTTAATGA AAACAAACCT TAAGCACTTT ACTTGGCTTC TAATAAGGCA TCCCAAGAAA 360 A 361 (2) INFORMATION FOR SEQ ID NO:260: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 349 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:260: CAATACATGT ATACAGTGTA CACTGATCAA ATAAGAGTAA TTAGCATATT TATCACCTCA 60 TTTCTTTTGT GGTGAGAACA TTTAAAATCC TTTCTTTTTG CTATTTTGAA ATATACAGTA 120 CATTGCTATT AAGTATAGTC ATCTGGCTGT GCAATAAAAC ACCAGNACTT ACCCCTCCTG 180 TCTGTGACTT TGTACCCTGT TCACCACCCC TCCAATCCTC TAGTAACTAC CATTCTACTC 240 TCTACTTCTA TGAGCCTGAC TTTTTAAAAT TCCACATGTA AGTGAGATTA CATGGTATTA 300 TTCTCTCNGT GGCTGGCTTA TTTCACTTTA ACATAATGTC CTCTAAATT 349 (2) INFORMATION FOR SEQ ID NO:261: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 415 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:261: GGAAGATGAG GATCTAGGTG TGAGCGTGCA GAGCCCTGAG GCTGGGCAGG CAGGGAGCTC 60 TGCCTGCACA ATGATGTAGC CATGTGTGGC CACACCAGCA CTGGGCAGCA CCTCTGGGGA 120 GGGGGGCAGG GCAAGGACAA CTGGAGAGAC AAAGCCAGAT GGGGCCACGT CCTTAGAAGT 180 GTGTGTGCAC GCACATGTGT GTGTGTGTGT GTGTAATACG CAGGGCAGAA ACACACCATG 240 TAGGTCAGGC AGGACAGAAA CACATCATGT AGGCCAGGCG TGGTGGCTCA GGCCTGTAAT 300 GCCAGCACTT AGGNAGGCCA AAGTGGGCGG ATCACCTGAG GTCAGGAGTT CGAGACCAGC 360 CTGGCCAACA TTGCAAAACC TCATCTCTAC TAAAATTCTA AAATTAGCCA GGCGT 415 (2) INFORMATION FOR SEQ ID NO:262: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 382 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:262: GGCATGGGGT CTGGCTTTAA TGTGTAACTG ACGTGGGTCA CTGAAACTGT TCAGGCTGAT 60 CTTGAACTCC TAGGCTCAAG TGATCCTGCT GCCTTGGCCT CCCAAAGTGC TGGAATTACA 120 GGAATGAGTC ACAGCACCCA GCCGGCTGTG TTTTGTTTTT TGTTTTTTAC CCCGACAGGT 180 NCTCAGTCAG TCGTTAGCTG GAGTGAAGTG GCGTAACACA GCTCACTGCA GCCTTGATCT 240 CCTGGGCTCA AGTGATCCTT CCATTTCTTC CTTCCAGAGT AACTGGTACT GCAGGCCCAC 300 GGCACCACAC ATGGCTAATT TTTAAATTTC GTAGAGACGA GGTCTTGCCA TGTTTGCTCA 360 GGCTCCAGCT GTTGTATTCT TT 382 (2) INFORMATION FOR SEQ ID NO:263: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 447 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:263: TGTATCAACT CAGAATTTCC AGAGAGCTCT TCCTGGCTGA AAAGATGTCC AAGGATCATC 60 TCCGGAATGG AAGAGGTGAG GCCTGTTAGC TTGTGGGCTG CCCAATCCAT CCAACCCTTG 120 GCATTGGGAT CAATGTTGAT GAGGACAAGA CCTTCAACAG TGTCCGGGTG GTTAAGAGCA 180 TATCTCGCCA GGATGTAGGC TCCAGCTCCA ACACCAACTC CAATTATTGT AGAGAAATTT 240 AGGTACTGCA GGACGCAAGG GATCATGTCT GCAAGCTGGT CCAGAGATGG GTACTGATAT 300 CCCAAAGGGA ACACAGGGGC TCCCTCTTCC ATTCCAGGGG CATCCACATG GACCCGCACA 360 AAGTTCTGAA TGATTTCCTG CATGTCCTCG AACTKGAACA GTGGCTGGAG GAAAGATTTA 420 TAGTTGAGTC CACATCGGGT AGGTAAG 447 (2) INFORMATION FOR SEQ ID NO:264: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 317 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:264: TTTTCGCTGT CAACAGACAG TTTATTCTAT ATACAAACAC AATTTTGTAC ACTGCAATTA 60 AATAGAATGG AATGAGCGCT CCTCCGCATT CCTCCCCGAG TGACTGGTTT GGCCGCCGGC 120 CACTCCATCC CCGAGTGGGA CTGGACCACG GCCCTGGNTG CTGCCACTGA TGTTGGNGCC 180 TGCACCCCAC GTCCCTATGC CCGAGGCGCA ANTCTGCTCT CCCGGGGACC CCAAGNCTGG 240 NGCACACGCG GGGAGGGCGG GGCCATGGAG AAGGCACTGC AGGGAGCACC AGGCAGAGCC 300 GTGTTGAGGC CGGCCGG _ 317 (2) INFORMATION FOR SEQ ID NO:265: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:265: GCAGAGCAGG TGGAAGTGAT CAGGAACCAT AGTTGACAGT TCCAATCAGT AGCTTAAGAA 60 AAAACCGTGT TTGTCTCTTC TGGAATGGTT AGAAGTGAGG GAGTTTGCCC CGTTCTGTTT 120 GTAGAGTCTC ATAGTTGGAC TTTCTAGCAT ATATGTGTCC ATTTCCTTAT GCTGTAAAAG 180 CAAGTCCTGC AACCAAACTC CCATCAGCCC AATCCCTGAT CCCTGATCCC TTCCACCTGC 240 TCTGCTGATG ACCCCCCCAG CTTCACTTCT 270 (2) INFORMATION FOR SEQ ID NO:266: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 297 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:266: ATGAGGCGAG GCCTGCGAAG TGGCTGGCAT GCAGCAGGTG CTAATGAGTG TTGCAAAGGT 60 GATGTCACGC AGGCAGCTTC CCGTGGCCAG AGAAACATTG CAGAGAAGGG ATAAGTAGGG 120 CTTAGTGACT TTGACGGGTC AATGGAAGAA TGACCCAAAG AAGGCTTCAA GGCCAGGCCT 180 GCAGTTCTCC ACCACAAAGG CCCTCACTGA TAGCACCCAC TCCCCCACAC TCAGCTTTNG 240 GGCCTAGGTC TGGGTCACCC AGCTAGAAGC CACAGGACCC TGAGGCGTCC GAGGGGT 297 (2) INFORMATION FOR SEQ ID NO:267: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 387 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:267: CTTGTTTTCA TCATGAGCTC GATCAGATGT CTCTCGATCT TCAGACTGGT GGTGTCCTAT 60 AATGTCCTGT GCACGCATTC TTGAGCTTTC CAGGATTTCT GTCTGTTCTC TCTGTTTATC 120 TACAGAAGAA ACTTTCTCCT TGAGTTCCTG TTCTTCGTAG CGCCTTGAAC TCTCTTTCCT 180 TTCTGGTTTA CGATCCTCCT CTTTCCATCT ACCCTGTCTG TCTTCTGTGA GGTGCGAGGG 240 ACTAAGAGAA CGAGATTCTT GAGGTCGTAC AACTTGGCTC AAGAGTCTGT GTTTTTTCAT 300 TTNTNATCAT CTCCACTGTT GTAGGCATCA CTGTCCGGAG AATGTTCACG CCGGCGCTTT 360 CGGGGGACTG TCTAGGGCTG GGACTCC 387 (2) INFORMATION FOR SEQ ID NO:268: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 318 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:268: CCTGAAGGTT ACCTCTTTGG AGAGAACATG GATCTGAACT TCCTGGGCAG CCGCCCGGTC 60 CAGTTTCCCT ACGTCACTCC TGCCCCCCAC GAGCCCGTGA AGACGCTGCG GAGCTGGTGA 120 ACATCCGCAA AGACTCCCTG CGGCTGGTGA GGTACAAAGA CGATGCCGAC AGCCCCACCG 180 AGGACGGCGA CAAGCCCCGG GTGCTCTACA GCCTGGAGTT CACCTTCGAC GCCGATGCCC 240 GCGTGGCCAT CACCATCTAC TTCCAGGCAT CGGAGGAGTT CCTGAACGGC AGGGCAGTAT 300 ACAGCCCCAA GAGCCCCT 318 (2) INFORMATION FOR SEQ ID NO:269: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 422 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:269: ACATGTCTAT TCAGGTCTTT TGCCCATTTT GAAATAGCAT TGCTTGTTCT TTTGCTGGAT 60 ATTAACCCCT TGTCAGGTGC ACAGTTTGCA AGTTACCTTT TCTCATCCTA TAGGTTATCT 120 CCTCACTCTT GATTGTTTCT GTTGCTGTGC AGTAGCTTTT AAGTTTGGTG TAATACCATT 180 GTGTTTTCTC TGCTGCCCTT TTAAGTTTCA CTGGGTCAAA AGTTTAAAAT TTGTGAATTC 240 CTATATTTTT AGGGCAATTC TCCTGCCACT GTTGGAATTA TGCCTCAATC TATGCAGTAG 300 AATATTAGTG TGAAATGCTT CTGTACCAAT GGAGATGATG CTGGATGGTC TCTATCATAA 360 ACCCATACCT CATCAACACA AACTGCAATT ACACAAGGGC TCTATATCAT GGATCTCCAT 420 TT 422 (2) INFORMATION FOR SEQ ID NO:270: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 376 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:270: GAAGAAGAGC CCAGACCTAG GGGAGTATGA TCCACTTACC CAGGCTGACA GTGATGAGAG 60 CGAAGACGAT CTGGTGCTTA ACCTGCAGAA GAATGGAGGG GTCAAAAATG GGAAGAGTCC 120 TTTGGGAGAA GCGCCAGAAC CCGACTCAGA TGCTGAGGTT GCAGAGGCTG CAAAGCACAT 180 CTTTCAGAAG TCACCACGGA GGGCTACCCC TCAGAACCCC TTNGGGGCCT GGAACAGAAG 240 GCGGCCTCCT CCCTGGTGTC ATATGTGCGC ACGTCTGTCT TCCTGCTTGA CTTTGGGGAT 300 CTCGATGATC CTGGTGCTCC TGTGTGCTTT CCTGATCCCC TGTCCTCCCA GAGATCTTGA 360 CAGAACTGGA GCCGCA 376 (2) INFORMATION FOR SEQ ID NO:271: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 346 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:271: TGTTCACGTT CCCTTTCTTT GTCTTTCTTT TTCCTATCTT TATCTATACT TCGACTCCTC 60 TCCTTTTTCC TCTCTTGTTC TTTAGCCTCA CCTTTATGCT TATGACTGTN CCCACTAAGA 120 TTTCCACGTT GATCATCAAT TTTACGNCTA TCTCGACTCC TACTGCGACT GGCACGATTG 180 GTTCGTCTAT CCCTTGAGCG ACTTCTACGA ATGCTTATGA AAAAGAATCA AGTTGGNCAC 240 CAAATGTTTC ATAGCAGTAG GAAATTTCTT TTAGAGACTT CTGATGGGAA ATTTGAAGTG 300 TATGTTGCTA TCAGATCAAG TGCAGGAGAG GTATAAGGCT ACTGGA 346 (2) INFORMATION FOR SEQ ID NO:272: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 394 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:272: GTTGTTGTTG TTGAGTCGGA GTCTCGCACT GTTGCCTGGG CTGGAGTGCA ATGGTGCAAT 60 CTCGGCTCAC TGTAACCTCC GCCTCCCAGG TTCAAGCCAT TCTCTTGCTT CAGCCTCCTA 120 GTAGCTGGGA TTACAGGCAC CTGCCAGCAC ACCTGGCTAA TTTTTTATAT TTTNAGTACA 180 GACAGGGTTT CACTATGTTG GCCAGGCTGG NCTTGAACTC CTGACCTTGT GATCTGCCCA 240 CCTCAGCCTN CCAAAGTTTT TCAGAATTTT TTAAGGAAAC ACTTTTAACC CTTAAGGCTT 300 TCTTTCAAAC TCAGATCCCC TTACACAATT GATCAGACGT GGCAAAGTTT TGCTTCAAAG 360 TTTTTGGACT GGGTTTCCAC TTTAGGCTTA CTGA 394 (2) INFORMATION FOR SEQ ID NO:273: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 259 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:273: CAACCTGTAC CCAGGCTGCG AGAACGTRAG TTTRAGGAGC CGCAGCATGA TGTTCGAGCC 60 GGGTCTTACC AAAGGRATGC TGGAGGTGTT TKTGGCCCCG ACCCACCACC CGCACTGCTC 120 GGCCGATGAC CAGTCCACCA AGGSCATCGA CATCCAGAAC GCTTATTTRA ATGGAGTTGG 180 CGATTTCAGC GTGTGGGAGT TCTCTGGAAA TCCTGTGTAT TTCTGCTGTW ATRACTATTT 240 TGCTGCAAAT AATCCCACG 259 (2) INFORMATION FOR SEQ ID NO:274: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 348 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:274: TCCCAGTTGT CCCGATTGTA ACTCAAAGGG TGGAATATCA AGGTCGTTTT TTTCATTCCA 60 TGTGCCCAGT TAATCTTGCT TTCTTTGTTT GGCTGGGATA GAGGGGTCAA GTTATTAATT 120 TCTTCACACC TACCCTCCTT TTTTTCCCTA TCACTGAAGC TTTTTAGTGC ATTAGTGGGG 180 AGGAGGGTGG GGAGACATAA CCACTGCTTC CATTTAATGG GGTGCACCTG TCCAATAGGC 240 GTAGTATCCG GACAGAGCAC GTTTGCAGAA GGGGGACTCT TCTTCCAGGT AGCTGAAAGG 300 GGGAAGACCT GACGTACTCT GGGTTAGGTT AGGACTTGCC CTCGTGGT ' 348 (2) INFORMATION FOR SEQ ID NO:275: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 396 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:275: GTTTGGTGAA TTTGGTCTGT GATAAAATTG GAGTTCAAGA AACAAACAGG AAACTACAAG 60 TGCCCCTTCG CCCCCAGGTC ACCCGAGTGG CAGGGCAGTG ACCGCTGCTC TCAGGCTGCC 120 CAGTGTGGAC CTGCCTGTCG GAATGCTCCT CCTCCACGTC CCCTCGCTCC TGTGTCCCAG 180 CCACATGCAC CTTCCCTCTA CCTCTGGGAT CCCTGCACCA GGTCTGCCCC TGTCTTCTCA 240 GGGCTGCTCC TNTTGGNCCA CAGGACCTCA GCTGGAATGT TGCCTCCTCC AAGAGGCCTT 300 CCTGACTATT CAGCTCACAG TGGCCACCCA GCCACAATCT GCCATGTGCT TTGGGGGATT 360 GTCTGTTAAC TGGCAACATA CTGGCAGCCC ATAACT 396 (2) INFORMATION FOR SEQ ID NO:276: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 381 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:276: GGTGTCGGGG AGGCTGCGCA AGGGGGCGAG CCCGGGCAGC CGGCGCAACC CCCGNCCCAG 60 CCGCACCCAC CGCCGCCCCA GCAGCAGCAC AAGGAAGAGA TGGCGGCCGA GGCTGGGGAA 120 GCCGTGGCGT CCCCCATGGA CGACGGGTTT NTGAGCCTGG ACTCGCCCTC CTATGTCCTG 180 TACAGGGACA GAGCAGAATG GGCTGATATA GATCCGGTGC CGCAGAATGA TGGCCCCAAT 240 CCCGTGGTCC AGATCATTTA TAGTGACAAA TTTTAGAGAT GTTTATGATT ACTTCCGAGC 300 TGGTCCTGCA GCGTTGATGA AAGAAGTGAA CGAGCTTTTA AGTTAACCCG GGATTGCTAT 360 TNAGTTAAAT GCAAGCCAAT T 381 (2) INFORMATION FOR SEQ ID NO:277: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 206 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:277: TTAATACGAC AGGGCTGGCG CCCGAGTAAT TCAAGCCCTT CGGAAGTGTC ACCGGCTGCC 60 AGGCCTCGGA TGCAATCCTG GAGGCGGGAG ATTCGGCCTN AAGACTGGCT CGAGCCGCCC 120 AGGGGCTCCA TGGGAGACTA ACGCGGAAGT YCCAGCCGTC CCAGTGCCGT GACGTCCCCC 180 CTTGGTGGGG CCTGCACCCG ACTACT 206 (2) INFORMATION FOR SEQ ID NO:278: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 260 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:278: ACCTGTAATC CCNGCACTTT GGGAGGCTGA GGTGGGCAGA TCACGAGGTC AGGAGATAGA 60 GACCATCCTG GCTAACACGG TGAAACCCCA TCTCTACTAG AAAAATACAA AAAATTAGCC 120 GGGCATGGTG GCGGGCGCCT GTAGTCCCAG CTACTCGGGA GGCTGAGGCA GGAGAATGGC 180 GGGAACCCGG GAGGCGGANT TGCAGTGAGC TGAGATGCGC CCGTCTCTCC AGCCTGGGCA 240 ATAGAGTGGG ACTCCATCTC 260 (2) INFORMATION FOR SEQ ID NO:279: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 308 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:279: GTGTCTGGGC TCAGGGTTGG CCAGCTTGCA GAGGAGCAAG CTAGTAGAAA TATTGCAGGG 60 TTCCCAAAAC CAGGTCAAGC AAGATGCCAT GTCACCCCTG AGCATGCCTG TCTTCCCAGG 120 GGTGTACCTC TTGGCTGGCA AAGCCAAGGC CAGTGGGNAC TTGTATAAAT CACATGGGTA 180 TGTTCTTGGT TCAGTGATCT TGGAGTGATG ATGGTAACTN ATGAACAGAG AACTTTYYAG 240 AACTTKGGTC CTGTCTTCCT CCCTGAACCT AGACAAGTTT CACCCCTCCT CCTGTACCCA 300 ACCCCATT 308 (2) INFORMATION FOR SEQ ID NO:280: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 402 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:280: ATTTTAGCAG CTTTCTTGAA ATTTAAAATA TATGTGTAAG TATCTCATTT ATATGCATTT 60 CTAGTTTCTT TATACAACAG AATAACTTCT TTTACATCAA ATTTCTGAAT TTGACTAAAT 120 TTAGAAATAA TGGAATCTCA TCCATTAAAT ATAGTCATAG AAGGAAGGAA ATATGAAAAT 180 TAGGATTTCA GATGTTTGAA CATAAAAGAT AATTTTAAAC ATTGTCAGTA ATCTATTTCT 240 TTTTTTTTTC GAGACGGAGT TTTGCTCTGT CACCCAGGCT GGAGTGCAGT GGCGCGGTCT 300 TGGCTTACTG CACCCTCTGC CTCCCAGTTC AAGTGGATTC TCCTGCCTCG NCCTCCTGAG 360 TAGCTGGGGT TACAGGGGCA TGCCAACATG CCGGGGCTAA TT 402 (2) INFORMATION FOR SEQ ID NO:281: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 313 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:281: GAGAATCCGT CTTAAAAAGA AAAAAAGAAA ATTATAGAGG GAGATGAGGT GGGACAGAGT 60 CTGGCAGTTC ATCAGGGGGA CTGAGAAGGT GGCATTTGGA GGAGAGGAGG CAGTGAGCTG 120 TGCAGTGTCC AGGCAGCCAC CCTTCCCAGC GGCCACCATG ACGGTGTCCT CATTGCTTTA 180 ACCATTAGTA ATCATTCATT CATTCATTCA TTTATCCGAC GTCAGCTGGA GGNCCTGCCC 240 GNGGGGCATG CGCTTAGATT TNGGAGGCCT TCCGGGATGC TTGCGCTCCA ACGGGGGAAG 300 GCCGACTTGG GCT 313 (2) INFORMATION FOR SEQ ID NO:282: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 217 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:282: TGACCTCAGT TGATCCACCC ACCTTGGCCT CCCAAAGTGC TAGTATTATG GGCGTGAACC 60 ACCATGNCCA GCCGAAAAGC TTTTGAGGGG CTGACTTCAA ATCCATGTAG GGAAGTAAAA 120 TGGANGGAAA TTGGGGTGCA TTTTCTAAGG ACCTTTCTAA CANATGGCTA TAATNTAAGG 180 GGTTTAGGGT CCTTTTTTTT TTTTCAGGGA TACATTT 217 (2) INFORMATION FOR SEQ ID NO:283: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 327 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:283: TAGAGAGCGC TTTACTCCTG GTCCCATGGC GTAAAGATGT GGCTGGGCCT GACAAGGCTC 60 AGCCTCCAGT CTTAAGATGG GCACAGAAGG GCAAGAAGTA AGATGACGAG TCCCAGAATT 120 AGGACAAGCC ATGAGCCAAG GCCTGGTCTG AGCAAGGGCA GCCCCCTGTC CCAGACACAG 180 GCACCCCCAA TCTCACTTTG GACAGAGCCA ACGTGGGGGG ATCCTCCCGG GCCTGGGCCT 240 GTCAAGTCTG CCTGCAGGAC CCTGCCATTG TGCTCAAATC ACAACCATTT TTTGCTTCCA 300 ACATTTTAGG GTGCTTGTGC AGTGAGT 327 (2) INFORMATION FOR SEQ ID NO:284: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 340 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:284: CTTTGGAAAT GTAAATTGTT ACAAACTTAC TTTAGAGCAA ATTTAGTCAT CCTTCAAAAA 60 TTTAAATGTA TACTTATTTC CTAAGAATTC GTTTGGCTCA CACAATTGTG AAAAGATAGA 120 TGTACACCAG TGTTCATTAC AACAATTATG CAACAAATCT ATTATGTGCC AGACATTATT 180 CGGAACTCTG GGAATACATA AGTGAACAAA GCAGATTCCT GATCTCAGGA CCTGGGGTCA 240 GGGGTCAGGA GAAGCCAAAA AACACGCTNG AGAAATACTT TATGCAGTGT GGGGGGAGTG 300 CTACCAGCAG AGCAGGGGAT GGNGATGTGA AATCTTGTGT 340 (2) INFORMATION FOR SEQ ID NO:285: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 335 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:285: GACATTCACG GAGGTGGGTT CGACCTCCGG TTCCCCCACC ATGACAATGA GCTGGCACAG 60 TCGGAGGCCT ACTTTGAAAA CGACTGCTGG GTCAGGTACT TCCTGCACAC AGGCCACCTG 120 ACCATTGCAG GCTGCAAAAT GTCAAAGTCA CTAAAAAACT TCATCACCAT TAAAGATGCC 180 TTGAAAAAGC ACTCAGCACG GCAGTTGCGG CTGGCCTTCC TCATGCACTC GTGGAAGGAC 240 ACCCTGGACT ACTCCAGCAA CACCATGGAG TCAGCGCTTC AATATGAGAA GTTCTTGAAT 300 GAGTTTTTCT TTAAATGTGA AAGATATCCT TCGCG 335 (2) INFORMATION FOR SEQ ID NO:286: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 399 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:286: GCACAATTAT TAAAAAGAGG CCACTTAAAT TCAACTCTCC ATGGATACAG TGTCTGTGGC 60 AATGTTTAAT TAGAGATTAA AATTGAGGAA TTGAATAATT GAGGTTGCTA ATGAATTTGA 120 AAACTCAGCA AAGCAAGGAG AGCTGAGCGT TTTTCCGACT TAGCTTTTCT TTCTCTAACC 180 CTTTTCTCAT TTCCTACTAT TATCACATNT CTGGCCTTGA CTGCTGAGTT TATTACTACC 240 CATAACCCTG GCCTAAGTGG AAACAAAAAA GCTGTAGCCT CTTTGCTGAG CTCCTGGAGA 300 CATTTGGTCT ATTGGATTTA TGACATGTTC AGAAGCTTGC AGTTGCAGGA GGCTGACAAT 360 GATGAAAATG AGATATGNTG GGCCACCACG CTTTTCTGT 399 (2) INFORMATION FOR SEQ ID NO:287: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 294 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:287: TTCCAGTTGA ATTCACCAGT GGACAAAATG AGGAAAACAG GTGAACAAGC TTTTTCTGTA 60 TTTACATACA AAGTCAGATC AGTTATGGGA CAATAGTATT GAATAGATTT CAGCTTTATG 120 CTGGAGTAAC TGGCATGTGA GCAAACTGTG TTGGCGTGGG GGTGGAGGGG TGAGGTGGGC 180 GCTAAGCTTT TTTTAAGATT TTNCAGGTAC CCCTCACTAA AGGCACCGAA GCTTAAAGTA 240 GGACAACCAT GGAGCCTTCC TGTGGCAGGA GAGACAACAA AGCGCTATTA TCCT 294 (2) INFORMATION FOR SEQ ID NO:288: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 391 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:288: TCTACAGATG AGGAAAGCAA GCCTCAAGCA AGGGGGGCCT GATCCTTTCC CTGTTCCCTG 60 TGTATTCCCT GTCTGTGGCA AAGCCCATTG CCTTGATTCT CTTCTCTTTA CTTTCATGTT 120 GAGAAGTAGT TTCTTTCTGC AGTTTATTTA ATTTACTGGC AAAATGACGT ATTTTTTTTT 180 CAGCAATGTT TCAGCTAGAT ATTTGCTTTA TGCATGTAAT GTCAATGAAG TACTCATAAG 240 TTTTCAAGAA ATGACTGATA TAAATCATGT GTTCCACTAC ATAGTCTAAA TATTTAGTAT 300 TTGGTCATCT ATTTTAATAT GTTCAAATTC TGTTAAACAA GNCATAGTCA CTATGTGAAG 360 ATAAAAATAG NCAAAGTTGC ATTATGACTT T 391 (2) INFORMATION FOR SEQ ID NO:289: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 198 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:289: CTTATATTCT ACTTTATTTG GTAAAACTCA GAAACTAACA ATTCACATCC TCCCACCTTC 60 TTCTTTCCGA AGAAGGCAGT TTGCAGAGAC AAAAGGGCTG TGGCGTGGGG ATCATCCACC 120 ATCTCCAGGT TTTACACCCA GGCTACCCAT GGCTTGGCAG TCAGGCCTCT AGGCTGATTG 180 CTCTCAGAGG CAATAGAA 198 (2) INFORMATION FOR SEQ ID NO:290: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 353 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:290: GGTTTTCATC TTCGGTTTAC AAAAGTCCTA CTATTTATTT ATTTTAACTT TAATTTAAAT 60 ATCACCTACC TTAGGTAGAA GTTTTCCTTT GTGTAATATA ATATAAAACC GACATTTCTT 120 GGGGGCATAA TAGTAAAGAT GTTAACATTT TTTGGTTCTT TTTGGATGCT GTATTTGTGC 180 TTCTTCTGAA AGTGATGTGT GCCAAGATGG CTCATGTAAC CCAGTTTTGA CTAGGCTATT 240 GATATTCTGT CTGGTTAATT TATTGAACTG GCTTAAAGCT ATACATATTT CCTTTTAGNT 300 AACTATGTAA GATATTCTAG ATATATTGGT CTACTGATTC ATAATATCAC TGG 353 (2) INFORMATION FOR SEQ ID NO:291: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 163 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:291: CCTGGTAGGC CTGCTACACA GTCTTGCAAC GNCCCTCGTG CTTGGGCTTC TGCGGTGAGG 60 CAGGGGAGTC TGCTTGTCTT AGATGTTGGT GGTGCAGTCC CAGGACCAAG CTTAAGGAGA 120 GGAGAGCATC TGCTCTGAGA CGGATGGAAG GAGAGAGGTT GAG 163 (2) INFORMATION FOR SEQ ID NO:292: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 397 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:292: ACGGGAAGGT GAGTATGTNA GTATGTNTGC CAGACAATGG TGTTTCCATG TCAATGGAGG 60 TTTCTCAGAG AGAGGTGATC TGGCTGGAGA AAGCTTAATC TGGTGGCAAT GGACAGGTGA 120 CTTTAAGAAG TGGGGAACGA GGGAAGGAGG CCAGTTTGAA AATNATAACA AGGGTCCAGA 180 CTCAGTGATG CAGCAGTGAC CATGAGAACA GAGCAGCTGC AGGTAGAAGA TGGAGACAGA 240 ACTNGGGAGA TCTGGTGGAG GTAAGCCGCG TGGAAAGATG ATGTCAGGTT TATACCTAGA 300 GGACACATGA TCCATTCACA AAGCCAGGGG NAACCTAAAG AGAAAACACT TAGAATTTTN 360 GGAGAANAGG CTAGGGCTGG GCCTTAGACA TGGGCTG 397 (2) INFORMATION FOR SEQ ID NO:293: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 360 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:293: GAGGTAAAAT TTACATACAG TGAAATCCAA ATCTTAAGTG TACCACTAGA TAAATTTTGA 60 TAAATGCATT ATGCCTGGTC TTCACACACC CTTTTCAATA TATAGAAAAT NTCCAGATAA 120 TTTATTTTGT TGTTTTTTTC ACACACTAAG TTCTAGACTT TTCCAGGTCC GAGGGAACTA 180 TTAGGGGGGA AAGTACTTGT NATAGTAAAA AAGATTTTAG GTGTGTTTGT TTTTAAGGTG 240 CAGAAACACA TCGCAGATTT AAGGTCTGCA ATCTCTGCTT TTTGTTATTG TTCCAGTTTT 300 GATCTCAGTG ACATTACAAG CAAGCAGAAA CACTCAGACA TGAAATGGCC CAGTGCCTGT 360 (2) INFORMATION FOR SEQ ID NO:294: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 321 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:294: TTTTTTTCAG GNTTCAACCG TTTTATTGGG AGGTTTTGTT TTCTGTGAAA TACACTAGAG 60 GGTGGGGAAG GGGACACATT CACTTTGCAA GATAAGGGTT TCCCACCACT AAAGGAAAGG 120 CATGGGGCAG GGCACACTGG GGTTTGGGTC CGTTTTCCCA CCTCCTTCTG CTTGGCTCAC 180 TTTTCTTTTC TCTCAGCAAG TACCACAGAA CACAAAGACA AGAAACAAAA CAGCAAATCA 240 ACCTCCAACG GGGCCATGCC AAGCCTTCCC CACTCCCCCA GGCTGGGCAA GGGCTGGGAG 300 GGGGCTGGGG CAGCTCACTC G 321 (2) INFORMATION FOR SEQ ID NO:295: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 165 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:295: GACACACAGC GCCTCCGGCC CCGCACAGGG GGCATGTCCA GAGGTGCTGT GTGTCACCAA 60 CTGGTCTTCT AATTTGGAAG GAGTTGGAAA GGCCTTTTTG TTGATGAAAA GTTGGAAACA 120 GTGGCACATA TCTNAGAGGG AGGAACGAGG CAGCGTGGTG AAGCG 165 (2) INFORMATION FOR SEQ ID NO:296: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 315 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:296: CGAATACAGG TAGTGCCCAG CTGGTTGGGC TGGCCCAGGA AAATNCTGCT GTGTCAAATA 60 CTGCTGGCCA GGATGAAGCC ACAGCTAAGG CTGTGTTGGA GCCCATTCAG AGCACCAGTC 120 TAATTGGGAC TTTAACCAGG ACATCTGACA GTGAGGTTCC AGATGTGGAA TCTCGTGAAG 180 ACTTAATTAA AAATCACTAC ATGGCAAGNA TAGTGGAACT TACGTCTCAG TTGCAGCTGG 240 CTGACAGTAA GTCAGTGCAT TTTTATGCCG AGTGCCGAGC ACTGTCTAAA AGACTNGCCT 300 TGGCTGNAAA GTCTA 315 (2) INFORMATION FOR SEQ ID NO:297: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 244 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:297: AGTACGGTTN NCGCTNAAGC TTGATNATCG RATTGCCAAT CTNCATATTT GTGTTAGAAT 60 CATTTGTTTT TGTGTCTTCA TGTTTCTATA AGATAGGACC AATATTCTTT ATTGGGCTTT 120 GATTTTATTT TGTAACTTAA ATGTATTAAG GCAATAAATG TAATTTTCCA CTNAAAACTA 180 TCATTATAGA TTTGGTTACT ACCTACTGCT CAGCAATTTT TTTTCTTATC AAAATTCTTC 240 CTGG 244 (2) INFORMATION FOR SEQ ID NO:298: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 152 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:298: CCTGAACAGG TAATGAGAAA AATTTACACA CAAGTGATTT TGAAAACAGA ATGGGTTGCT 60 TACAAATTAC AGGAAATGTT ATAACACAAA CCAGAAGAAT TCAATGGAAG GCAATAAGGG 120 ATTCTGAAAT GAAAATTATA AAAGTATCAN GA 152 (2) INFORMATION FOR SEQ ID NO:299: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 374 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:299: CGATGTTTTT AATGTCATCA CACGTTGTCT CAAAATGAGT GGTGGCATCΔ TATGTGCGGG 60 AAATAAAGAT CTGGCTTTCT GTTCCCAAGT CTTTTGGTAC CAGGAGGTCA CTGATGCTAA 120 CAAATTTCTG TTCAATTGGT TCCAAGAGCT CCAAAGCTGG TCTGATTTCC TTCTCAGGCT 180 CCTTGGTTTC CACAGTTGTA CTAACTATAG CAATGTACTT CCCTTGTGCT GCTACATTGT 240 GCGCAAAGGA GATCATGCAG ACGTAGATAT CTGACTTTCG ATTGACTTTG GTTCTGTGGA 300 ATAATGATCT GGCAGGAGTT GGCATCATTG GTGTTCTTTG ATGGGGGTGG CTGAGGGATG 360 CAAATAACCT CTTG 374 (2) INFORMATION FOR SEQ ID NO:300: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 365 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:300: GGCTCACCAA GCTCAGCAAG TACGTGTACT TCTTCGAGGC CTGCCGGCTG CTGCAGAAGA 60 TGATTGACAT CTCCCTGGAT GGCTTCCTGC TGACTCCGGT GCAGAAGATC TGCAAGTACC 120 CTCTGCAGCT GGCCGAGCTG CTCAAATACA CGCACCCCCA GCACAGGGAC TTCAAGGATG 180 TTGAAGCCGC CTTGCATGCC ATGAAGAACG TGGCCCAGCT CATCAACGAG CGGAAGGGTA 240 GACTTGAGAA CATCGACAAG ATTGCTCAGT GGCAGAGCTC CATAGAGGAC TGGGAGGGAG 300 AAGGATCTCT TGGTCAGGAG CTCAGAACTC ATCTACTCGG GGGGAGCTGA CCTCGGGTTA 360 CACAG 365 (2) INFORMATION FOR SEQ ID NO:301: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 224 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:301: GGTATTCAAA CAAATAGCCT GAGAATTTNG GGGGGATCTG AAATAGAGTA CTATGCTATG 60 TTGGCTAAAA CTGGTGTCCA TCACTACAGT GGCAATANTA TTGAACTGGG CACAGCATGC 120 GGAAAATACT ACAGAGTGTG CACACTGGCT ATCATTGATC CAGGTGACTC TGACATCATT 180 AGAAGCATGC CAGANCAGAC TGGTGAAAAG TAAACCTTTT CACG 224 (2) INFORMATION FOR SEQ ID NO:302: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 363 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:302: AGTTTCACTC TTGTTGCCCA GGCTGGAGTG CAATGGCGTG ATCTCGGCTC ASTGCAATCK 60 GCACCTTCCG GKTTCAAGCG ATTCTCCTGC CTCAGCCTCC CAAGTAGTTG GGATTACAGG 120 CATGCGCCAC CATGCCCGGC CAATTTTKTA TTTTTCGTAC ACACAGGGTT TCTCCATGTT 180 GGTCAGGCTG GTCTCAAACT CCCAACCTCG GTGATCCGTC CACCTCGGCC TCTCAAAGTG 240 CTGGGATTAT AGGCATGAGC CACTGTGTCC GGCCAGCTCA AACAATTTTA ATGCTTCTTT 300 CAAGNCTATT AGAAACCTTT AATTGCTTCT TAAGTTTCTC CCCCAACTAT GGAGGAAGCA 360 TAT - 363 (2) INFORMATION FOR SEQ ID NO:303: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 253 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:303: ATGCAGGAAS ATCTACCARG CAAATCGAAA ACAAAAAAAG GCAGGGGTTG CAATCCATCT 60 CTCTGATAAA ACAGACTTTA AACCAACAAR RRTCAAAAGA CACAGAGARG GCCATARCAT 120 AATAGTAAAG CGGATCAATT CAACAAGAAG AGCTAACTAT CCTAAATATA TATGCACCCA 180 ATACAGGAGC AACTAGATTC ATAAAGCAAG TCCTGGAGGT GCCTACAGAG GAGGCTTAGG 240 CTCCCACACA TTA • 253 (2) INFORMATION FOR SEQ ID NO:304: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 416 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:304: TTTTTTTGAG ATGGAGTACT CGCTCTCTTG CCCGGGCTGG AGTGCAGTGG CGCGATCTCG 60 GCTCACCTGC AACCCCTGCC TCCCCAGTTC AAGAGGTTCT CCTGCCTCAG CCTCCCGGGT 120 GGCTGGAATT GCAGGCACAC ACCACCATGC CCAGCTGCTT TCTTGTATTT TTAGTGGAGA 180 CGTGGTTTCA CCATGTTGGC CAGGCTGGTC TTGAGCTCCT GACCTTAAGT GATCCGCCAG 240 CCTTGGCCTC CCAAAGTGCT GGGATTACAG GCGTGAGCAC CGTGCCCAGG CTGTTTTTTA 300 ACTGACTTTG GATTTTACTC CCTTTCTATG CAAATTTATT TTAGAATCTG TTCCTTAACC 360 TTAGGGGGTT GGGTTAGACA AGTTTCAAGG GAGCCTCAAG TGKAAATTGC TTAAGG 416 (2) INFORMATION FOR SEQ ID NO:305: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 223 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:305: CACACCCAGC TAATTTTTGT ATTTTTAGTA GAGACGGGGT TTCACCATGT TGGCTTGGCT 60 GGTCACGAAC TCCTGGCCTT GAGTGATCCC CCTGCCTCAG CCTCCCAAAG TGCTGGGATT 120 ACAGGTGTGA GTCAGCGTGC CCAGCCCAGA TTTTATTGTT TTAATTACAA ATTTTACGTA 180 AGTTGTTTCT GCACATTTAT ATTTGCACAC TTGTGCTAGT GAG 223 (2) INFORMATION FOR SEQ ID NO:306: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 169 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:306: GTTTTGCCAC ATTGGCCAGG CTGGTCTCGA ACTCCCGACC WGTGAGCCA CCTGCCTTGG 60 CCTCTCAAAG TGCTGGGATT ACAGGCGTGA GCACCACGCC CGACCCATAG CTCTTTACAA 120 CTGCCTTGTA AAGAAAGCAT CATTTGGCAC TGTTAGTATT TCTCTTGAA 169 (2) INFORMATION FOR SEQ ID NO:307: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 303 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:307: GATTTGGTAC AGAGTATGTC AGGAAGACAA CTCAGATTGC CATTTTAAAT AAAGTTGTAC 60 ATGAACAATA ATTGGAATCA TCAGGTAATT TTTTTAAACA AAGGTTCTTC ATTTACTGTT 120 ATGATTGGAA AAAAAATTAG AAAATAAAGT AAGTSCCATA GGCTAATTAA AAAATAAAAC 180 CTTGGCCGGG CGCGGTGGCT TACGCCTATA ATCCCAGCAC TTTGGGAGGC CGAGACGGGC 240 AGATCACGNG GTCAGGAGAT TGAGACCATC CTGGCTAACA CGGTGAAACC CCATCTGTAC 300 TTG 303 (2) INFORMATION FOR SEQ ID NO:308: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 143 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:308: ATCTAGGAGG CTGAGGTGGG ATCGCCCCAG TACTGGAGGT CAGGGCTGCA GTCAGCCATG 60 ATCATGCCAC TACACTCCAK CCTGGGTGAC AGAGTGAGAC CCTCTSTCAA AAAACCTCAG 120 TCAATVCAAA CATACAGTAT ATT 143 (3) INFORMATION FOR SEQ ID NO:309: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 199 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:309: CCCACCCTCA TAANCCCCAC TGGGGAGTCT GGGGGCCTCT ATTGCCATGT GCCTGGAATN 60 ATNATATGCT CATCACTTTA TGAAGAATAA AATTTGTNTT TCCTGCCTTA AAGTTACATT 120 CGTTCTTCCG CTCAAATCCT GATCTGGTCC ATTAAAGAGT GTTCGCAGAC AAAGTTTCTG 180 AAAGATTAGA GAAGAATCC 199 (2) INFORMATION FOR SEQ ID NO:310: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 426 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:310: TCCCTGTACC ACCTCTTCCT GAATACGGAG GAAAAGTTCG TTATGGACTG ATCCCTGAGG 60 AATTCTTCCA GTTTCTTTAT CCTAAAACTG GTGTAACAGG ACCCTATGTA CTCGGAACTG 120 GGCTTATCTT GTACGCTTTA TCCAAAGAAA TATATGTGAT TAGCGCAGAG ACCTTCACTG 180 CCCTATCAGT ACTAGGTGTA ATGGTCTATG GAATTAAAAA ATATGGTCCC TTTGTTGCAG 240 ACTTTGCTGA TAAACTCAAT GAGCAAAAAC TTGCCCAACT AGAAGAGGCG AAGAAGTTCT 300 TCCATCCAAC ACATCCAGAA TGCAATTGGA TACGGAGAAG GTCACAACAG GCACTGGTTT 360 CCAGGAAGCG CCATTTACCG TTTTTMATGG GMCAAAGGGA GTTACATTGG CTATGGCTTT 420 TGGAAG 426 (2) INFORMATION FOR SEQ ID NO:311: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 489 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:311: TCGACTCGGT CCTGGATGTG GTGAGGAAGG AGTCAGAGAG CTGTGACTGT TTCCAGGGCT 60 TCCAGCTGAC CCACTCTCTG GGGGGCGGCA CGGGGTCCGG GATGGGCACC CTGCTCATCA 120 GCAAGATCCG GGAAGAGTAC CCAGACCGCA TCATGAACAC CTTCAGCGTC ATGCCCTCAC 180 CCAAGGTGTC AGACACGGTR GTGGAGCCCT ACAACGCCAC CCTMTCGGTC CACCAGCTGG 240 TGGAAAACAC AGATGAAACC TACTGCATTG ACAACGAGGC CCTGTATGAC ATCTGCTTCC 300 GCACCCTGAA GCTGACCACC CCCACCTACG GGGACCTCAA CCACCTGGTG TCGGCCACCA 360 TGAGCGGGGT AACACCTGCT TGCGCTTYCC GGGCCAGCTG AACGAGACCT GGCAAAGTGG 420 CGGTTGACAT GGTGCCTTTC CTGGCTGAAT TTTTAATGCC CGGTTTGGGC CCTACCAGCC 480 GGGGAAGCA 489 (2) INFORMATION FOR SEQ ID NO:313: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 302 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:313: CTTCTCATGC CAGTCTAATG ATTGTTTTTA GAAAAGGATA TACATTGACC TTCAATGTAA 60 TAAGAAATGC AACACTTTAC GGTGTCCAAC TGCTAAGATT TATTTCCAAC TTGTCAGACA 120 CAACTATTTT GCCCAATCCA AATCAAAGGG AATCAAGGCT GTGAAATCCA CACAGGACAT 180 CAACGCACAC ATAAATGAAA ACTACAGATG TGTCAGAGGC AACCATATAC ACACAAATAA 240 TGTAACTACT AAATTCCATG AAGTAGCTGT CCAGGGAATA CTTTCCAAAT AACCTTCAGC 300 AG 302 (2) INFORMATION FOR SEQ ID NO:315: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 339 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:315: CGCGTTATTT AAATTGTGAA AAATAATGAA TATTAATTTG GAGCATAATA TTTAAATACA 60 TGAAAAAAGC TGGCTGGGAA ATGTTGGCAT GACTTTTCCC AGATGTTAGC ACTGCTTCAA 120 CTTTTGAGAG NGCACTCTGA GTGTAAGTTT ACTAGACTGA CATTACTAAA ATCATTGGTG 180 CTATAGAGGC AGGAGAATAC GGGGAATAAG AAAGCCAGTT GCAAGCCAAC AATCCTAAAA 240 CTCCTCCTTT TGCCATGGAC TGACGGCATA TTAAATGAGA TCATGCATTT TAAGGNATTA 300 ACAGTGTACA CCACATGTGC GTGTTCCAAT AAAAGGAAG 339 Note regarding Claims: Certain SEQ ID NOS are excluded from some claims based on their homology to known non-human sequences (See Table 2) .

Claims: WHAT IS CLAIMED IS: 1. An enriched oligonucleotide having a sequence designated as one of: SEQ ID NO: 1 - 315; or having a sequence complementary thereto. 2. An enriched oligonucleotide having a sequence designated as one of: SEQ ID NO: 1 - 315, except SEQ ID NOS: 22 or 187; or allelic variation or complementary sequence thereto or portion thereof at least 15 nucleotides in length. 3. An isolated oligonucleotide that includes a sequence designated as one of: SEQ ID NO: 1 - 315, except SEQ ID NOS: 22, 187; or allelic variation or complementary sequence thereto or portion thereof at least 15 nucleotides in length. 4. An enriched or isolated oligonucleotide operably coding for a human gene product, which includes a region coding for the same amino acid sequence as the coding region of a gene corresponding to a sequence designated as one of: SEQ ID NO: 1 - 315. 5. The sequence of Claim 4, wherein said SEQ ID NO is listed in Table 6. 6. The sequence of Claim 4, wherein said SEQ ID NO is listed in Table 7. 7. The sequence of Claim 4, wherein said SEQ ID NO is identified in Table 10 in a metabolic functional grouping. 8. The sequence of Claim 4, wherein said SEQ ID NO is identified in Table 10 in a structural functional grouping. 9. The sequence of Claim 4, wherein said SEQ ID NO is identified in Table 11 in a developmental control grouping. 10. An enriched or isolated oligonucleotide coding for a human gene product, which includes a coding region corresponding to the EST identified as: SEQ-ID NO: 1 - 315; or a sequence complementary thereto or comprising an allelic variation thereof. 11. The oligonucleotide of Claim 10, wherein said SEQ ID NO is 1-315. 12. The oligonucleotide of Claim 10, wherein the SEQ ID NO is 1001-1500. 13. The oligonucleotide of Claim 10, wherein the SEQ ID NO is 1501-2000. 14. The oligonucleotide of Claim 10, wherein the SEQ ID NO is 2001-2421. 15. The oligonucleotide of Claim 10, wherein said sequence further includes the entire sequence designated as any one of SEQ ID NOS: 1-315. 16. An enriched or isolated oligonucleotide fragment comprising at least 15 bp of a sequence of Claim 10 and wherein said SEQ ID NO excludes NOS 22 and 187. 17. An enriched or isolated oligonucleotide sequence corresponding to a human gene, which hybridizes to a sequence designated as any one of SEQ ID NOS 1-315, except SEQ ID NOS 22, 187, or to a sequence complementary thereto, under hybridization conditions sufficiently stringent to require at least 97% base pairing. 18. An oligonucleotide according to any one of Claims 1- 17, in substantially purified form. 19. A construct comprising a vector and an oligonucleotide according to any one of Claims 1-17. 20. The construct according to Claim 19, further comprising a promoter operably linked to said oligonucleotide. 21. A panel of at least 100 oligonucleotides according to Claim 3 or Claim 16. 22. An antisense oligonucleotide capable of blocking expression of the gene product of any one of the sequences of Claim 10. 23. A triple helix probe capable of blocking expression of the gene product of any one of the sequences of Claim 10.

Inventors: ADAMS MARK D, VENTER J CRAIG, ADAMS, MARK, D., VENTER, J., CRAIG
Applicants: US ARMY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH
Application year: 1992
Main classification: C07H21
IPC codes: C07K14, C12N15, C12Q1